



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/54, 9/12, A61K 38/45, C07K 16/40, C12Q 1/68, 1/48, C12N 15/11, A61K 31/70	A1	(11) International Publication Number: WO 99/01560 (43) International Publication Date: 14 January 1999 (14.01.99)														
(21) International Application Number: PCT/US98/13835 (22) International Filing Date: 1 July 1998 (01.07.98) (30) Priority Data: <table border="0"> <tr> <td>60/051,410</td> <td>1 July 1997 (01.07.97)</td> <td>US</td> </tr> <tr> <td>60/053,018</td> <td>21 July 1997 (21.07.97)</td> <td>US</td> </tr> <tr> <td>60/053,329</td> <td>21 July 1997 (21.07.97)</td> <td>US</td> </tr> <tr> <td>60/054,642</td> <td>4 August 1997 (04.08.97)</td> <td>US</td> </tr> <tr> <td>60/058,287</td> <td>9 September 1997 (09.09.97)</td> <td>US</td> </tr> </table> (71) Applicant (for all designated States except US): CAMBIA BIOSYSTEMS LLC [US/US]; Suite 110, 915 - 118th Avenue S.E., Bellevue, WA 98005 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KILIAN, Andrzej [AU/AU]; 42 Campbell Street, Canberra, ACT 2602 (AU). BOWTELL, David [AU/AU]; 22 Strathearn Avenue, Coburg, VIC 3058 (AU). (74) Agents: McMASTERS, David, D. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).	60/051,410	1 July 1997 (01.07.97)	US	60/053,018	21 July 1997 (21.07.97)	US	60/053,329	21 July 1997 (21.07.97)	US	60/054,642	4 August 1997 (04.08.97)	US	60/058,287	9 September 1997 (09.09.97)	US	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
60/051,410	1 July 1997 (01.07.97)	US														
60/053,018	21 July 1997 (21.07.97)	US														
60/053,329	21 July 1997 (21.07.97)	US														
60/054,642	4 August 1997 (04.08.97)	US														
60/058,287	9 September 1997 (09.09.97)	US														
(54) Title: VERTEBRATE TELOMERASE GENES AND PROTEINS AND USES THEREOF																
(57) Abstract <p>Nucleic acid molecules encoding vertebrate telomerase are provided. Gene products, expression vectors and host cells suitable for expressing telomerase are also provided. Methods for identifying inhibitors of telomerase activity and inhibitor compositions are disclosed.</p>																

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

VERTEBRATE TELOMERASE GENES AND PROTEINS AND USES THEREOF

TECHNICAL FIELD

This invention relates generally to telomerases, and particularly to the
5 human telomerase gene and protein and uses for diagnostics and therapy.

BACKGROUND OF THE INVENTION

Non-circular chromosomes require a specialized mechanism for
maintaining chromosome ends after each cell division because the polymerases
responsible for replication of chromosomal DNA are unable to fully replicate linear
10 DNA molecules, creating an "end replicating problem." To meet this challenge,
eukaryotic cells depend upon an enzyme, telomerase, to add short, typically G-rich,
relatively conserved repeats onto chromosomal ends. These repeat structures are
termed telomeres.

The presence of telomeres is essential for cell viability. The absence of
15 even a single telomere leads to cell cycle arrest in yeast, a eukaryotic cell (Sandell and
Zakian, *Cell* 75:729, 1993). Telomeres shorten during replication; telomerase restores
the telomeres. Thus, as expected, telomerase activity is primarily detected in actively
dividing cells. As such, telomerase activity is constitutive in unicellular organisms and
is regulated in more complex organisms, relatively abundant in germline and embryonic
20 tissues and cells as well as tumor cells. In contrast, telomerase activity is difficult to
detect in normal somatic human tissues. Moreover, rather than cessation of replication
resulting in decreased telomerase, recent data indicate that telomerase inhibition might
be one of the critical events in this transition. The seemingly direct correlation of
telomerase/replication activities have prompted much speculation that inhibitors of
25 telomerase could be a "universal" cancer therapeutic, effective for essentially all tumor
types, whereas stimulators of telomerase could overcome the observed natural
senescence of normal cells.

Spurred by these models, characterization of telomerase for culmination
in isolation and cloning of telomerase has been a high priority. The mechanism of
30 telomere elongation has been shown to center on the G-rich strand of the telomeric
repeats. This G-rich strand, which extends to the 3' end of the chromosome, is extended
by telomerase, a ribonucleoprotein, from the RNA component, which acts as a template.
Various components of this complex have been isolated and cloned. The RNA

component of the complex has been isolated and cloned from many different organisms, including humans (Feng et al. *Science* 269: 1236, 1995), mice and other mammalian species, *Saccharomyces cerevisiae*, *Tetrahymena*, *Euplotes*, and *Oxytricha* (see, Singer and Gottschling, *Science*, 266: 404, 1994; Lingner et al. *Genes & Develop.* 8: 1984, 5 1994; and Romero and Blackburn, *Cell* 67: 343, 1994). Protein components have been relatively refractory to isolation. Recently, the nucleotide sequences of several protein components have been determined (an 80 kD/95 kD dimeric protein from *Tetrahymena*, WO 96/19580; and a 67 kD protein from humans, WO 97/08314).

The present invention discloses nucleotide and amino acid sequences of 10 telomerase, uses of these sequences for diagnostics and therapeutic uses, and further provides other related advantages.

SUMMARY OF THE INVENTION

In one aspect, this invention generally provides isolated nucleic acid molecules encoding vertebrate telomerase (including variants thereof). Representative 15 examples of vertebrates include mammals such as humans, old world monkeys (e.g., macaques, chimps, and baboons), dogs, rats, and mice, as well as non-mammalian organisms such as birds. In a preferred embodiment, the nucleic acid molecule encoding a vertebrate telomerase is provided, wherein the nucleic acid molecule comprises the sequence presented in Figure 1, or hybridizes under stringent conditions 20 to the complement of the sequence presented in Figure 1, provided that the nucleic acid molecule is not EST AA281296.

In other preferred embodiments, the nucleic acid molecule comprises any of the sequences presented in Figure 11 or encodes any of the amino acid sequences presented in Figure 11, or hybridizes under normal stringency conditions to the 25 complement of the sequences thereof, provided that the nucleic acid molecule is not EST AA281296. In other embodiments, the nucleic acid molecule comprises any of the sequences presented in Figure 10, or hybridizes under normal stringency conditions to the complement of the sequences thereof.

In another aspect, the invention provides an oligonucleotide comprising 30 from 10 to 100 contiguous nucleotides from the sequence presented in Figure 1 or its complement and from 10 to 100 contiguous nucleotides from the sequences presented in Figure 10 or the complements thereof. The oligonucleotides may be labeled with a detectable label.

In yet another aspect, an expression vector is provided, comprising a 35 heterologous promoter operably linked to a nucleic acid molecule of human telomerase.

The vector may be selected from the group consisting of bacterial vectors, retroviral vectors, adenoviral vectors and yeast vectors. Host cells containing such vectors are also provided.

In another aspect, the invention provides an isolated protein comprising a
5 human telomerase protein. The protein may comprise the amino acid sequence presented in Figure 1 or variant thereof or any of the amino acid sequences presented in Figure 11 or variant thereof. In a related aspect, the protein is a portion of a human telomerase protein, which may derive from the sequences presented in Figures 1 or 11. In preferred embodiments, the portion is from 10 to 100 amino acids long.

10 In other aspects, antibodies that specifically binds to human telomerase protein or portions are provided.

In a preferred aspect, an oligonucleotide (*e.g.*, a nucleic acid probe or primer) is provided that is capable of specifically hybridizing to a nucleic acid molecule encoding a human telomerase under conditions of normal stringency. Within certain
15 embodiments, the nucleic acid molecule has a detectable label. Within certain embodiments, the nucleic acid molecule is selected such that it does not hybridize to nucleotides 1624-2012 presented in Figure 1. Within certain embodiments of the invention, the nucleic acid probe or primer may differ from a wild-type telomerase sequence by one or more nucleotides.

20 In a related aspect, the invention provides a pair of oligonucleotide primers capable of specifically amplifying all or a portion of a nucleic acid molecule encoding human telomerase. In specific embodiments, the nucleic acid molecule comprises the sequence presented in Figure 1, Figure 11, or complements thereof. In preferred embodiments, the pair of primers is capable of specifically amplifying
25 sequence comprising all or a part of region 1, region α , region β , region 2, region 3 region X or region Y. In a related aspect, the invention provides an oligonucleotide that hybridizes specifically to a nucleic acid sequence in region 1, region α , region β , region 2, region 3 region X or region Y.

Methods for diagnosing cancer in a patent are also provided. These
30 methods comprise preparing tumor cDNA and amplifying the tumor cDNA using primers that specifically amplify human telomerase nucleic acid sequence, wherein the detection of telomerase nucleic acid sequences is indicative of a diagnosis of cancer. The amount of detected sequences may be compared to the amount of amplified telomerase sequence to a control, wherein increase telomerase nucleic acid sequences
35 over the control is indicative of a diagnosis of cancer.

In yet another aspect, a method of determining a pattern of telomerase RNA expression in cells is provided, comprising preparing cDNA from mRNA isolated from the cells, amplifying the cDNA using primers according to claim 35, therefrom determining the pattern of telomerase RNA expression. In preferred embodiments, the method further comprises detecting the amplified product by hybridization with an oligonucleotide having all or part of the sequence of region 1, region α , region β , region 2, region 3 region X or region Y. These methods may be used to diagnose cancer in a patient, wherein the pattern is indicative of a diagnosis of cancer.

The invention also provides non-human transgenic animals whose cells contain a human telomerase gene that is operably linked to a promoter effective for the expression of the gene. In preferred embodiments, the animal is a mouse and the promoter is tissue-specific. In a related aspect, the invention provides a mouse whose cells have an endogenous telomerase gene disrupted by homologous recombination with a nonfunctional telomerase gene, wherein the mouse is unable to express endogenous telomerase.

The invention also provides inhibitors of human telomerase activity, as well as assays for identifying inhibitors of telomerase activity wherein the inhibitor binds to telomerase and is not a nucleoside analogue. The inhibitor may be an antisense nucleic acid complementary to human telomerase mRNA, a ribozyme and the like. The inhibitors may be used to treat cancer.

Also provided are methods for identifying an effector of telomerase activity, comprising the general steps of (a) adding a candidate effector to a mixture of telomerase protein, RNA component and template, wherein the telomerase protein is encoded by an isolated nucleic acid molecule as described above; (b) detecting telomerase activity, and (c) comparing the amount of activity in step (b) to the amount of activity in a control mixture without candidate effector, therefrom identifying an effector. Within further embodiments the effector is an inhibitor. With yet other embodiments the the nucleic acid molecule encodes human telomerase.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth below which describe in more detail certain procedures or compositions (*e.g.*, plasmids, etc.), and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-E present a DNA sequence (SEQ ID No:____) and predicted amino acid sequence (SEQ ID No:____) of human telomerase.

Figure 2 presents an alignment of *Euplotes aediculatus* p123 (SEQ ID No:____), yeast (EST2) (SEQ ID No:____) and human (HT1) telomerase protein (amino acids 29-1132) sequences. Reverse transcriptase motifs are indicated. The region of high homology among all three proteins is defined as the Telomerase region. The sequences are aligned with ClustalW.

Figure 3 is a scanned image of a Northern analysis showing that the telomerase catalytic subunit is expressed in LIM 1215 colon carcinoma cells but not in CCD primary fibroblasts. An mRNA of approximately 3.8 kb hybridizes to the hT1 probe. An additional cross-hybridizing mRNA of higher molecular weight is indicated by the top arrowhead. Cross-hybridization to ribosomal RNA present in the polyA⁺ RNA preparation is indicated. The same blot is also hybridized to a probe from the GAPDH gene as a loading control (lower panel). Marker sizes are indicated in kb.

Figure 4 is a scanned image of a Southern analysis showing that the telomerase catalytic subunit is encoded by a single gene and is not amplified in LIM 1215 cells. Genomic DNA isolated from peripheral human blood and LIM 1215 cell line is probed with a hT1 probe. The blot also contains dilutions of probe plasmid to control for the sensitivity of detection. The plasmid is diluted to approximately 10, 5 and 1 genome equivalents. H, *Hind* III; E, *Eco* RI; P, *Pst* I; X, *Xba* I; B, *Bam* HI.

Figure 5 shows the results of amplification of cDNAs synthesized from various tissues. Amplification is performed using primers from the hT1 cDNA sequence that span an intron in the hT1 gene, and the products are blotted and probed with a radiolabeled oligonucleotide from the hT1 sequence. Amplification is also performed on the same samples with a pair of primers from the β -actin gene as a loading control. a: hT1 cDNA control; b: human genomic DNA control; c: no template control; d: normal colon RNA; e: normal testis RNA; f: normal lymphocyte RNA; g: melanoma RNA (cerebral metastasis); h: melanoma RNA (subcutaneous ankle metastasis); i: melanoma RNA (liver metastasis); j: melanoma RNA (lung metastasis); k: melanoma RNA (axillary lymph node metastasis); l: melanoma RNA (skin metastasis); m: breast carcinoma RNA; n: breast carcinoma RNA; o: breast carcinoma RNA; p: breast carcinoma RNA.

Figure 6 presents results showing hT1 expression in pre-crisis cells and post-crisis cell lines. Upper panel: Nested amplification using primers within the original EST. Lower panel: Control RT-PCR using β -actin primers. a: BET-3K passage

(p) 7 (pre-crisis); b: BET-3K p32 (post-crisis); c: BFT-3K p14 (pre-crisis); d: BFT-3K p22 (post-crisis); e: BFT-3B p15 (pre-crisis); f: BFT-3B p29 (post-crisis); g: GM897 (ALT); h: IIICF/c (ALT); i: IIICF-T/B1 (ALT); j: No template control.

Figures 7A-C show some alternative splicing patterns of the hT1 transcript. A, Schematic representation of six splicing variants. B, Combinations of some identified RNA variants. C, Sequences of putative exon/intron junctions of RNA variants. Variants are marked as in part A. A complete DNA sequence (with protein translation) (SEQ ID No:) of variant 3 is presented. Amino acids corresponding to a potential c-Abl/SH3 binding site are underlined. Putative exon/intron junctions are marked with | and sequence coordinates are as in Figure 1. Putative spliced exons are in lower case and putative unspliced introns are in bold.

Figure 8 shows various splicing patterns of hT1 transcript in different tumor samples. Nested amplification (14 cycles) is performed using HT2026F and HT2482R primers on primary RT-PCR products generated with HT1875F and HT2781R primers. a: Lung carcinoma; b: Lymphoma; c: Lung carcinoma; d: Medulloblastoma; e: Lymphoma; f: Lymphoma; g: T47D; h: Pheochromocytoma; i: Lymphoma; j: Glioma; k: Lymphoma; l: No template control.

Figure 9 shows the results of amplification on cDNA synthesized from LIM 1215 cDNA. As shown, reverse transcriptase motif A is deleted from splicing variants containing sequence α . Primer combinations are: a, HTM2028F + HT2356R; b, HT2026F + HT2482R; c, HTM2028F + HT2482R; d. HT2026F + HT2482R.

Figures 10A-B present DNA sequences of variant regions of telomerase.

Figures 11A-W presents DNA and amino acid sequences of exemplary variant telomerase proteins.

Figure 12 is a scanned image of a telomerase activity assay.

Figures 13A-D present a schematic diagram of plasmid pAK128.4 and the DNA sequence of the plasmid.

Figures 14A-E present a schematic diagram of plasmid pAK128.7 and the DNA sequence of the plasmid.

Figures 15A-D present a schematic diagram of plasmid pAK128.14 and the DNA sequence of the plasmid.

DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention, it may be helpful to an understanding thereof to define certain terms used herein.

As used herein, "wild-type telomerase" generally refers to a polypeptid that enzymatically synthesizes nucleic acid sequences comprising simple repeat sequences (e.g., CCCTAA, see Zakian, *Science* 270: 1601, 1995) to ends of chromosomes. The amino acid sequence of one representative wild-type telomerase from human has been deduced and is presented in Figure 1 (SEQ ID No. ____). Within the context of this invention, it should be understood that telomerases of this invention include not only wild-type protein, but also variants (including alleles) of the wild-type protein sequence. Such variants may not necessarily exhibit enzymatic function. Briefly, such variants may result from natural polymorphisms, including RNA splice variants, generated by genetic recombination, or be synthesized by recombinant methodology, and moreover, may differ from wild-type protein by one or more amino acid substitutions, insertions, deletions, rearrangements or the like. Typically, when the result of synthesis, amino acid substitutions are conservative, i.e., substitution of amino acids within groups of polar, non-polar, aromatic, charged, etc. amino acids. In the region of homology to the wild-type sequence in the RTase motif regions variants will preferably have at least 90% amino acid sequence identity, and within certain embodiments, greater than 92%, 95%, or 97% identity. Outside the RTase motif region, variants will preferably have 75% amino acid identity, and within certain embodiments, at least 80%, 85%, 90%, 92%, 95% or 97% identity.

As will be appreciated by those skilled in the art, a nucleotide sequence encoding telomerase may differ from the wild-type sequence presented in the Figures; due to codon degeneracies, nucleotide polymorphisms, or amino acid differences. In other embodiments, variants should preferably hybridize to the wild-type nucleotide sequence at conditions of normal stringency, which is approximately 25-30°C below T_m of the native duplex (e.g., 1 M Na⁺ at 65°C; 5X SSPE, 0.5% SDS, 5X Denhardt's solution, at 65°C or equivalent conditions; see generally, Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1987; Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing, 1987). T_m for other than short oligonucleotides can be calculated by the formula $T_m = 81.5 + 0.41\%(G+C) - \log(Na^+)$. Low stringency hybridizations are performed at conditions approximately 40°C below T_m , and high stringency hybridizations are performed at conditions approximately 10°C below T_m . Variants preferably have at least 75% nucleotide identity to wild-type sequence in the RTase motif region, preferably at least 80%, 85%, and most preferably at least 90% nucleotide identity.

As used herein, a "promoter" refers to a nucleotide sequence that contains elements that direct the transcription of a linked gene. At minimum, a

promoter contains an RNA polymerase binding site. More typically, in eukaryotes, promoter sequences contain binding sites for other transcriptional factors that control the rate and timing of gene expression. Such sites include TATA box, CAAT box, POU box, AP1 binding site, and the like. Promoter regions may also contain enhancer elements. When a promoter is linked to a gene so as to enable transcription of the gene, it is "operatively linked".

An "isolated nucleic acid molecule" refers to a polynucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid construct, that has been separated from its source cell (including the chromosome it normally resides in) at least once in a substantially pure form. Nucleic acid molecules may be comprised of a wide variety of nucleotides, including DNA, RNA, nucleotide analogues, or some combination of these.

I. TELOMERASE, TELOMERASE GENES AND GENE PRODUCTS

As noted above, the invention provides compositions relating to vertebrate telomerase genes and gene products, and methods for the use of the genes and gene products. Given the disclosure provided herein, a telomerase gene can be isolated from a variety of cell types that express telomerase, including immortalized or transformed cells. As exemplified herein, a cDNA and variants encoding telomerase from human cells are identified, isolated, and characterized. Telomerase protein is then readily produced by host cells transfected with an expression vector encoding telomerase.

A. Isolation of telomerase gene

As described herein, the invention provides genes encoding telomerase. Within one embodiment of the invention, a gene encoding human telomerase can be identified by amplification of a cDNA library using a primer pair designed from an EST sequence. The EST sequence GenBank Accession No. AA281296, is identified by sequence identity and similarity to a *Euplotes aediculatus* telomerase gene (GenBank accession no. U95964; Lingner et al., *Science* 276: 561, 1997). Sequence comparisons between the *Euplotes* telomerase gene and the EST show approximately 38% amino acid identity and 59% amino acid similarity.

Telomerase genes may be isolated from genomic DNA or cDNA. Genomic DNA is preferred when the promoter region or other flanking regions are desired. Genomic DNA libraries constructed in chromosomal vectors, such as YACs (yeast artificial chromosomes), bacteriophage vectors, such as λ EMBL3, λ gt10,

cosmids, or plasmids, and cDNA libraries constructed in bacteriophage vectors (e.g., λ ZAPII), plasmids, or others, are suitable for screening. Such libraries may be constructed using methods and techniques known in the art (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, 1989) or
5 purchased from commercial sources (e.g., Clontech, Palo Alto, CA). The DNA may be isolated from vertebrate cells, such as human cells, mouse cells, other rodent or primate cells, avian cells, and the like.

Within one embodiment, the telomerase gene is isolated by amplification using cDNA library DNA as templates. Using the reported EST sequence, human
10 telomerase may be isolated. Briefly, sets of amplification primers are designed based upon the EST nucleotide sequence. Examples of such primers are presented in Table 2 (see also Example 1). Amplification of cDNA libraries made from cells with high telomerase activity is preferred. The primers described herein amplify a fragment that has a length predicted from the EST sequence from a LIM1215 cDNA library.
15 LIM1215 is a human colon cancer cell line. Confirmation of the nature of the fragment is obtained by DNA sequence analysis.

DNA fragments encompassing additional sequence are amplified in reactions using a primer that hybridizes to vector sequence in conjunction with one of the EST primers. By using vector primers from either side of the cloning site in
20 combination with the EST primers, a 1.6 kb fragment derived from the 3' region of h-TEL (human telomerase) and a 0.7 kb fragment derived from the 5' region are isolated. These fragments are verified as containing telomerase coding sequence by amplification with a pair of primers internal to the EST sequence. The two fragments are cloned into pBluescript and subjected to DNA sequence analysis. Additional DNA sequence is
25 obtained by C-RACE and amplification procedures to obtain the 5' end of a cDNA as well as by hybridization and isolation of clones from the cDNA library.

The compiled DNA sequence and predicted amino acid sequence of a reference human telomerase are presented in Figure 1. As shown, the coding region of the reference telomerase is 3396 bases long and has an approximately 620 base long 3'
30 untranslated region. The predicted amino acid sequence is 1132 amino acids long and may be delineated into four major domains: N-terminal, basic, reverse transcriptase (RT) and C-terminal. Furthermore, human telomerase contains regions of homology to other telomerases (e.g., from *Euplotes* and *S. pombe*) and reverse transcriptases. These motifs are identified herein and in Kilian et al. (*Human Molecular Genetics*, 12: 2011-
35 2019, 1997) as domains 1, 2, A, B, C, and D, in Nakamura et al., (*Science*, 277: 955-959) as domains 1, 2, A, B', C, D, and E, and in Meyerson et al. (*Cell*, 90: 785-795,

1997) as motifs 1-6. Regardless of the name used, these motifs encompass amino acids 621-626 (motif 1) and 631-634 (motif 2), 708-720 (motif A), 827-839 (motif B), 863-871 (motif C), and 895-902 (motif D). Because the boundaries of these motifs are based on similarity and identity with other telomerases, the functional boundary of each motif may be different.

In addition, variants of the reference telomerase sequence are obtained by amplifications, which are described herein. Their DNA and predicted amino acid sequences are presented in Figure 11 and discussed in further detail below. Briefly, some of these variants encode truncated proteins and others have different C-terminal sequences. These variants likely result from alternative RNA splicing because telomerase appears to be a single copy gene in humans (see Example 2).

Alternatively, other methods may be used to obtain a nucleic acid molecule that encodes telomerase. For example, a nucleic acid molecule encoding telomerase may be obtained from an expression library by screening with an antibody or antibodies reactive to telomerase (see, Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, NY, 1987; Ausubel et al. *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley-Interscience, NY, 1995). In another embodiment, nucleic acid molecules encoding telomerase may be isolated by hybridization screening of cDNA or genomic libraries. Oligonucleotides for hybridization screening may be designed based on the DNA sequence of human telomerase presented herein. Oligonucleotides for screening are typically at least 11 bases long and more usually at least 20 or 25 bases long. In one embodiment, the oligonucleotide is 20-30 bases long. Such an oligonucleotide may be synthesized in an automated fashion. To facilitate detection, the oligonucleotide may be conveniently labeled, generally at the 5' end, with a reporter molecule, such as a radionuclide, (e.g., ^{32}P), enzymatic label, protein label, fluorescent label, or biotin. A library is generally plated as colonies or phage, depending upon the vector, and the recombinant DNA is transferred to nylon or nitrocellulose membranes. Hybridization conditions are tailored to the length and GC content of the oligonucleotide. Following denaturation, neutralization, and fixation of the DNA to the membrane, membranes are hybridized with labeled probe. Suitable hybridization conditions may be found in Sambrook et al., *supra*, Ausubel et al., *supra*, and furthermore hybridization solutions may contain additives such as tetramethylammonium chloride or other chaotropic reagents or hybotropic reagents to increase specificity of hybridization (see for example, PCT/US97/17413). Following hybridization, suitable detection methods reveal hybridizing colonies or phage that are then isolated and propagated. Candidate clones

or amplified fragments may be verified as containing telomerase DNA by any of various means. For example, the candidate clones may be hybridized with a second, non-overlapping probe or subjected to DNA sequence analysis. In these ways, clones containing a telomerase gene or gene fragment, which are suitable for use in the present invention, are isolated.

Telomerase DNA may also be obtained by amplification of cDNA or genomic DNA. Oligonucleotide primers for amplification of a full-length cDNA are preferably derived from sequences at the 5' and 3' ends of the coding region. Amplification of genomic sequences will use primers that span intronic sequences and may use conditions that favor long amplification products (see Promega catalogue). Briefly, oligonucleotides used as amplification primers preferably do not have self-complementary sequences nor have complementary sequences at their 3' end (to prevent primer-dimer formation). Preferably, the primers have a GC content of about 50% and contain restriction sites to facilitate cloning. Generally, primers are between 15 and 50 nucleotides long, and more usually between 20 and 35 nucleotides long. The primers are annealed to cDNA or genomic DNA and sufficient amplification cycles are performed to yield a detectable product, preferably one that is readily visualized by gel electrophoresis and staining. The amplified fragment is purified and inserted into a vector (e.g., a viral, phagemid or plasmid vector, such as λ gt10 or pBS(M13+)) and propagated.

Telomerase genes from a multitude of species can be isolated using the compositions provided herein. For closely related species, the human sequence or portion thereof may be utilized as a probe on a genomic or cDNA library. For example, a fragment of the telomerase gene that encompasses the catalytic site (approximately corresponding to amino acids 605-915 of Figure 1) may be labeled and used as a probe on a library constructed from mouse, primate, rat, dog, or other vertebrate, warm-blooded, or mammalian species. An initial hybridization at normal stringency may yield clones or fragments encoding telomerase. If no hybridization is observed, relaxed (low) stringency hybridizations may be pursued. Guidelines for varying the stringency of the hybridization may be acquired from Sambrook et al., *supra*, and other well-known sources. Such probes may also be used on libraries from evolutionarily diverse species, such as *Drosophila*, although hybridization conditions will typically be more relaxed.

Other methods may alternatively be used to isolate telomerase genes from non-human species. These methods include, but are not limited to, amplification using primers derived from conserved areas (e.g., RTase motifs), amplification using

degenerate primers from various regions of telomerase including the RTase region, antibody probing of expression libraries, telomerase RNA probing of expression libraries, and the like. A gene sequence is identified as a telomerase by amino acid similarity and / or nucleic acid identity. Generally, amino acid similarity, which allows
5 for conservative differences, is preferred to identify a telomerase. From diverse species, amino acid similarity is generally at least 30% and preferably at least 40% or at least 50%. Nucleic acid identity may be lower and thus difficult to assess. Several readily available computer analysis programs, such as BLASTN and BLASTP, are useful to determine relatedness of genes and gene products. Candidate telomerase genes are
10 examined for enzyme activity by one of the functional assays described herein or other equivalent assays.

B. Variant telomerase genes

Variants (including alleles) of the telomerase nucleic acid or amino acid sequence provided herein may be readily isolated from natural variants (*e.g.*,
15 polymorphisms, splice variants, mutants), synthesized, or constructed. Depending upon the intended use, mutants may be constructed to exhibit altered or deficient telomerase function. Particularly useful telomerase genes encode a protein lacking enzyme activity but that has a dominant negative phenotype. The telomerase variants, moreover, may lack one or more of known telomerase activities, including reverse transcriptase
20 activity, nucleolytic activity, telomere binding activity, dNTP binding activity, and telomerase RNA (hTR) binding activity.

One skilled in the art recognizes that many methods have been developed for generating mutants (*see, generally*, Sambrook et al., *supra*; Ausubel et al., *supra*). Briefly, preferred methods for generating a few nucleotide substitutions
25 utilize an oligonucleotide that spans the base or bases to be mutated and contains the mutated base or bases. The oligonucleotide is hybridized to complementary single stranded nucleic acid and second strand synthesis is primed from the oligonucleotide. Similarly, deletions and/or insertions may be constructed by any of a variety of known methods. For example, the gene can be digested with restriction enzymes and religated
30 such that some sequence is deleted or ligated with an isolated fragment having cohesive ends so that an insertion or large substitution is made. In another embodiment, variants are generated by "exon shuffling" (*see* U.S. Patent No. 5,605,793). Variant sequences may also be generated by "molecular evolution" techniques (*see* U. S. Patent No. 5,723,323). Other means to generate variant sequences may be found, for example, in
35 Sambrook et al. (*supra*) and Ausubel et al. (*supra*). Verification of variant sequences is typically accomplished by restriction enzyme mapping, sequence analysis, or probe

hybridization, although other methods may be used. The double-stranded nucleic acid is transformed into host cells, typically *E. coli*, but alternatively, other prokaryotes, yeast, or larger eukaryotes may be used. Standard screening protocols, such as nucleic acid hybridization, amplification, and DNA sequence analysis, will identify mutant
5 sequences.

In preferred embodiments, variant telomerases are inactive with respect to enzyme activity and impart a dominant negative phenotype to a host cell. Regardless of the actual mechanism, when a dominant negative telomerase is expressed in a cell, the native active telomerase is rendered inactive. In the catalytic domain, RTase motifs
10 share conserved aspartic acid residues. Human telomerase also contains these critical residues: Asp 712, Asp 718, Asp 868, and Asp 869. Mutation of one or more of these Asp residues to a non-conservative amino acid (e.g., alanine) will likely destroy enzymatic activity and or affect telomere shortening. For each of these mutants, dominant negativity is assayed. Preferred mutants are dominant negative and induce a
15 senescence phenotype in certain embodiments. Other dominant negative variants may be generated by deletion of one or more of the RTase motifs or alteration of the region involved in DNA priming (such as motif E), binding site for the RNA component, the template binding site, the metal ion binding site (such as motif C), and the like.

In other embodiments, the nucleic acid molecule encoding telomerase
20 may be fused to another nucleic acid molecule. As will be appreciated, the fusion partner gene may contribute, within certain embodiments, a coding region. Thus, it may be desirable to use only the catalytic site of telomerase (e.g., amino acids 609-915), individual RTase motifs (described above), any of the splicing variant telomerases described herein, the telomerase RNA binding site and the like. The choice of the
25 fusion partner depends in part upon the desired application. The fusion partner may be used to alter specificity of the telomerase, provide a reporter function, provide a tag sequence for identification or purification protocols, and the like. The reporter or tag can be any protein that allows convenient and sensitive measurement or facilitates isolation of the gene product and does not interfere with the function of the telomerase.
30 For reporter function, β -glucuronidase (U.S. Patent No: 5,268,463), green fluorescent protein and β -galactosidase are readily available as DNA sequences. A peptide tag is a short sequence, usually derived from a native protein, which is recognized by an antibody or other molecule. Peptide tags include FLAG®, Glu-Glu tag (Chiron Corp., Emeryville, CA) KT3 tag (Chiron Corp.), T7 gene 10 tag (Invitrogen, La Jolla, CA), T7
35 major capsid protein tag (Novagen, Madison, WI), His₆ (hexa-His), and HSV tag (Novagen). Besides tags, other types of proteins or peptides, such as glutathione-S-

transferase may be used.

C. Fragments and oligonucleotide derived from telomerase genes

In addition, portions or fragments of telomerase gene may be isolated or constructed for use in the present invention. For example, restriction fragments can be isolated by well-known techniques from template DNA, *e.g.*, plasmid DNA, and DNA fragments, including restriction fragments, can be generated by amplification. Furthermore, oligonucleotides can be synthesized or isolated from recombinant DNA molecules. One skilled in the art will appreciate that other methods are available to obtain DNA or RNA molecules having at least a portion of a telomerase sequence. Moreover, for particular applications, these nucleic acids may be labeled by techniques known in the art with a radiolabel (*e.g.*, ^{32}P , ^{33}P , ^{35}S , ^{125}I , ^{131}I , ^3H , ^{14}C), fluorescent label (*e.g.*, FITC, Cy5, RITC, Texas Red), chemiluminescent label, enzyme, biotin and the like.

Methods for obtaining fragments are well-known in the art. Portions that are particularly useful within the context of this invention contain the catalytic site, individual RTase motifs, the putative intronic sequences (see Figure 10), and the like. Oligonucleotides are generally synthesized by automated fashion; methods and apparatus for synthesis are readily available (*e.g.*, Applied Biosystems Inc, CA). Oligonucleotides may contain non-naturally occurring nucleotides, such as nucleotide analogues, a modified backbone (*e.g.*, peptide backbone), nucleotide derivatives (*e.g.*, biotinylated nucleotide), and the like. As used herein, oligonucleotides refers to a nucleic acid sequence of at least about 7 nucleotides and generally not longer than about 100 nucleotides. Usually, oligonucleotides are between about 10 and about 50 bases, more often between about 18 and about 35 nucleotides long. Oligonucleotides can be single-stranded or in some cases double-stranded. As used herein, portions of a nucleic acid refer to a polynucleotide that contains less than the entire parental nucleic acid sequence. For example, a portion of telomerase coding sequence contains less than a full-length telomerase sequence. A 'portion' is generally at least about seven nucleotides, and may be as many as 10, 20, 25 or more nucleotides in length. A fragment refers to a polynucleotide molecule of any length and can encompass an oligonucleotide, although more usually, but not to be limiting, the term oligonucleotide is used to denote short polynucleotides and the term fragment is used to denote longer polynucleotides.

Oligonucleotides for use as primers for amplification and probes for hybridization screening may be designed based on the DNA sequence of human telomerase presented herein. Oligonucleotide primers for amplification of a full-length

cDNA are preferably derived from sequences at the 5' and 3' ends. Primers for amplification of specific regions are chosen to generate products of an easily detectable size. In preferred embodiments, primers are chosen that flank the sequences subject to alternative RNA splicing. In preferred embodiments, one set of primers is chosen such
5 that both the product that spans spliced-in sequence as well as the product that spans spliced-out sequence are suitable sizes to be detected under the same reaction conditions. In other embodiments, two sets of primers are used to detect the alternative spliced RNAs. For example, one set of primers flanks the splice junction in order to detect a spliced-out product. The second set of primers may be derived very close to the
10 junction (such that a spliced-out amplification product is the same size or barely larger than a primer-dimer length) or one or more of the set may be derived from the spliced-in sequence (such that the spliced-out RNA would not yield any product). An amplified

Amplification primers preferably do not have self-complementary sequences nor have complementary sequences at their 3' end (to prevent primer-dimer
15 formation). Preferably, the primers have a GC content of about 50% and may contain restriction sites to facilitate cloning. Amplification primers usually are at least 15 bases and usually are not longer than 50 bases, although in some circumstances and conditions shorter or longer lengths can be used. More usually, primers are from 17 to 40 bases long, 17 to 35 bases long, or 20 to 30 bases long. The primers are annealed to
20 cDNA or genomic DNA and sufficient amplification cycles, generally 20-40 cycles, are performed to yield a product readily visualized by gel electrophoresis and staining or by hybridization. The amplified fragment can be purified and inserted into a vector, such as λ gt10 or pBS(M13+), and propagated, isolated and subjected to DNA sequence analysis, subjected to hybridization, or the like.

25 An oligonucleotide hybridization probe suitable for screening genomic, cDNA or other types (e.g., mutant telomerase sequences) of libraries, probing southern, northern, or northwestern blots, amplification products, and the like may be designed based on the sequences provided herein. Oligonucleotides for hybridization are typically at least 11 bases long, generally less than 100 bases long, and preferably at
30 least 15 bases long, at least 20 bases long, at least 25 bases long, and preferably 20-70, 25-50, or 30-40 bases long. To facilitate detection, the oligonucleotide may be conveniently labeled, generally at the 5' end, with a reporter molecule, such as a radionuclide, (e.g., ^{32}P), enzymatic label, protein label, fluorescent label, or biotin. (see Ausubel et al., and Sambrook et al., *supra*). A library is generally plated as
35 colonies or phage, depending upon the vector, and the recombinant DNA is transferred to nylon or nitrocellulose membranes. Following denaturation, neutralization, and

fixation of the DNA to the membrane, membranes are hybridized with labeled probe, and washed. Suitable detection methods reveal hybridizing colonies or phage that are then isolated and propagated. Methods for transferring nucleic acids to membranes and performing hybridizations are well known. In certain embodiments, additives to hybridization solution, such as a chaotrope (e.g., tetramethylammonium chloride) or a hybotrope (e.g., ammonium trichloroacetate; see PCT/ US97/17413) are added to increase sensitivity and specificity of hybridization. A probe specifically hybridizes to a nucleic acid if it remains detectably annealed after washing under conditions equivalent to hybridization conditions (expressed herein as the number of degrees less than T_m).

D. Splicing variants of human telomerase

In addition to the reference telomerase DNA and protein sequences presented in Figures 1, several RNA splice variants are observed. Although some of the variants may reflect incompletely processed mRNA, it is noteworthy that such variants are abundant in an RNA sample (LIM1215) preselected for polyadenylated mRNA. These findings, together with their clustering in the RT domain, suggest that the insertion variants more likely reflect regulation of hT1 protein expression. For example, variants in which exons are deleted (see α , β , Fig. 7) are likely alternative mature coding for variant proteins. Additional evidence in support of alternative proteins comes from sequence analysis of cDNA clones identified in a LIM1215 cDNA library that contained both deletions and insertions compared to the reference sequence.

At least seven different putative introns appear to be retained in mRNAs (see Figure 7, which displays 6 of the 7 introns). The introns may be independently retained, thus, a particular mRNA may have none, any one, two, etc. up to seven introns. The maximum number of different mRNAs resulting from seven independently spliced introns is 2^7 , or 128 different mRNAs. DNA sequences of these introns are presented in Figure 10. The 5' most intron, called sequence "X", is an unknown length, and only a partial sequence is presented.

The reference telomerase sequence (Figure 1) includes intron α and intron β . In the following discussion, the effect of presence/absence and location of each intron is presented on the basis that it is the only alteration. It will be appreciated that a particular intron may alter the sequence of the translated product, regardless of whether other introns are spliced in or out. For example, the presence of intron 1 results in a frameshift and truncated protein, regardless of whether introns α , β , 2 or 3 are spliced in or out.

The presence of intron "X" results in a truncated protein that contains approximately 600 N-terminal amino acids and lacks all of the RTase motifs. The presence of intron "Y" at base 222 results in a frameshifted protein that terminates within three codons past the intron. As the Y intron is very GC rich, approximately 5 78%, which is difficult to sequence, it is possible that intron Y causes an insertion of about 35 amino acids and not a frameshift.

Intron 1 at nucleotide 1950 is 38 bp and its presence in mRNA causes a frame-shift and ultimate translation of a truncated protein (stop codon at nt 1973). This truncated protein contains only RTase domains 1 and 2.

10 Intron α , located from bases 2131-2166 is frequently observed spliced out of telomerase mRNA. A protein translated from such an RNA is deleted for 12 amino acids, removing RTase motif A. This motif appears to be critical for RT function; a single amino acid mutation within this domain in the yeast EST2 protein results in a protein that functions as a dominant negative and results in cellular 15 senescence and telomere shortening.

Another of the variant sequences, the β -exon deletion at base 2286-2468, encodes a truncated protein, due to a reading frameshift at base 2287, which is joined to base 2469, and subsequently a termination codon at base 2605. This variant protein has RTase domains 1, 2, A, B, and part of C, but lacks another motif; in addition to the 20 RTase domain motifs, another sequence motif (AVRIRGKS) identified in the β insert of hT1 matches a P-loop motif consensus AXXXXGK(S) (Saraste et al., *Trends Biochem. Sci.* 15, 430-434, 1990). This motif is found in a large number of protein families including a number of kinases, bacterial dnaA, recA, recF, mutS and ATP-binding helicases (Devereaux et al., *Nucleic Acids Res.*, 12, 387-395, 1984). The P-loop 25 is thus present only in a subpopulation of the h-TEL mRNAs in most RNA samples analyzed and completely absent from several tumor samples (Figure 8).

Intron 2 at base 2843 contains an in-frame termination codon, resulting in a truncated protein that has the entire RTase domain region, but lacks the C-terminus. As the C-terminus may play a regulatory role, protein activity will likely be affected. 30 When intron 3 is retained, a smaller protein is also produced because the intron contains an in-frame stop codon. Thus, the protein has an altered C-terminal sequence. What activity such proteins might have is currently unknown. The crystal structure of the HIV-1 reverse transcriptase demonstrates that a short form of the protein (p51) that lacks the RNAase domain is inhibited by the C-terminal 'connection' folding into the catalytic cleft. If hT1 is assumed to adopt a similar structure to HIV-RT, then C- 35 terminal hT1 protein variants may reflect a similar mechanism of regulation.

In addition to variants that lack the reference C-terminal domain, a variant with intron 3 at base 2157 expresses an alternative C-terminal domain. Furthermore, the coding region donated by intron 3 has a potential SH3 binding site, SGQPEMEPPRRPSGCVG, which matches the consensus c-Abl SH3 binding peptide (PXXXXPXXP) found in proteins such as ataxia telangiectasia mutated (ATM). A second example of this motif is found within the N-terminal end of the hT1 protein in the peptide HAGPPSTSRRPPRPWDTP. Other alternative C-terminal domains are found in telomerase cDNAs; the EST12462 (GenBank Accession No. AA299878) has about 50 bases of identical sequence up to base 2157 and then diverges from the reference telomerase sequence as well as intron 3. This new sequence has an internal stop codon in 50 bases that would result in a truncated C-terminus.

The variant detected in one ALT cell line (Fig. 6, lane i) opens up the possibility that the basic domain of hT1 may contribute to the ALT mechanism in at least some ALT cell lines. Interestingly, this ALT cell line expresses the hTR gene. One possible mechanism of ALT could involve dysregulated telomerase components that are inactive in the TRAP assay.

The following table summarizes the splice variants and resulting proteins. For simplicity, only a single variant is listed for each resulting protein. Furthermore, as noted above, the presence of the Y intron appears to cause a frameshift resulting in a truncated protein, but may cause an insertion. Thus, each reading frame of the Y intron is presented and the table is constructed as if the insertion does not cause a truncated protein. An independent assortment of these known introns would lead to 128 different mRNA sequences. The DNA and amino acid sequences for the variants in Table 1 are presented in Figure 11.

Table 1

Protein	Insert sequences					
	Y	1	α	β	2	3
truncated #1	0	+	0	0	0	0
truncated #2	0	0	+	0	0	0
reference protein	0	0	+	+	0	0
truncated #3	0	0	+	+	+	0
altered C-terminus	0	0	+	+	0	+
lacks motif A	0	0	0	+	0	0
truncated #3; lacks motif A	0	0	0	+	+	0
lacks motif A; altered C-terminus	0	0	0	+	0	+
truncated #1 (ver 2)	+	+	0	0	0	0
truncated #2 (ver 2)	+	0	+	0	0	0
reference protein (ver 2)	+	0	+	+	0	0
truncated #3 (ver 2)	+	0	+	+	+	0
altered C-terminus (ver 2)	+	0	+	+	0	+
lacks motif A (ver 2)	+	0	0	+	0	0
truncated #3 (ver 2)	+	0	0	+	+	0
lacks motif A; altered C-terminus (ver 2)	+	0	0	+	0	+

E. Vectors, host cells and means of expressing and producing protein

Telomerase protein may be expressed in a variety of host organisms. In one embodiment, telomerase is produced in bacteria, such as *E. coli*, for which many expression vectors have been developed and are readily available. Other suitable host organisms include other bacterial species, and eukaryotes, such as yeast (e.g., *Saccharomyces cerevisiae*), mammalian cells (e.g., CHO and COS-7), and insect cells (e.g., Sf9).

A DNA sequence encoding telomerase, a portion thereof, a variant, fusion protein or the like, is introduced into an expression vector appropriate for the host. In certain embodiments, telomerase is inserted into a vector such that a fusion protein is produced. The telomerase sequence is derived from an existing fragment, cDNA clone, or synthesized. A preferred means of synthesis is amplification of the

gene from cDNA using a set of primers that flank the coding region or the desired portion of the protein. As discussed above, the telomerase sequence may contain alternative codons for each amino acid with multiple codons. The alternative codons can be chosen as "optimal" for the host species. Restriction sites are typically
5 incorporated into the primer sequences and are chosen with regard to the cloning site of the vector. If necessary, translational initiation and termination codons can be engineered into the primer sequences.

At minimum, the vector must contain a promoter sequence. Other regulatory sequences may be included. Such sequences include a transcription
10 termination signal sequence, secretion signal sequence, origin of replication, selectable marker, and the like. The regulatory sequences are operationally associated with one another to allow transcription or translation.

The plasmids used herein for expression of telomerase include a promoter designed for expression of the proteins in a host cell (*e.g.*, bacterial). Suitable
15 promoters are widely available and are well known in the art. Inducible or constitutive promoters are preferred. Such promoters for expression in bacteria include promoters from the T7 phage and other phages, such as T3, T5, and SP6, and the *trp*, *lpp*, and *lac* operons. Hybrid promoters (*see*, U.S. Patent No. 4,551,433), such as *tac* and *trc*, may also be used. Promoters for expression in eukaryotic cells include the P10 or
20 polyhedron gene promoter of baculovirus/insect cell expression systems (*see, e.g.*, U.S. Patent Nos. 5,243,041, 5,242,687, 5,266,317, 4,745,051, and 5,169,784), MMTV LTR, CMV IE promoter, RSV LTR, SV40, metallothionein promoter (*see, e.g.*, U.S. Patent No. 4,870,009) and other inducible promoters. For expression of the proteins, a promoter is inserted in operative linkage with the coding region for the telomerase
25 protein.

The promoter controlling transcription of the telomerase may itself be controlled by a repressor. In some systems, the promoter can be derepressed by altering the physiological conditions of the cell, for example, by the addition of a molecule that competitively binds the repressor, or by altering the temperature of the growth media.
30 Preferred repressor proteins include, but are not limited to, the *E. coli* lacI repressor, which is responsive to IPTG induction, the temperature sensitive λ cl857 repressor, and the like. The *E. coli* lacI repressor is preferred.

In other preferred embodiments, the vector also includes a transcription terminator sequence, which has either a sequence that provides a signal that terminates
35 transcription by the polymerase that recognizes the selected promoter and/or a signal sequence for polyadenylation.

Preferably, the vector is capable of replication in the host cells. Thus, when the host cell is a bacterium, the vector preferably contains a bacterial origin of replication. Preferred bacterial origins of replication include the fl-ori and col E1 origins of replication, especially the ori derived from pUC plasmids. In yeast, ARS or
5 CEN sequences can be used to assure replication. A well-used system in mammalian cells is SV40 ori.

The plasmids also preferably include at least one selectable marker that is functional in the host. A selectable marker gene includes any gene that confers a phenotype on the host that allows transformed cells to be identified and selectively
10 grown. Suitable selectable marker genes for bacterial hosts include the ampicillin resistance gene (*Amp^r*), tetracycline resistance gene (*Tc^r*) and the kanamycin resistance gene (*Kan^r*). The kanamycin resistance gene is presently preferred. Suitable markers for eukaryotes usually require a complementary deficiency in the host (*e.g.*, thymidine kinase (*tk*) in *tk*- hosts). However, drug markers are also available (*e.g.*, G418
15 resistance and hygromycin resistance).

The sequence of nucleotides encoding the telomerase may also include a secretion signal, whereby the resulting peptide is synthesized as precursor protein and is subsequently processed and secreted. The resulting processed protein may be recovered from periplasmic space or fermentation medium. Secretion signals suitable
20 for use are widely available and are well known in the art (von Heijne, *J. Mol. Biol.* 184:99-105, 1985). Prokaryotic and eukaryotic secretion signals that are functional in *E. coli* (or other host) may be employed. The presently preferred secretion signals include, but are not limited to, those encoded by the following *E. coli* genes: *pelB* (Lei et al., *J. Bacteriol.* 169:4379, 1987), *phoA*, *ompA*, *ompT*, *ompF*, *ompC*, beta-lactamase,
25 and alkaline phosphatase.

One skilled in the art appreciates that there are a wide variety of suitable vectors for expression in bacterial cells and which are readily obtainable. Vectors such as the pET series (Novagen, Madison, WI), the *tac* and *trc* series (Pharmacia, Uppsala, Sweden), pTTQ18 (Amersham International plc, England), pACYC 177, pGEX series,
30 and the like are suitable for expression of a telomerase. Baculovirus vectors, such as pBlueBac (*see, e.g.*, U.S. Patent Nos. 5,278,050, 5,244,805, 5,243,041, 5,242,687, 5,266,317, 4,745,051, and 5,169,784; available from Invitrogen, San Diego) may be used for expression of the telomerase in insect cells, such as *Spodoptera frugiperda* sf9 cells (*see*, U.S. Patent No. 4,745,051). The choice of a host for the expression of a
35 telomerase is dictated in part by the vector. Commercially available vectors are paired with suitable hosts.

A wide variety of suitable vectors for expression in eukaryotic cells are available. Such vectors include pCMVLacI, pXT1 (Stratagene Cloning Systems, La Jolla, CA); pCDNA series, pREP series, pEBVHis (Invitrogen, Carlsbad, CA). In certain embodiments, telomerase gene is cloned into a gene targeting vector, such as
5 pMC1neo, a pOG series vector (Stratagene).

Telomerase protein is isolated by standard methods, such as affinity chromatography, size exclusion chromatography, metal ion chromatography, ionic exchange chromatography, HPLC, and other known protein isolation methods. (*see generally* Ausubel et al., *supra*; Sambrook et al., *supra*). An isolated purified protein
10 gives a single band on SDS-PAGE when stained with Coomassie blue.

In one embodiment, the telomerase protein is expressed as a hexa-his fusion protein and isolated by metal-containing chromatography, such as nickel-coupled beads. Briefly, a sequence encoding His₆ is linked to a DNA sequence encoding a telomerase. Although the His₆ sequence can be positioned anywhere in the molecule,
15 preferably it is linked at the 3' end immediately preceding the termination codon. The His-hTI fusion may be constructed by any of a variety of methods. A convenient method is amplification of the TEL gene using a downstream primer that contains the codons for His₆.

F. Peptides and proteins of telomerase

20 In one aspect of the present invention, peptides having telomerase sequence are provided. Peptides may be used as immunogens to raise antibodies, as inhibitors or enhancers of telomerase function, in assays described herein and the like. Peptides are generally five to 100 amino acids long, and more usually 10 to 50 amino acids. Peptides are readily chemically synthesized in an automated fashion
25 (PerkinElmer ABI Peptide Synthesizer) or may be obtained commercially. Peptides may be further purified by a variety of methods, including high-performance liquid chromatography. Furthermore, peptides and proteins may contain amino acids other than the 20 naturally occurring amino acids or may contain derivatives and modification of the amino acids.

30 Peptides of particular interest within the context of this invention have the sequence of the intron sequences (Figure 10), the RTase motifs, and the like. In certain embodiments, telomerase proteins have the amino acid sequences presented in Figures 1 or 11, or a portion thereof which is at least 8 amino acids in length (and may be 10, 15, 20 or more amino acids in length). In other embodiments, the protein has one
35 or more amino acid substitutions, additions, deletions. In yet other embodiments, the protein has an amino acid sequence determined by a nucleic acid sequence that

hybridizes under normal stringency conditions to the complement of any of the sequences in Figure 11. As indicated above, variants of telomerase include allelic variants.

II. TELOMERASE ASSAYS

5 A variety of assays are available to determine telomerase activity and expression. Such assays include *in vitro* assays that measure the ability of telomerase to extend a telomeric DNA substrate, nucleolytic activity, primer (telomere) binding activity, dNTP binding activity, telomerase RNA (hTR) binding activity, *in vivo* gain-of-function assays, *in vivo* loss-of function assays, *in situ* hybridization, RNase probe
10 protection, Northern analysis, amplification of cDNA, antibody staining, and the like.

A. Assays for catalytic activity

Various assays for catalytic activity are described in U.S. Patent Nos. 5,629,154; 5,639,613; 5,645,986 among others. In one conventional assay for telomerase activity, a single-stranded DNA primer having the sequence of the host
15 telomere (e.g., [TTAGGG]_n) and the telomerase enzyme are used (see Shay et al., *Methods in Molecular Genetics* 5:263, 1994; Greider and Blackburn, *Cell* 43:405, 1985; Morin, *Cell* 59:521, 1989; U.S. Patent No. 5,629,154). A preferred assay incorporates a detergent-based extraction with an amplification-based assay. This assay, called TRAP (telomeric repeats amplification protocol), has improved sensitivity (Kim et al., *Science*
20 266: 2011, 1994). Briefly, in TRAP, telomerase synthesizes extension products, which then serve as templates for amplification. The telomerase products are amplified with a primer derived from a non-telomeric region of the oligonucleotide and a primer derived from the telomeric region. When the amplification products are analyzed, such as by gel electrophoresis, a ladder of products is observed when telomerase activity is present.
25 Permutations of this assay have been described (Krupp et al., *Nucl. Acids Res.* 25: 919, 1997; Savoyesky et al., *Nucl. Acids Res.* 24: 1175, 1996). As well, other telomerase assays are available (Faraoni et al., *J. Chemother* 8: 394, 1996, describing an *in vitro* chemosensitivity assay; Tatematsu et al., *Oncogene* 13: 2265, 1996, describing a "stretch PCR assay"; Lin and Zakian, *Cell* 81: 1127, 1995, describing an *in vitro* assay
30 for *Saccharomyces*).

In addition, catalytic or other activities may be measured by an *in vitro* reconstitution system (see Examples). Briefly, the assays, such as those described herein, are performed using purified telomerase protein that is produced by recombinant

meant and other necessary components, such as the telomerase RNA component, other proteins such as described in WO 98/14593.

B. Assays for other activities

Nucleolytic activity may be assessed by protocols described for example
5 in Collins and Grieder, *Genes and Development* 7: 1364, 1993). The nucleolytic activity is excision of a nucleotide (G from the telomeric repeat TTAGG) from the 3' end of a nucleotide sequence that is positioned at the 5' boundary of the DNA template. Briefly, the activity can be measured by a reaction that uses a nucleic acid template with a 3' nucleotide that is blocking, *i.e.*, cannot serve as a primer for a polymerase, unless
10 removed by nucleolytic activity.

Telomere binding activity and assays are described in for example Harrington et al., *J. Biol. Chem.* 270: 8893, 1995. In general, any assay such as a gel-shift assay, that detects protein-nucleic acid interactions may be used. DNTP and RNA binding activity assays are described in Morin, *Eur. J. Cancer* 33: 750 for example.

15 C. Gain and loss of function

In vivo gain-of-function assays may be performed by transfecting an expression vector encoding telomerase into cells that have no or little detectable endogenous activity. Activity is then measured by an *in vitro* assay, such as those described herein. Another gain of function assay can be performed in tumor cells or
20 other cells expressing telomerase or reverse transcriptase. A telomerase gene is transfected into the cells, expressed at high levels, and these cells are treated with inhibitors of reverse transcriptase. Telomerase activity is then observed as decreased sensitivity to such inhibitors. Furthermore, rescue of function in the yeast telomerase mutant EST2 may be measured.

25 Loss of function may be measured in cells expressing high levels of telomerase activity, such as LIM 1215 cells or other tumor cells. In this assay, anti-sense oligonucleotide molecules are introduced into the cells, generally in an expression vector. Telomerase gene is verified by diminished telomerase activity. In another assay, antibodies to telomerase that inhibit function can be used to demonstrate a
30 functional molecule.

D. Expression of telomerase

Expression of telomerase in various cells may be assayed by standard assays using the sequences provided herein. For example, *in situ* hybridization with radioactive or fluorescent-labeled probes (fragments or oligonucleotides) may be used

on tissue sections or fixed cells. Alternatively, RNA may be isolated from the cells and used in Northern, RNase probe protection assays, and the like. Probes for particular regions and probes that are variant specific will generate expression profiles of the various telomerase transcripts.

5 In a preferred embodiment, telomerase expression is assayed by amplification. Primer pairs for telomerase, including primer pairs for particular variants, are used to amplify cDNA synthesized from cellular RNA. The cDNA may be synthesized from either total RNA or poly(A)+ RNA. Methods and protocols for RNA isolation are well known. The cDNA may be initiated by an oligo(dT) primer, random
10 primers (e.g., dN₆), telomerase specific primer, and the like. The choice of a primer will depend at least in part on the quantity of RNA and the purpose of the assay. Amplification primers are designed to amplify any one of, particular combinations, or all of the variants present in vertebrate cells. Conditions for amplification are chosen to be commensurate with the primer length, base content, length of amplified product and
15 the like. Various amplification systems are available (see Lee et al., *Nucleic Acid Amplification Technologies*, BioTechniques Books, Eaton Publishing, Natick, MA, 1997; Larrick, *The PCR Technique: Quantitative PCR*, BioTechniques Books, Eaton Publishing, Natick, MA, 1997).

Other assays for measuring expression qualitatively and quantitatively
20 are well known. RNase probe protection and Northern analysis are amenable when the amount of telomerase mRNA is sufficient. When very few cells are available, a single cell analysis is desirable, or when the fraction of telomerase RNA in the sample is very low, an amplification protocol is preferred. RNase probe protection, in particular, is well suited for detecting splice variants, mutations, as well as quantitating these RNAs.

25 As discussed above, in preferred embodiments, expression of the various RNA species is monitored. The different species may be assayed by any method which distinguishes one of the species over the others. Thus, length determination by Northern, RNase probe protection, cloning and amplification are some of the available methods. In preferred embodiments, RNase probe protection and amplification are
30 used. For RNase probe protection, the probe will generally be a fragment derived from the junction of the reference sequence and the intron sequence or derived from the sequence surrounding the intron insertion site. For example, a fragment of the reference telomerase that spans nucleotide 1950-1951 (e.g., nucleotides 1910-1980) will protect the reference sequence as a 71 base fragment, but will protect a telomerase with intron 1
35 as two fragments of 41 and 30 bases. In contrast, a fragment that contains nucleotides 1910-1950 and 30 bases of intron 1 will protect an intron 1 variant as a 71 base

fragment and the reference telomerase as a 41 base fragment. Fragments for RNase probe protection are chosen usually in the range of 30 to 400 bases and are positioned to yield readily distinguishable protection products.

Another method that can be used to distinguish variants is amplification.

- 5 *Amplification primer design and strategy are described above. Briefly, primers that will individually amplify each spliced-in or spliced-out variant are preferred. Multiple reactions can be performed to identify variants with more than one splice-in or splice-out event.*

- 10 *Methods that measure telomerase protein are also useful within the context of the present invention. By way of example, antibodies to telomerase may be used to stain tissue sections or permeabilized cells. Antibodies may also be used to detect protein by immunoprecipitation, Western blot and the like. Furthermore, subcellular localization of telomerase and telomerase variants may be determined using the antibodies described herein.*

15 *E. Antibodies to telomerase*

- Antibodies to the telomerase proteins, fragments, or peptides discussed herein may readily be prepared. Such antibodies may specifically recognize wild type telomerase protein and not a mutant (or variant) protein, mutant (or variant) telomerase protein and not wild type protein, or equally recognize both the mutant (or variant) and
20 *wild-type forms. Antibodies may be used for isolation of the protein, inhibiting (antagonist) activity of the protein, or enhancing (agonist) activity of the protein. As well, assays for small molecules that interact with telomerase will be facilitated by the development of antibodies.*

- Within the context of the present invention, antibodies are understood to
25 *include monoclonal antibodies, polyclonal antibodies, anti-idiotypic antibodies, antibody fragments (e.g., Fab, and F(ab')₂, F_v variable regions, or complementarity determining regions). Antibodies are generally accepted as specific against telomerase protein if they bind with a K_d of greater than or equal to 10⁻⁷M, preferably greater than of equal to 10⁻⁸M. The affinity of a monoclonal antibody or binding partner can be*
30 *readily determined by one of ordinary skill in the art (see Scatchard, Ann. N.Y. Acad. Sci. 51:660-672, 1949).*

- Briefly, a polyclonal antibody preparation may be readily generated in a variety of warm-blooded animals such as rabbits, mice, or rats. Typically, an animal is immunized with telomerase protein or peptide thereof, which is preferably conjugated
35 *to a carrier protein, such as keyhole limpet hemocyanin. Routes of administration include intraperitoneal, intramuscular, intraocular, or subcutaneous injections, usually in*

an adjuvant (e.g., Freund's complete or incomplete adjuvant). Particularly preferred polyclonal antisera demonstrate binding in an assay that is at least three times greater than background.

Monoclonal antibodies may also be readily generated from hybridoma
5 cell lines using conventional techniques (see U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993; see also *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Briefly, within one embodiment, a subject animal such as a rat or mouse is injected with telomerase or a portion thereof. The protein may be administered as an emulsion in an adjuvant such as Freund's
10 complete or incomplete adjuvant in order to increase the immune response. Between one and three weeks after the initial immunization the animal is generally boosted and may tested for reactivity to the protein utilizing well-known assays. The spleen and/or lymph nodes are harvested and immortalized. Various immortalization techniques, such as mediated by Epstein-Barr virus or fusion to produce a hybridoma, may be used. In a
15 preferred embodiment, immortalization occurs by fusion with a suitable myeloma cell line to create a hybridoma that secretes monoclonal antibody. Suitable myeloma lines include, for example, NS-1 (ATCC No. TIB 18), and P3X63 - Ag 8.653 (ATCC No. CRL 1580). The preferred fusion partners do not express endogenous antibody genes. Following fusion, the cells are cultured in medium containing a reagent that
20 selectively allows for the growth of fused spleen and myeloma cells such as HAT (hypoxanthine, aminopterin, and thymidine). After about seven days, the hybridomas may be screened for the presence of antibodies that are reactive against a telomerase protein. A wide variety of assays may be utilized, including for example countercurrent immuno-electrophoresis, radioimmunoassays, radioimmunoprecipitations, enzyme-
25 linked immuno-sorbent assays (ELISA), dot blot assays, western blots, immunoprecipitation, inhibition or competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988).

Other techniques may also be utilized to construct monoclonal antibodies
30 (see Huse et al., *Science* 246:1275-1281, 1989; Sastry et al., *Proc. Natl. Acad. Sci. USA* 86:5728-5732, 1989; Altling-Mees et al., *Strategies in Molecular Biology* 3:1-9, 1990; describing recombinant techniques). Briefly, mRNA is isolated from a B cell population and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in suitable vectors, such as λ ImmunoZap(H) and λ ImmunoZap(L).
35 These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al., *supra*; Sastry et al., *supra*). Positive plaques may

subsequently be converted to a non-lytic plasmid that allows high level expression of monoclonal antibody fragments from *E. coli*.

Similarly, portions or fragments, such as Fab and Fv fragments, of antibodies may also be constructed utilizing conventional enzymatic digestion or recombinant DNA techniques to yield isolated variable regions of an antibody. Within one embodiment, the genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using nucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources (*e.g.*, Stratacyte, La Jolla, CA). Amplification products are inserted into vectors such as ImmunoZAP™ H or ImmunoZAP™ L (Stratacyte), which are then introduced into *E. coli*, yeast, or mammalian-based systems for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V_H and V_L domains may be produced (*see* Bird et al., *Science* 242:423-426, 1988). In addition, techniques may be utilized to change a "murine" antibody to a "human" antibody, without altering the binding specificity of the antibody.

Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (*see* *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques.

F. Proteins that interact with telomerase

Proteins that directly interact with telomerase can be detected by an assay such as a yeast 2-hybrid binding system. Briefly, in a two-hybrid system, a fusion of a DNA-binding domain-telomerase protein (*e.g.*, GAL4-telomerase fusion) is constructed and transfected into a cell containing a GAL4 binding site linked to a selectable marker gene. The whole telomerase protein or subregions of telomerase may be used. A library of cDNAs fused to the GAL4 activation domain is also constructed and co-transfected. When the cDNA in the cDNA-GAL4 activation domain fusion encodes a protein that interacts with telomerase, the selectable marker is expressed. Cells containing the cDNA are then grown, the construct isolated and characterized. Other assays may also be used to identify interacting proteins. Such assays include ELISA, Western blotting, co-immunoprecipitations and the like.

III. INHIBITORS AND ENHANCERS OF TELOMERASE ACTIVITY

Candidate inhibitors and enhancers (collectively referred to as "effectors") may be isolated or procured from a variety of sources, such as bacteria, fungi, plants, parasites, libraries of chemicals (e.g., combinatorial libraries), random peptides or the like. Effectors may also be peptides or variant peptides of telomerase, variants of telomerase, antisense nucleic acids, antibodies to telomerase, inhibitors of promoter activity of telomerase, and the like. Inhibitors and enhancers may be also be rationally designed, based on the protein structure determined from X-ray crystallography (see, Livnah et al., *Science* 273:464, 1996). In certain preferred embodiments, the inhibitor targets a specific telomerase, such as a variant.

An inhibitor may act by preventing binding of telomerase to other components of the ribonucleoprotein complex or to the telomere, by causing dissociation of the bound proteins, or by other mechanism. An inhibitor may act directly or indirectly. In preferred embodiments, inhibitors interfere in the binding of the telomerase protein to either the telomerase RNA or to the telomeres. In other preferred embodiments, the inhibitors are small molecules. In a most preferred embodiment, the inhibitors cause a cell to cease replication. Inhibitors should have a minimum of side effects and are preferably non-toxic. Inhibitors that can penetrate cells are preferred.

In other preferred embodiments, an effector is a protein or peptide of telomerase that acts in a dominant negative fashion (see, Ball et al., *Current Biology* 7:71, 1997; *Current Biology* 6:84, 1996). For example, a peptide of telomerase that competitively inhibits the binding of telomerase to telomeres will disrupt the lengthening of telomeres. Generally, these peptides have native sequence, but variants may have increased activity (see, Ball et al., *supra*). Variants may be constructed by the methods described herein. Other peptides may bind telomerase and inhibit one or more of its activities, but do not have telomerase amino acid sequence. Such peptides may be identified by the assays described herein. The proteins or peptides may also increase telomerase activity. For effective inhibition, peptide inhibitors are preferably expressed from vectors transfected or infected into host cells, but may also be introduced by other means, such as liposome-mediated fusion, and the like. Eukaryotic vectors are well known and readily available. Vectors include plasmids, viral-based vectors, and the like.

In another preferred embodiment, the inhibitor is a ribozyme. "Ribozyme" refers to a nucleic acid molecule which is capable of cleaving a telomerase nucleic acid sequence. Ribozymes may be composed of DNA, RNA, nucleic acid analogues, or any combination of these (e.g., DNA/RNA hybrids). A "ribozyme gene"

refers to a nucleic acid molecule which, when transcribed into RNA, yields the ribozyme, and a "ribozyme vector" refers to an assembly that is capable of transcribing a ribozyme gene of interest, and may be composed of either DNA or RNA. Within certain embodiments of the invention, the vector may include one or more restriction site(s) and selectable marker(s). Furthermore, depending on the choice of vector and host cell, additional elements such as an origin of replication, polyadenylation site, and enhancers may be included in the vectors described herein.

As noted above, the present invention also provides ribozymes having the ability to inhibit expression of the telomerase gene. Briefly, a wide variety of ribozymes may be generated for use within the present invention, including for example, hairpin ribozymes (*see e.g.*, Hampel et al., *Nucl. Acids Res.* 18:299-304, 1990, EPO 360,257, and U.S. Patent No. 5,254,678), hammerhead ribozymes (*see e.g.*, Rossi, J.J. et al., *Pharmac. Ther.* 50:245-254, 1991; Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 328:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988; Haseloff and Gerlach, *Nature* 334:585, 1988; Haseloff et al., U.S. Patent No. 5,254,678), hepatitis delta virus ribozymes (*see, e.g.*, Perrotta and Been, *Biochem.* 31:16, 1992), Group I intron ribozymes such as those based upon the *Tetrahymena* ribosomal RNA (*see, e.g.*, Cech et al., U.S. Patent No. 4,987,071) RNase P ribozymes (*see, e.g.*, Takada et al., *Cell* 35:849, 1983); as well as a variety of other nucleic acid structures with the capability to cleave a desired or selected target sequence (*see e.g.*, WO 95/29241, and WO 95/31551). Within certain embodiments of the invention, the ribozymes may be altered from their traditional structure in order to include tetraloops or other structures that increase stability (*see, e.g.*, Anderson et al., *Nucl. Acids Res.* 22:1096-1100, 1994; Cheong et al., *Nature* 346:680-682, 1990), or which make the ribozyme resistant to RNase or endonuclease activity (*see e.g.*, Rossi et al., *Pharmac. Ther.* 50:245-254, 1991).

Within one embodiment of the invention, hairpin and hammerhead ribozymes are provided with the capability of cleaving telomerase nucleic acid sequences. Briefly, hairpin ribozymes are generated so that they recognize the target sequence $N_3XN^*GUC(N_{3-6})$, wherein N is G, U, C, or A, X is G, C, or U, and * is the cleavage site. Similarly, hammerhead ribozymes are generated so that they recognize the sequence NUX, wherein N is G, U, C, or A. The additional nucleotides of the hammerhead ribozyme or hairpin ribozyme is determined by the target flanking nucleotides and the hammerhead consensus sequence (*see Ruffner et al., Biochemistry* 29:10695-10702, 1990). The preparation and use of certain ribozymes is described in

Cech et al. (U.S. Patent No. 4,987,071). The ribozymes are preferably expressed from a vector introduced into the host cells.

Ribozymes of the present invention, as well as DNA encoding such ribozymes can be readily generated utilizing published protocols (e.g., Promega, Madison Wis., Heidenreich et al., *J. FASEB* 70:90-6, 1993; Sproat, *Curr. Opin. Biotechnol.* 4:20-28, 1993). Alternatively, ribozymes may be generated from a DNA or cDNA molecule which encodes a ribozyme and which is operably linked to a RNA polymerase promoter (e.g., SP6 or T7). An RNA ribozyme is generated upon transcription of the DNA or cDNA molecule.

In other preferred embodiments, inhibitors diminish promoter activity of telomerase. A eukaryotic promoter comprises sequences bound by RNA polymerase and other proteins participating in control of the transcription unit. Telomerase transcription appears to be highly regulated; the protein is expressed mainly in stem, embryonic, and cancer cells, and expressed at much lower levels, if at all, in most somatic cells. Thus, the promoter is a potential target for inhibitors. The inhibitors may disrupt or prevent binding of one or more of the factors that control transcription of telomerase, causing transcription to diminish or cease. The levels of transcription need only fall to a low enough level that at least one telomere becomes absent.

Another inhibitor of the present invention is antisense RNA or DNA to telomerase coding or non-coding sequence. Antisense nucleic acids directed to a particular mRNA molecule have been shown to inhibit protein expression of the encoded protein. Based upon the telomerase sequences presented herein, an antisense sequence is designed and preferably inserted into a vector suitable for transfection into host cells and expression of the antisense. The antisense may bind to any part of the hTI RNA. In certain embodiments, the antisense is designed to bind specifically to one or more variants. Specific binding means that under physiological conditions, the antisense binds to RNAs that have the complementary sequence, but not other RNAs. Because telomerase RNAs that contain any particular intron sequence may be a heterogeneous group of variants due to independent assortment of splice variants, more than one species of RNA may be bound and inactivated. The antisense polynucleotides herein are at least 7 nucleotides long and generally not longer than 100 to 200 bases, and are more typically at least 10 to 50 bases long. Considerations for design of antisense molecules and means for introduction into cells are found in U.S. Patent Nos. 5,681,747; 5,734,033; 5,767,102; 5,756,476; 5,749,847; 5,747,470; 5,744,362; 5,716,846).

In addition, enhancers of telomerase activity or expression are desirable in certain circumstances. At times, increasing the proliferation potential of cells will have a therapeutic effect. For example, organ regeneration or differentiation after injury or diseases, nerve cell or brain cell growth following injury, proliferation of hematopoietic stem cells used in bone marrow transplantation or other organ stem cells, and the like may be limiting and thus benefit from an enhancer of telomerase. Enhancers may stabilize endogenous protein, increase transcription or translation, or act through other mechanisms. As is apparent to one skilled in the art, many of the guidelines presented above apply to the design of enhancers as well.

Screening assays for inhibitors and enhancers will vary according to the type of inhibitor and nature of the activity that is being inhibited. Assays include the TRAP assay or variation, a non-amplification based polymerase assay, yeast two-hybrid, release of repression in yeast transfected with a vertebrate telomerase, and the like. For screening compounds that interact with the promoter for telomerase, a reporter gene driven assay is convenient.

IV. USES FOR TELOMERASE

Nucleotide sequence for telomerase and telomerase protein are used in a variety of contexts in this invention. In preferred embodiments, the compositions of the present invention are used either as diagnostic reagents or as therapeutics.

A. *Diagnostics*

Expression of mRNA encoding telomerase and/or protein may be used for detection of dividing cells, especially tumor cells and stem cells. Detection methods include antibody staining or tagged telomerase binding compounds for detection of protein, nucleic acid hybridization in situ for mRNA, hybridization on DNA "chips", Northern analysis, RNase probe protection, amplification by PCR or other method, ligase-mediated amplification and the like. Furthermore, expression of RNA splice variants may be assayed conveniently by amplification, RNase probe protection, other disclosed methods and the like. In particular, oligonucleotide primers surrounding the site of frequent splice variants, such as the primers described herein (*e.g.*, Htel Intron T and HT 2482R) may be used to detect splice variants in various cell types. As shown in the examples, various tumor cell types exhibit different RNA splice variations. Correlation of the splice variant pattern with tumor stage, metastasis potential and the like may be determined. As such, assays for the particular variants may be used as a diagnostic. Cells with increased telomerase activity, such as cancer cells or

hyperproliferative cells, may be identified by assaying qualitatively or quantitatively by any of the assays described herein. Typically, telomerase activity or expression will be compared between suspect cells and normal counterpart cells from the same or different individual. Increased activity indicative of a tumor or excessive proliferation is established by direct comparison or by detecting activity in cells otherwise known to be absent in telomerase activity or expression. In addition, monitoring cancer progression or response to therapy can be performed using the assays described herein and comparing activity or expression over a time course.

The variant detected in one ALT cell line, which expresses telomerase, suggests that the basic domain of hT1 may contribute to the ALT mechanism in at least some ALT cell lines. One possible mechanism of ALT could involve dysregulated telomerase components that are inactive in the TRAP assay. Thus, identification of the variants may be useful for following tumorigenesis.

Alternative mRNA splicing is a common mechanism for regulating gene expression in higher eukaryotes and there are many examples of tissue-specific, development-specific and sex-specific alterations in splicing events. Importantly, 15% of mutations linked to disease states in mammals affect splicing patterns (Horowitz and Krainer *Trends Genet.*, 10, 100-106, 1994). Changes in cell physiology can also induce altered splicing patterns. Indeed, tumorigenesis itself has been suggested to enhance the expression of mRNA spliced variants by compromising the alternative splicing mechanisms. Although other, novel minor alternatively spliced hT1 variants may play a role in tumor development, the altered relative expression levels of the major transcripts found in various tumors compared to normal cells, and in post-crisis cell lines compared to limited life-span pre-crisis cells, are likely to play a major role in the establishment and progression of cancers. In addition, the existence of the alternative spliced variants of hT1 that are seen in both testis and colonic crypt, as well as tumor cell lines, suggests complex regulation of this gene in normal development.

Expression of the major hT1 products is found in most tumors and in all telomerase-positive immortalized cell lines. Transcriptional control of hT1 may therefore be a major aspect of the regulation of telomerase activity, in addition to other functions. For example, telomerase may be involved in the healing of chromosome breaks in addition to its role in maintaining telomere length in the germline. The composition of telomerase may vary according to these functional roles.

Therefore, the intron sequences may be especially useful for diagnostic applications. For example, detection and identification of diseases, such as cancer, aging, wound healing, neuronal regeneration, regenerative cells (e.g., stem cells), may

be important preludes to determining effective therapy. In this regard, detection of wound healing can facilitate development and identification of an ameliorative compound. Currently, wound healing assays are expensive and time consuming, whereas an amplification or hybridization-based assay would be quick and cost effective. In any of these applications, detection may be quantitative or qualitative. In a qualitative assay, a particular amplification primer pair or hybridization probe for one of the variant sequences (*e.g.*, introns that are variably spliced) can be used to detect the presence or absence of the variant sequence.

Probes useful in the context of the present invention include nucleic acid molecules that hybridize to the sequences presented in Figure 10 or to their complements. Probes for hybridization are generally at least 24 bases, but may range from 12 to full-length sequence. The probes may comprise additional sequence that does not hybridize to hT1 DNA or RNA. Probes are generally DNA, but may be RNA, PNA, or derivatives thereof. Hybridization conditions will be chosen appropriate for the length of the probe and method of hybridization (*e.g.*, on nylon support, on silicon-based chip). Conditions are well known in the art. One of the sequences in Figure 10 is a genomic sequence, not found in telomerase mRNA. A probe derived from this sequence may be used to detect genomic DNA in RNA preparations and amplification reactions. Hybridization probes may be labeled with a radiolabel, chemiluminescent label, or any of the myriad other known labels.

Hybridization can be performed on mRNA preparations, cDNA preparations, affixed to a solid support, in solution, or in situ tissues, and the like. One type of hybridization analysis is annealing to oligonucleotides immobilized on a solid substrate, such as a functionalized glass slide or silicon chip. Such chips may be commercially procured or made according to methods and procedures set out in *e.g.*, PCT/US94/12282; U.S. Patent No. 5,405,783; U.S. Patent No. 5,412,087; U.S. Patent No. 5,424,186; U.S. Patent No. 5,436,327; U.S. Patent No. 5,429,807; U.S. Patent No. 5,510,270; WO 95/35505; U.S. Patent No. 5,474,796. Oligonucleotides are generally arranged in an array form, such that the position of each oligonucleotide sequence can be determined.

For amplification assays, primer pairs that either flank the introns or require the presence of the intron for amplification are desirable. Many such primer pairs are disclosed herein. Others may be designed from the sequences presented herein. Generally, the primer pairs are designed to only allow amplification of a single intron, however, in some circumstances detection of multiple introns in the same RNA preparation may be preferred.

Other diagnostic assays, such as *in situ* hybridization, RNase protection, and the like may be used alternatively or in addition to the assays discussed above. The principles that guide these assays are provided by the present invention, while the techniques are well known.

5 Transgenic mice and mice that are null mutants (*e.g.*, "knockout mice") may be constructed to facilitate testing of candidate inhibitors. The telomerase gene is preferably under control of a tissue-specific promoter for transgenic mice vector constructs. Mice that overexpress telomerase can be used as a model system for testing inhibitors. In these mice, cells overexpressing telomerase are expected to be
10 continuously proliferating. Administration of candidate inhibitors is followed by observation and measurement of cell growth. Inhibitors that slow or diminish growth are candidate therapeutic agents.

Telomerase may also be transfected into cells to immortalize various cell types. Transient immortalization may be achieved by non-stable transfection of an
15 expression vector containing telomerase. Alternatively, proliferation of stable transformants of telomerase gene under control of an inducible promoter can be turned on and off by the addition and absence of the inducer. Similarly, the presence and absence of an inhibitor of telomerase activity may be used to selectively immortalize cells. Expression of part of all of the protein in yeast may act as a dominant negative, as
20 many human proteins interact with components of a complex in yeast, but do so imperfectly and therefore unproductively. As such, these genes act as dominant negatives. Thus, the yeast will eventually senesce. Such cells may be used in screens for inhibitory drugs, which will allow growth of yeast past the time of senescence.

Purified telomerase protein, reference variant protein, or fragments, may
25 be used in assays to screen for inhibitory drugs. These assays will typically be performed *in vitro* and utilize any of the methods described above or that are known in the art. The protein may also be crystallized and subjected to X-ray analysis to determine its 3-dimensional structure.

B. Therapeutics

30 The compositions and methods disclosed herein may also be used as therapeutics in the treatment of diseases and disorders to effect any of the telomerase activities in a cell. Treatment means any amelioration of the disease or disorder, such as alleviating symptoms of the disease or disorder, reduction of tumor cell mass and the like. For example, inhibitors of enzyme activity may be used to restrict proliferation of
35 cells.

Many diseases and disorders are tightly associated with proliferation and proliferative potential. One of the most apparent diseases involving unwanted proliferation is cancer. The methods and compositions described herein may be used to treat cancers, such as melanomas, other skin cancers, neuroblastomas, breast carcinomas, colon carcinomas, leukemias, lymphomas, osteosarcomas, and the like. Other diseases and disorders amenable for treatment within the context of the present invention include those of excessive cell proliferation (increased proliferation rate over normal counterpart cells from the same or different individual) such as smooth muscle cell hyperplasias, skin growths, and the like. Yet other diseases and disorders would benefit from increased telomerase activity. Enhancers of telomerase may be used to stimulate stem cell proliferation and possibly differentiation. As such, expansion of hematopoietic stem cells could be administered in the bone marrow transplant context. As well, many tissues have stem cells. Proliferation of these cells may be beneficial for wound healing, hair growth, treatment of diseases, such as Wilm's tumor, and the like.

Certain of the inhibitors or enhancers may be administered by way of an expression vector. Many techniques for introduction of nucleic acids into cells are known. Such methods include retroviral vectors and subsequent retrovirus infection, adenovirals or adeno-associated viral vectors and subsequent infection, complexes of nucleic acid with a condensing agent (e.g., poly-lysine), these complexes or viral vectors may be targeted to particular cell types by way of an incorporated ligand. Many ligands specific for tumor cells and other cells are well known in the art.

As noted above, within certain aspects of the present invention, nucleic acids encoding ribozymes, antisense, dominant-negative telomerases, portions of telomerase and the like may be utilized to inhibit telomerase activity by introducing a functional gene to a cell of interest. This may be accomplished by either delivering a synthesized gene to the cell or by delivery of DNA or cDNA capable of *in vivo* transcription of the gene product. More specifically, in order to produce products *in vivo*, a nucleic acid sequence coding for the product is placed under the control of a eukaryotic promoter (e.g., a pol III promoter, CMV or SV40 promoter). Where it is desired to more specifically control transcription, the gene may be placed under the control of a tissue or cell specific promoter (e.g., to target cells in the liver), or an inducible promoter.

A wide variety of vectors may be utilized within the context of the present invention, including for example, plasmids, viruses, retrotransposons and cosmids. Representative examples include adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Yei et al., *Gene Therapy* 1:192-200, 1994; Kolls et al., *PNAS* 91(1):215-219,

1994; Kass-Eisler et al., *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993; Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum Gene Ther.* 4(4):403-409, 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993), adeno-associated type 1 ("AAV-1") or
5 adeno-associated type 2 ("AAV-2") vectors (see WO 95/13365; Flotte et al., *PNAS* 90(22):10613-10617, 1993), hepatitis delta vectors, live, attenuated delta viruses and herpes viral vectors (e.g., U.S. Patent No. 5,288,641), as well as vectors which are disclosed within U.S. Patent No. 5,166,320. Other representative vectors include retroviral vectors (e.g., EP 0 415 731; WO 90/07936; WO 91/02805; WO 94/03622;
10 WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218. For methods and other compositions, see U.S. Patent Nos. 5,756,264; 5,741,486; 5,733,761; 5,707,618; 5,702,384; 5,656,465; 5,547,932; 5,529,774; 5,672,510; 5,399,346, and 5,712,378.)

Within certain aspects of the invention, nucleic acid molecules may be
15 introduced into a host cell utilizing a vehicle, or by various physical methods. Representative examples of such methods include transformation using calcium phosphate precipitation (Dubensky et al., *PNAS* 81:7529-7533, 1984), direct microinjection of such nucleic acid molecules into intact target cells (Acsadi et al., *Nature* 352:815-818, 1991), and electroporation whereby cells suspended in a
20 conducting solution are subjected to an intense electric field in order to transiently polarize the membrane, allowing entry of the nucleic acid molecules. Other procedures include the use of nucleic acid molecules linked to an inactive adenovirus (Cotton et al., *PNAS* 89:6094, 1990), lipofection (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1989), microprojectile bombardment (Williams et al., *PNAS* 88:2726-2730,
25 1991), polycation compounds such as polylysine, receptor specific ligands, liposomes entrapping the nucleic acid molecules, spheroplast fusion whereby *E. coli* containing the nucleic acid molecules are stripped of their outer cell walls and fused to animal cells using polyethylene glycol, viral transduction, (Cline et al., *Pharmac. Ther.* 29:69, 1985; and Friedmann et al., *Science* 244:1275, 1989), and DNA ligand (Wu et al., *J. of Biol.*
30 *Chem.* 264:16985-16987, 1989), as well as psoralen inactivated viruses such as Sendai or Adenovirus. In one embodiment, the nucleic acid molecule is introduced into the host cell using a liposome.

Administration of effectors will generally follow established protocols. The compounds of the present invention may be administered either alone, or as a
35 pharmaceutical composition. Briefly, pharmaceutical compositions of the present invention may comprise one or more of the inhibitors or enhancers as described herein,

in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like, carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol, proteins, polypeptides or amino acids
5 such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and preservatives. In addition, pharmaceutical compositions of the present invention may also contain one or more additional active ingredients. Effectors may be further coupled with a targeting moiety that binds a cell surface receptor specific to the proliferating cells.

10 Compositions of the present invention may be formulated for the manner of administration indicated, including for example, for oral, nasal, venous, intracranial, intraperitoneal, subcutaneous, or intramuscular administration. Within other embodiments of the invention, the compositions described herein may be administered as part of a sustained release implant. Within yet other embodiments, compositions of
15 the present invention may be formulized as a lyophilizate, utilizing appropriate excipients which provide stability as a lyophilizate, and subsequent to rehydration.

As noted above, pharmaceutical compositions also are provided by this invention. These compositions contain any of the above described ribozymes, DNA molecules, proteins, chemicals, vectors, or host cells, along with a pharmaceutically or
20 physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including
25 glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents.

In addition, the pharmaceutical compositions of the present invention may be prepared as medicaments for administration by a variety of different routes,
30 including for example intraarticularly, intracranially, intradermally, intrahepatically, intramuscularly, intraocularly, intraperitoneally, intrathecally, intravenously, subcutaneously or even directly into a tumor. In addition, pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions.
35 Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient

ingredients or diluents (*e.g.*, water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition. Pharmaceutical compositions are useful for both diagnostic or therapeutic purposes.

Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease. Dosages may be determined most accurately during clinical trials. Patients may be monitored for therapeutic effectiveness by appropriate technology, including signs of clinical exacerbation, imaging and the like.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

IDENTIFICATION AND ISOLATION OF THE HUMAN TELOMERASE GENE

5

A human telomerase gene is identified in a cDNA library constructed from a cancer cell line. The cDNA is subjected to DNA sequence analysis (Kilian et al., *supra*).

10 An EST sequence, GenBank Accession No. AA281296, is identified as partial telomerase gene sequence by a BLAST search against the *Euplotes* telomerase sequence, GenBank Accession No. U95964 ($p=3.2 \times 10^{-6}$). Amino acid sequence identity between the two sequences is approximately 38% and amino acid sequence similarity is approximately 60%.

To obtain longer clones of hT1, a number of cDNA libraries prepared from tumor cells are screened by amplification using primers from within the EST sequence. Primers HT1553F and HT1920R, based on the EST sequence, are used to amplify an approximately 350 bp fragment in a variety of cDNA libraries. The amplification reaction is performed under "hot start" conditions. Amplification cycles are 4 min at 95°C; 1 min at 80°C; 30 cycles of 30 sec at 94°C, 30 sec at 55°C, 1 min at 20 72°C; and 5 min at 72°C. An amplified product of the expected size (~350 bp) is detected in only 3 of the 12 libraries screened. No fragment is detectable in a testis cDNA library, somatic cell libraries, and a variety of cancer cell cDNA libraries. However, an abundant 350 bp fragment is detected in a cDNA library from LIM 1215 cells, a colon cancer cell line. In this library, and in several others, an additional 25 fragment of around 170 bp was amplified.

Two approaches are followed to obtain longer clones from the LIM1215 library: screening plaques with a 32 P-labeled EST probe and amplification on library DNA. A single positive plaque, designated 53.2, with a 1.9 kb insert is obtained by hybridization of the library with the EST probe. DNA sequence analysis of this clone 30 demonstrates that it extends both 5' and 3' of the EST sequence, but did not contain a single open reading frame (ORF). A fragment obtained from amplification analysis of the library is similar in sequence to the 53.2 fragment but also contains two additional sequences of 36bp and >300bp. Both insertions demonstrate characteristics of splice acceptor and donor sequences at their boundaries relative to the 53.2 sequence and may 35 represent unspliced introns. Amplification using primers T7 and HT1553F, yields an approximately 1.6 kb fragment; and using primers T3 and HT1893R, yields an

approximately 0.7 kb fragment. Each of these fragments support amplification of a 320 bp fragment using primers HTEL1553F and HT1893R.

Longer clones may also be obtained by amplification of mRNA samples. Reverse transcriptase PCR (RT-PCR) on LIM1215 mRNA identifies a number of
5 additional PCR products, including one with a 182 bp insertion relative to 53.2 that results in a single open reading frame (ORF). cDNA is synthesized from RNAs isolated from normal and tumor tissues. RT-PCR followed by nested amplification is performed using the Titan RT-PCR system (Boehringer-Mannheim). Amplification conditions are as follows: 95°C for 2 min, two cycles of 94°C for 30 sec, 65°C for 30 sec and 68°C for
10 3 min, 2 cycles of 94°C for 30 sec, 63°C for 30 sec, 68°C for 3 min, 34 cycles of 94°C for 30 sec, 60°C for 30 sec and 68°C for 3 min. RT-PCR products are diluted 100 fold, and 1 µl is used for nested amplification using *Taq* polymerase with buffer Q (Qiagen). Amplification conditions are as above, except that the final step is 14 cycles. For normal tissues and tumors, amplification products are resolved by electrophoresis in
15 1.5% agarose gel, transferred to Zetaprobe membrane and probed with radiolabeled oligonucleotide HT1691F.

The DNA sequence is also extended 5' and 3' using a combination of cRACE and 3' RACE, respectively, on LIM1215 mRNA to give a fragment of 3871 bp designated hT1 (Figure 1). Two rounds of cRACE are carried out to extend the
20 sequence of hT1 and map the transcription initiation site. 500 ng LIM1215 polyA+ RNA is used as the template. First strand cDNA synthesis is primed using the HT1576R primer. The first round of amplification on the ligation product (using the XL-PCR system) employs the HT1157R and HT1262F primers. Amplification products are purified using Qiagen columns, and further amplified using primers
25 HT1114R and HT1553F. A resulting 1.4 kb band is subjected to DNA sequence analysis, and a new set of primers are designed based on this sequence. For the second round of cRACE, the first strand cDNA is primed with the HT220R primer. The first round of amplification utilizes the HT0142R and HT0141F primers. Products are purified as above and amplified using HT0093 and HT0163F primers. A product of
30 100 bp is observed and subjected to sequence analysis in two independent experiments to define the 5' end of the hT1 transcript. The 5' end of the transcript is also obtained by amplification using primer HtelFulcodT 5'-
AGGAGATCTCGCGATGCCGCGCGCTC-3' and HtelFulcodB 5'-
TCCACGCGTCCTGCCCCGGTG-3' on LIM1215 RNA. The resulting amplified
35 product was digested with Mlu I and Bgl II and ligated to the remaining telomerase cDNA sequence.

The 3'-most sequences of the transcript are obtained by two rounds of amplification (XL-PCR system) using EBHT18 in both rounds as the reverse primer, and HT2761F and HT3114F as the forward primers in the first and second rounds, respectively.

5 The size of hTl accords well with the size estimated from the Northern blot (see below) for the most abundant RNA species in LIM1215 RNA. Approximately 3.9 kb of DNA sequence is presented in Figure 1. The sequence found in the EST is located from nucleotides 1624-2012. The predicted amino acid sequence of the largest open reading frame is also presented in Figure 1. As presented, the protein is 1132
10 amino acids.

Table 2

	<u>Name</u>	<u>Oligo Sequence</u>
15	HT0028F	5' - GCTGGTGCAGCGCGGGGACC
	HT 5'Met	5' - CACAAGCTTGAATTCACATCTCACCATGAAGGAGCTGGTGGCCCCGAGT
	HT0093R	5' - GGCACGCACACCAGGCACTG
	HT0141F	5' - CCTGCCTGAAGGAGCTGGTG
	HT0142R	5' - GGACACCTGGCGGAAGGAG
20	HT0163F	5' - CCGAGTGCTGCAGAGGCTGT
	HT0220R	5' - GAAGCCGAAGGCCAGCACGTTCTT
	HT1262F	5' - GTGCAGCTGCTCCGCCAGCACA
	HT1114R	5' - GTTCCCAAGCAGCTCCAGAAACAG
	HT1157R	5' - GGCAGTGCGTCTTGAGGAGCA
25	HT1553F	5' - CACTGGCTGATGAGTGTGTAC
	HT1576R	5' - GACGTACACACTCATCAGCCAG
	HT1590F	5' - GGTCTTTCTTTTATGTCACGGAG
	HT1691F	5' - CACTTGAAGAGGGTGCAGCT
	HT1875F	5' - GTCTCACCTCGAGGGTGAAG
30	HT1893R	5' - TTCACCCTCGAGGTGAGACGCT
	HT1920R	5' - TCGTAGTTGAGCACGCTGAAC
	HT2026F	5' - GCCTGAGCTGTACTTTGTCAA
	HTM2028F	5' - CTGAGCTGTACTTTGTCAAGGACA
	HT2230F	5' - GTACATGCGACAGTTCGTGGCTCA
35	HT2356R	5' - CATGAAGCGTAGGAAGACGTCAAGA
	HT2482R	5' - CGCAAACAGCTTGTTCTCCATGTC

- HT2761F 5' - CTATGCCCGGACCTCCATCAGA
HT2781R 5' - CTGATGGAGGTCCGGGCATAG
HT3114F 5' - CCTCCGAGGCCGTGCAGT
HT3292B 5' - CACCTCAAGCTTTCTAGATCAGTCCAGGATGGTCTTGAAGTCA
5 HT3689R 5' - GGAAGGCAAAGGAGGGCAGGGCGA
EBHT18 5' - CACGAATTCGGATCCAAGCTTTTTTTTTTTTTTTTTT
HT-RNA-F 5' - GGGTTGCGGAGGGTGGGC
HT-RNA451R 5' - GCAGTGGTGAGCCGAGTCCTG
HT-RNA598F 5' - CGACTTTGGAGGTGCCTTCA
10
HTel 5'T 5' - GCTGGTGCAGCGCGGGGACC
HTel979T 5' - GAGGTGCAGAGCGACTACTCCA
HTel1335T 5' - GTCTCACCTCGAGGGTGAAG
HTel171T 5' - GGCTGCTCCTGCGTTTGGTGGA
15 HTel21B(Top) 5' - GCCAGAGATGGAGCCACCC
HTel21B(bot) 5' - GGGTGGCTCCATCTCTGGC
HTel-7B 5' - CCGCACGCTCATCTCCACGT
HTel+256B 5' - GCTTGGGGATGAAGCGGTC
HtelIntronT 5' - CGCCTGAGCTGTACTTTGTCA
20 Htel 3'CODB 5' - CACCTCAAGCTTTCTAGATCAGCTAGCGGCCAGCCCAACTCCCCCT
Htel 1210B 5' - GCAGCACACATGCGTGAAACCTGT
Htel 1274B 5' - GTGTCAGAGATGACGCGCAGGAA
Htel 1624b 5' - ACCCACACTTGCCGTGCTCTGAGT
hTR TAC 5' - ACTGGATCCTTGACAATTAATGCATCGGCTCGTATAATGTGTGGAGGGTTGCGGAGGG
25 TGGGC
hTR 5'T7 5' - CTGTAATACGACTCACTATAGGGTTGCGGAGGGTGGGC
hTR 3'PstI 5' - CACCTGCAGACATGCGTTTCGTCTCACGGACTCATCAGGCCAGCTGGCGACGCATGTGT
GAGCCGAGTCCTG
30 BT-177 5' - GGATCCGCCGCGAGGACCCGTCTG
BT-178 5' - CGAAGCTTTCAGTGGGCCGGCATCTGAAC
BT-179 5' - CGAAGCTTTCACAGGCCAGCCCAACTCC
BT-182 5' - GCGGATCCAGAGCCACGTCTACGTC
BT-183 5' - GCGGATCCGTTTCAGATGCCGGCCAC
35

EXAMPLE 2

hT1 SEQUENCE AND ALIGNMENT WITH OTHER TELOMERASES

Multiple sequence alignment demonstrates that the predicted hT1 protein
5 is co-linear with the *Euplotes* and *S. cerevisiae* telomerase catalytic subunits over their
entire lengths (Figure 2). Although the overall homology between the three proteins is
relatively low (approximately 40% similarity in all pairwise combinations) the overall
structure of the protein seems to be well conserved. Four major domains: N-terminal,
basic, reverse transcriptase (RT) and C-terminal are present in all three proteins. The
10 highest area of sequence similarity is within the RT domain. Notably, all the motifs
characteristic of the *Euplotes* RT domain are present and all amino acid residues
implicated in RT catalysis are conserved in the hT1 sequence (Lingner et al., *Science*
276: 561-567, 1997).

Recently, protein phosphatase 2A treatment of human breast cancer cell
15 extracts has been shown to inhibit telomerase activity (Li et al., *J. Biol. Chem.* 272:
16729-16732, 1997). It is not known whether this effect is direct, but it raises the
possibility of regulation of telomerase activity by protein phosphorylation. The
predicted hT1 protein does contain numerous potential phosphorylation sites, including
11 SP or TP dipeptides, which are potential sites for cell cycle dependent kinases.

20

EXAMPLE 3

CHARACTERIZATION OF TELOMERASE GENE

25 Northern analysis and Southern analysis are performed to determine the
size of the telomerase transcript and whether telomerase gene is amplified in tumors
cells.

For Northern analysis, polyA mRNA is isolated from LIM 1215 cells
and from CCD fibroblasts. CCD is a primary human fibroblast cell line. Briefly cells
30 are lysed by homogenization in a buffered solution (0.1 M NaCl, 10 mM Tris, pH 7.4, 1
mM EDTA) containing detergent (0.1% SDS) and 200 µg/ml of proteinase K. SDS is
added to the lysate to a final concentration of 0.5%, and the lysate is incubated at 60°C
for 1 hr and 37°C for 20 min. The lysate is then incubated for 1 hr with a slurry oligo
dT-cellulose that has been pre-cycled in 0.1 M NaOH and equilibrated in 0.5 M NaCl,
35 10 mM Tris pH 7.4, 1 mM EDTA, and 0.1% SDS. The resin is collected by
centrifugation, batch washed in the equilibration buffer, and loaded into a column. The

mRNA is eluted with warmed (37°C) buffer (10 mM Tris pH 7.4, 0.1 mM EDTA) and ethanol precipitated.

Approximately 3 µg of polyadenylated RNA is electrophoresed in a 0.85% formaldehyde-agarose gel (see Sambrook et al., *supra*) and transferred overnight to Genescreen plus (Bio-Rad, CA). The membrane is hybridized with a ³²P-labeled telomerase-specific probe (390 bp insert corresponding to the EST sequence). After washing the blot at high stringency, a prominent ~3.8 kb band is observed in mRNA from LIM 1215, but not in mRNA from CCD fibroblasts (Figure 3). Subsequent hybridization of the same membrane with a probe for glyceraldehyde 6-phosphate dehydrogenase demonstrated an equivalently strong band in both mRNAs, indicating that each lane contained a similar amount of high quality RNA. The presence of larger transcripts (especially a ~8 kb heterodispersed band) is also visible only in LIM1215 RNA (Fig. 10, upper panel.). These findings provide an indication of additional hT1-specific mRNA and also that hT1 may be preferentially expressed in tumor versus normal cells.

For Southern analysis, DNA is isolated from human peripheral blood mononuclear cells and LIM 1215. Approximately 10 µg of DNAs are digested with *Hind* III, *Xba* I, *Eco* RI, *Bam* HI, and *Pst* I, electrophoresed in a 1% agarose gel, and transferred to a nylon membrane. For controls, plasmid DNA containing human telomerase is titrated to approximately the equivalent of 10 copies, 5 copies, and 1 copy per 10 µg genomic DNA and electrophoresed on the same gel. A 390 bp fragment of telomerase gene (containing the EST sequence) is ³²P-labeled and hybridized under normal stringency conditions. The filter is washed in 2X SSC, 0.1% SDS at 55°C. A scanned phosphor image is presented in Figure 4. As shown, the telomerase gene does not appear to be amplified or rearranged in LIM1215 as there is not significant difference in the pattern or intensity of hybridization when comparing LIM 1215 to PBMC DNA. Moreover, telomerase appears to be a single copy gene, as all digestions except *Pst* I yielded a single band.

EXAMPLE 4

hT1 EXPRESSION PATTERNS

Although telomerase activity has been widely associated with tumor cells and the germline, it has only recently been recognized that certain normal mammalian tissues express low levels of telomerase activity. hT1 expression is not detected in primary fibroblast RNA, and amplification of several commercially

available cDNA libraries from lung, heart, liver, pancreas, hippocampus, fetal brain, and testis using primers for the EST region, did not reveal any products.

However, the expression of hT1 in normal tissues that have previously been shown to have telomerase activity (colon, testis and peripheral blood lymphocytes) are examined, as well as a number of melanoma and breast cancer samples. RNA is isolated from normal human colon, testis and circulating lymphocytes, and from tissue sections of tumor samples, and subjected to RT-PCR analysis. Amplification products from cDNA are easily distinguished from products resulting from contaminating genomic DNA, as a product of ~300 bp is observed using cDNA as a template and a product of 2.7 kb is observed using genomic DNA as a template. hT1 transcripts are detected in both colon and testis, in the majority of tumor samples, and very weakly in the lymphocyte RNA (Figure 5, upper panel). Interestingly, two of the breast cancer samples are negative for hT1 expression, despite containing comparable amounts of RNA to the other samples, as judged by amplification of β -actin as a positive control (Figure 5, lower panel).

Acquisition of telomerase activity appears to be an important aspect of the immortalization process. The expression of hT1 in a number of matched pairs of pre-crisis cell cultures and post-crisis cell lines is determined using RT-PCR followed by amplification from nested primers (Figure 6, upper panel). These cell lines are telomerase negative (pre-crisis cell line) and positive (post-crisis cell lines), respectively, using the TRAP assay (Bryan et al., *EMBO J.* 14: 4240-4248, 1995). In two matched pairs, BFT-3B and BET-3K, hT1 is detected only in the post-crisis cell lines (compare lanes a and b, lanes e and f). While the post-crisis line (lanes d, f) in the BFT-3K set shows an abundant hT1 band, a fragment of the same size is also weakly present in the pre-crisis (lanes c, e) culture sample. In addition, two of the three post-crisis cell lines demonstrate the presence of an additional unexpected fragment of 320 bp, and this product is also observed when colon and testis mRNA are analyzed on high resolution gels.

Three immortalized telomerase-negative (ALT) cell lines are also analyzed for hT1 expression (Figure 6, lanes g, h, i). Two of the lines appear negative for hT1 expression, but in one line (IICF-T/B1), a product of approximately 320 bp is again amplified (Figure 6, lane i), similar to the post-crisis, colon and testis samples. DNA sequence analysis of the 320 bp product from the line IICF-T/B1 (ALT) reveals the presence of a 38 bp insertion, relative to the expected product. The possibility that this is an amplification from genomic DNA rather than mRNA is ruled out by performing amplification with the same primers but using genomic DNA as the

template. Under these conditions, a 2.7 kb fragment is amplified and its authenticity confirmed by partial sequence analysis.

5

EXAMPLE 5

IDENTIFICATION OF ALTERNATIVE SPLICING PATTERNS OF TELOMERASE mRNA

DNA sequence analysis of clones from the LIM1215 cDNA library and the RT-PCR data presented above for the pre-crisis and post-crisis cultures indicated
10 that there is a number of different sequence variants within the hT1 transcript. To systematically survey for variants, RT-PCR is performed using primer pairs covering the whole sequence. No variants are observed in the N-terminal and the basic domains, but several variants are observed in the RT domain and, to a lesser extent, the C-terminal domain. Most notably, there are several RNA variants between RT Motif A
15 and RT Motif B (Figure 7A).

Samples of mRNA are prepared from several different tumors using conventional protocols. The tumors are: (1) SLL lung carcinoma, (2) Lymphoma C, (3) Lung carcinoma, (4) Medullablastoma A, (5) Lymphoma B, (6) Lymphoma E, (7) Tumor sample 47D, (8) Pheochromocystoma, (9) Lymphoma F, (10) Glioma, and (11)
20 Lymphoma G. The mRNAs from these samples are first reverse transcribed to cDNAs and then amplified using primers HT1875F and HT2781R, followed by amplification with nested primers HT2026F and HT2482R. Four different amplified products are observed in Figure 8: 220 bp (band 1), 250 bp (band 2), 400 bp (band 3) and 430 bp (band 4). Strikingly, there is considerable variation among the tumor samples tested
25 both in the total number of amplified products and in the quantitative distribution among the products.

Three of these products are isolated from a number of tumor tissues and subjected to DNA sequence analysis. One of them, a 220 bp fragment, is equivalent to the 53.2 cDNA from the LIM1215 library. The fragment of the ~250 bp (band 2)
30 contains a 36 bp in-frame insertion, the same insertion that was identified in an amplified product from a LIM1215 cDNA library. As the RT-PCR product had the same sequence as the product from the cDNA library, it is apparent that the 36 bp insertion is not an artifact generated during library construction. The largest product (band 4) contains a 182 bp insertion (the same as the larger product amplified earlier
35 from LIM1215 RNA) compared to the 250 bp amplicon. Unambiguous sequence for

the 400 bp band (band 3) is not obtained. Based on its size, it may contain the 182 bp insert but missing the 36 bp insertion present in bands 2 and 4 and absent from band 1.

To test the hypothesis that such a transcript exists, a primer, HTM2028F, is designed such that amplification ensues only when the 36 bp fragment was missing.

5 Amplification using HTM2028F and HT2026F primers in combination with HT2356R demonstrate that transcripts containing the 182 bp fragment but missing the 36 bp fragment are present in LIM1215 RNA (Figure 9, lanes a and b). The same top strand primers (HTM2028F and HT2026F) in combination with HT2482R primer amplify a number of products from LIM1215 RNA (Figure 9, lanes c and d), most of which
10 represent bands 1- 4 as determined by direct sequence analysis of PCR products. An amplified fragment of 650 bp using HTM2028F and HT2482R primers represents another, not yet fully characterized, alternatively spliced telomerase variant in the RT-MotifA/RT Motif B region. For clarity of presentation, the protein sequence giving the best match with *Euplotes* and *S. cerevisiae* proteins is presented in Figure 1 as the
15 reference sequence.

Specifically, there are at least seven inserts or introns that can be present (or absent) from telomerase RNA. (1) The 5'-most sequence (Y) is located between bases 222 and 223. (2) the insert (X) is located between bases 1766 and 1767. A partial sequence is determined and is presented in Figure 10. Termination codons are present
20 in all three reading frames. Thus, a truncated protein without any of the Rtas motifs would be produced. (2) A sequence, indicated as "1" in Figure 7, is located between bases 1950 and 1951. This intronic sequence is 38 bp (Figure 10) and appears to be present in ALT and most tumor lines. The presence of this sequence adds 13 amino acids and shifts the reading frame, such that a termination codon (TGA) is in frame at
25 nucleotide 1973. (3) A sequence, indicated as " α " in Figure 7, is located between bases 2130 and 2167. This sequence is 36 bp (Figure 10) and its absence removes RTase motif "A" but does not alter the reading frame. (4) A sequence, indicated as " β " in Figure 7 is present between bases 2286 and 2469. The insert is 182 bases (Figure 10) and its absence causes a reading frame-shift and a termination codon in RTase motif 5
30 at nucleotide 2604. (5) The sequence "2" in Figure 7 is present between bases 2823 and 2824. Its length is undetermined; its partial sequence is presented in Figure 10. The presence of this insert causes a truncated telomerase protein, as the first codon of the insert is a termination codon. (6) The sequence "3" is a 159 bp insert (Figure 10) between bases 3157 and 3158. Its presence leads to a telomerase protein with an altered
35 COOH-terminus. The insert contains a stop codon. Moreover, sequence "3" has a putative binding site for the SH3 domain of *c-abl* (PXXXXPXXP; PEMEPPRRP).

The transcript that most closely aligns with *Euplotes* and yeast telomerases by amino acid similarity contains sequences A and B, and does not contain sequence C. The nucleotide and amino acid sequences of eight variants resulting from mRNAs comprising combinations of sequences A, B, and C are presented in Figure 8.

5

EXAMPLE 6

RECOMBINANT EXPRESSION OF HUMAN TELOMERASE

10 Human telomerase is cloned into bacterial expression vectors. The sequence shown in Figure 1 is amplified from LIM 1215 mRNA in two pieces and then ligated together.

For the amplification, first strand cDNA is synthesized and used in an amplification reaction (Titan system, Boehringer, IN) with a mixture of DNA
15 polymerases, such that a proofreading thermostable enzyme (*e.g.*, *rTth*) is used with *Taq* DNA polymerase. As much of the mRNA in LIM 1215 lacks sequence B (Figure 9), the amplification primers are designed such that one primer of each pair is within sequence B, on either side of the *Sac* I site at nucleotide 2271 (Figure 1). The 5' portion is first amplified from cDNA using HT2356R and HT0028F primers (cycle conditions:
20 70°C, 2 min; then added primer sequences equilibrated to 50°C; 50°C, 30 min; 95°C, 2 min; 2 cycles of 94°C, 30 sec; 65°C, 30 sec; 3 cycles of 94°C, 30 sec; 63°C, 30 sec; 68°C 3 min; 32 cycles of 94°C, 30 sec; 60°C, 30 sec; 68°C, 3 min). The extreme 5' portion of the telomerase gene is then ligated in *Eco* RI/ *Sac* I digested pTTQ18 (Amersham International plc, Buckinghamshire, England) and pBluescriptII KS+, and the sequence
25 verified.

To obtain the 3' end, LIM 1215 cDNA is amplified using HT2230F and a HT3292B primer that is complementary to the sequence encoding the very C-terminus of telomerase. The amplification products are digested with *Hind* III and *Sac* I and inserted into pTTQ18 and pBluescript II KS+. The 5' and 3' ends are also cloned joined
30 at the native *Sac* I site in pTTQ18 both as a Hexa-His fusion and a non-fusion protein.

The plasmid pTTQ18-Htel is transfected into bacterial cells (*e.g.*, BL21(DE3)). Over expression of the protein is accomplished upon induction with IPTG. The bacteria are collected by centrifugation and lysed in lysis buffer (20 mM NaPO₄, pH 7.0, 5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0.5 µg/ml leupeptin, 1 µg/ml
35 aprotinin, 0.7 µg/ml pepstatin). This mixture is evenly suspended via a Polytron homogenizer and the cells are broken open by agitation with glass beads or passage

through a microfluidizer. The resulting lysate is centrifuged at 50,000 rpm for 45 min. The supernatant is diluted with 20 mM NaPO₄, 1 mM EDTA, pH 7.0 (buffer A). The diluted lysate supernatant is then loaded onto a SP-Sepharose or equivalent column, and a linear gradient of 0 to 30% SP Buffer B (1 M NaCl, 20 mM NaPO₄, 1 mM EDTA, pH 7.0) in Buffer A with a total of 6 column volumes is applied. Fractions containing telomerase are combined. Further purifications can be performed.

For hexa-His fusion proteins, the lysate is clarified by centrifugation and batch absorbed on a Ni-IDA-Sepharose column. The matrix is poured into a column and washed with buffer, typically either 50 mM Tris pH 7.6, 1 mM DTT; 50 mM MES pH 7.0, or IMAC buffer (for hexa-his fusions). The telomerase protein bound to the matrix is eluted in NaCl containing buffer.

EXAMPLE 7

RECOMBINANT EXPRESSION OF HUMAN TELOMERASE RNA COMPONENT

The human telomerase RNA component is first isolated by amplification from genomic DNA. The amplification primers are telRNA T and telRNA 598B (Figure 5). Amplification conditions are 95°C, 3 min; addition of polymerase; 80°C 2 min; 35 cycles of 94°C, 30 sec; 68°C, 2 min.

The amplified product is inserted into pBluescript after another amplification using hTR TAC (has a tac promoter sequence) and hTR 3'Pst (has a cis-acting ribozyme sequence) primers. The pBluescript insert is then isolated and ligated to pACYC177.

EXAMPLE 8

EXPRESSION OF HUMAN TELOMERASE SUBREGIONS

The RTase domain of human telomerase is determined by sequence comparison with Moloney MuLV reverse transcriptase. The fingers/palm region of Moloney MuLV reverse transcriptase forms a stable unit for crystallization (Georgiadis et al., *Structure* 3: 879, 1995). A number of residues and motifs are conserved in the active site of both proteins. Primers are designed to amplify the RTase domain and the fingers/palm domain for insertion into an expression vector and subsequent protein isolation.

Fragment ID	Primers	Amino acids
I	BT-177 / BT-178	AAEH...→ ...VQMPAH
II	BT-177 / BT-179	AAEH... → ...VGLGL
III	BT-182 / BT-179	RATS... → ...VGLGL
IV	BT-183 / BT-179	VQMPAH...→ ...VGLGL

Fragment I encodes the "fingers and palm" domain that corresponds to MoMuLV. The C-terminal "thumb" and "connection" (see, Kohlstaedt et al., *Science* 5 256: 1783, 1992) are deleted. Fragment II encodes the telomerase reverse transcriptase domain, as well as the C-terminal "connection" domain. The N-terminus is chosen by size comparison with the MoMuLV RTase structure. Fragment III encodes the C-terminus of the protein. The RATS sequence is located within the RTase domain (palm region) of the protein. Fragment IV encodes the C-terminal region containing the 10 "thumb" and "connection" domains and may function as a regulatory element. The connection domain in HIV-1 is able to block the catalytic cleft of HIV RTase in the absence of the RNase domain (Kohlstaedt et al, *supra*). In an analogous fashion, the C-terminal region may be useful as a regulatory (inhibitory) fragment. Moreover, sequence C has a putative binding site for the SH3 domain of *c-abl* (PXXXXPXXP; 15 PEMEPPRRP, see variant 2 sequence of Figure 8). *c-abl* protein interacts directly with the ATM (ataxia telangiectasia) protein (Shafman et al., *Nature* 389: 520, 1997), a protein apparently involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA damage response. Binding of *c-abl* protein may be assessed in standard protein-protein interaction methods. As such, an interaction of telomerase and 20 *c-abl* or other SH3-domain containing proteins (e.g., *erb2*) and regulation by movement of the telomerase C-terminus in and out of the catalytic cleft may be controllable using the constructs and products described herein. In one instance, regulation may be mediated by phosphorylation/dephosphorylation reactions.

All primers have either a *Hind* III or a *Bam* HI site. The amplification 25 reaction is performed in 1X *Pfu* buffer, 250 μM dNTPs, 100 ng each primer, clone 53.2 template DNA using the following cycling conditions: 94°C for 2 min; 25 cycles of either 55°C, 60°C. or 65°C for 2 min, 72°C for 2 min, 94°C for 1 min; followed by 72° C for 10 min. Products of the predicted length are obtained (966 bp for BT-177/BT-178; 1479 bp for BT-177/BT-179; 824 bp for BT-182/BT-179; 529 bp for BT-183/BT- 30 179). The amplified products are extracted with phenol:CHCL3 and precipitated with

ethanol. The products are resuspended and digested with the appropriate enzyme that cleaves in the primer sequence.

The digested products are ligated to pBluescript that is digested with enzymes that leave compatible ends. The inserts are digested with *Hind* III and partially digested with *Bam* HI for ligation to pGEX. The plasmid is transfected in BL21(DE3) cells and selected on ampicillin plates. Colonies are picked and grown overnight in liquid broth. An aliquot is diluted in Terrific Broth with 100 µg/ml ampicillin. The cells are grown at 37°C and induced with 0.5 mM IPTG at approximately O.D. 0.8. Growth is continued for 5 hours. Cells are collected by centrifugation and may be processed immediately or frozen at -70°C until needed.

Protein is purified from lysed cells. Cell pellets are lysed by vortexing in 50 mM Tris pH 8.0, 10 mM 2-ME, 1 mg/ml lysozyme, 0.5% Triton X-100, 1 µg/ml pepstatin, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 0.5 mM PMSF, and 2 mM EDTA and a freeze/thaw cycle. Lysates are clarified by centrifugation. Supernatant is added to a 50% slurry of GSH-Sepharose, rotated at 4°C for 2 hr. The matrix is washed twice with lysis buffer, followed by 50 mM Tris, pH 8.0, 10 mM 2-ME. For analysis by SDS-PAGE gel electrophoresis, sample buffer with 150 mM 2-ME is added and the samples boiled.

20

EXAMPLE 9

ISOLATION OF MURINE TELOMERASE GENE

The murine telomerase gene is isolated from genomic or cDNA library. A mouse genomic library is constructed in λFIX II vector from strain 129 DNA. The library is plated, and plaques are lifted onto nylon membranes. The membranes are hybridized with the insert from clone 53.1 (1.9 kb) under normal stringency conditions. Six hybridizing plaques are chosen for further analysis.

30

EXAMPLE 10

DEMONSTRATION OF TELOMERASE ACTIVITY USING HT-1 AND TELOMERASE VARIANTS

Full-length hT-1 sequence is cloned into an expression vector and the resulting protein is assayed for telomerase activity. Vector pRc/CMV2 (Invitrogen, Carlsbad, CA) is a eukaryotic expression vector that has a multi-cloning site positioned

between a promoter, the RSV LTR, and a polyadenylation signal and transcription termination sequences from the bovine growth hormone gene. Telomerase sequence in which Leu49 codon was converted to a Met codon was inserted into pRc/CMV2. One clone, pHTC51, is chosen for further study. The DNA sequence of the 5' junction was
5 determined and confirmed the orientation of the insert. Subsequently, the sequence of the 3' junction was determined and showed a deletion of the polyA signal, but no deletion of telomerase coding sequence.

The clone is transfected into HeLa GM847 cells at passages 44 and 68, SUSM-1 cells at passage 18, and RKF-T/A6 cells at passage 40. Cell extracts are
10 assayed for telomerase activity by the TRAP assay as described herein. As shown in Figure 12, a ladder of products indicative of telomerase activity is seen at the 1:100 dilution of extract from SUSM-1 cells and is not seen in control cells. A ladder is not readily detectable at the higher concentration of extract, which may be due to nuclease activity in the extract.

15 Three telomerase variants are constructed: pAKI.4 is telomerase with the beta region spliced out (Figure 13); pAKI.7 is telomerase with the alternative C-terminus insert 3 (Figure 14); and pAKI.14 is telomerase with the alpha region spliced out (Figure 15). The 5' end of the telomerase gene was inserted into each of these three vectors and the inserts moved to pCIneo expression vector. The variants, along with
20 reference telomerase in pCIneo are transiently transfected into GM847 cells, which are ALT cells having no detectable telomerase activity but which express the RNA subunit. Cell extracts are tested in a TRAP assay. The reference telomerase exhibits activity, as well as the telomerase with insert 3 (pAKI.7 insert), but the other variants do not express activity.

25

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. An isolated nucleic acid molecule encoding vertebrate telomerase.
2. The isolated nucleic acid molecule according to claim 1 wherein said vertebrate is a human.
3. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises the sequence presented in Figure 1, or hybridizes under normal stringency conditions to the complement of the sequence presented in Figure 1, provided that the nucleic acid molecule is not EST AA281296.
4. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes the amino acid sequence presented in Figure 1 or 11, or variant thereof.
5. An isolated nucleic acid molecule encoding any of the amino acid sequences presented in Figure 11, or hybridizes under normal stringency conditions to the complement of the sequences thereof, provided that the nucleic acid molecule is not EST AA281296.
6. An isolated nucleic acid molecule comprising any of the sequences presented in Figure 10, or hybridizes under normal stringency conditions to the complement of the sequences thereof.
7. An oligonucleotide comprising from 10 to 100 contiguous nucleotides from the sequence presented in Figure 1 or its complement.
8. An oligonucleotide comprising from 10 to 100 contiguous nucleotides from the sequences presented in Figure 10 or the complements thereof.
9. The oligonucleotide of either of claims 7 or 8, wherein the oligonucleotide is labeled.

10. The oligonucleotide of claim 9, wherein the label is a radiolabel, a chemiluminescent label, or biotin.
11. An expression vector, comprising a heterologous promoter operably linked to a nucleic acid molecule according any of claims 1-6.
12. The expression vector of claim 11, wherein the vector is selected from the group consisting of bacterial vectors, retroviral vectors, adenoviral vectors and yeast vectors.
13. A host cell containing a vector according to either claims 11 or 12.
14. The host cell of claim 13, wherein the cell is selected from the group consisting of human cell, monkey cell, mouse cell, rat cell, yeast cell and bacterial cell.
15. The host cell of claim 13, wherein the cell is a human cell.
16. An isolated protein comprising a vertebrate telomerase protein.
17. The protein of claim 16, wherein the vertebrate is a human.
18. The protein of claim 16, wherein the protein comprises the amino acid sequence presented in Figure 1 or 11, or variant thereof.
19. A portion of a vertebrate telomerase protein.
20. The portion of claim 19, wherein the amino acid sequence of the portion is presented in Figure 1.
21. The portion of claim 19, wherein the amino acid sequence of the portion is presented in Figure 11.
22. The portion of claim 19, wherein the portion is from 10 to 100 amino acids long.

23. An antibody that specifically binds to the protein according to either claim 16 or 19.
24. An antibody that specifically binds to a polypeptide encoded by a sequence selected from the group consisting of region 1, region α , region β , region 2 and region 3.
25. The antibody according to claim 24, wherein the antibody is a monoclonal antibody.
26. A hybridoma that produces an antibody according to claim 14.
27. A nucleic acid probe that is capable of specifically hybridizing to a nucleic acid molecule encoding a vertebrate telomerase under conditions of normal stringency, provided that the probe does not hybridize to nucleotides 1624-2012 presented in Figure 1.
28. The probe of claim 27, wherein the probe is from 12 to 200 nucleotides long.
29. The probe of claim 27, wherein the probe is from 20 to 50 nucleotides long.
30. The probe of claim 17, wherein the nucleic acid molecule has the sequence presented in Figure 1 or its complement thereof.
31. The probe of claim 17, wherein the nucleic acid molecule is labeled.
32. A pair of oligonucleotide primers capable of specifically amplifying all or a portion of a nucleic acid molecule encoding human telomerase.
33. The primers of claim 32, wherein the nucleic acid molecule comprises the sequence presented in Figure 1 or its complement.
34. The primers of claim 32, wherein the nucleic acid molecule comprises any of the sequences presented in Figure 11 or the complements thereof.

35. The primers of claim 32, wherein the pair of primers is capable of specifically amplifying sequence comprising all or a part of region 1, region α , region β , region 2, region 3 region X or region Y.

36. The primers of claim 35, wherein the primers flank nucleotide 222, 1950, 2131-2166, 2287-2468, 2843, or 3157 as presented in Figure 1.

37. The primers of claim 36, wherein only one of each primer pair flanks nucleotide 222, 1950, 2131-2166, 2287-2468, 2843, or 3157 as presented in Figure 1 and the other primer of the pair has sequence corresponding to one of the sequences presented in Figure 10 or complements thereof.

38. A pair of oligoprimers capable of specifically amplifying genomic sequence presented in Figure 10, wherein the primers amplify more than nucleotides 1 to 38.

39. An oligonucleotide that hybridizes specifically to a nucleic acid sequence in region 1, region α , region β , region 2, region 3 region X or region Y.

40. The oligonucleotide of claim 39, wherein the oligonucleotide is from 15 to 36 bases.

41. A method of diagnosing cancer in a patient, comprising preparing tumor cDNA and amplifying the tumor cDNA using primers that specifically amplify human telomerase nucleic acid sequence, wherein the detection of telomerase nucleic acid sequences is indicative of a diagnosis of cancer.

42. The method of claim 41, further comprising comparing the amount of amplified telomerase sequence to a control, wherein increase telomerase nucleic acid sequences over the control is indicative of a diagnosis of cancer.

43. The method of claim 41, wherein the primers span region 1, region α , region β , region 2, region 3 region X or region Y, wherein the pattern of amplification is indicative of a diagnoses of cancer.

44. The method of claim 43, wherein the primers are Htel Intron T and Htel 723B.

45. The method of claim 44, wherein the primers are Htel335T and Htel1022B.

46. A method of determining a pattern of telomerase RNA expression in cells, comprising preparing cDNA from mRNA isolated from the cells, amplifying the cDNA using primers according to claim 35, therefrom determining the pattern of telomerase RNA expression.

47. The method of claim 46, further comprising detecting the amplified product by hybridization with an oligonucleotide having all or part of the sequence of region 1, region α , region β , region 2, region 3 region X or region Y.

48. A method of diagnosing cancer in a patient, comprising determining a pattern of telomerase RNA expression, comprising amplifying telomerase from cDNA synthesized from tumor RNA, and detecting the amplified product by hybridization with an oligonucleotide having all or part of the sequence of region 1, region α , region β , region 2, region 3 region X or region Y, therefrom determining the pattern of telomerase RNA expression, wherein the pattern is indicative of a diagnosis of cancer.

49. The method of claim 48, further comprising comparing the pattern to a pattern obtained from a reference cancer.

50. A non-human transgenic animal whose cells contain a vertebrate telomerase gene that is operably linked to a promoter effective for the expression of the gene.

51. The animal of claim 50, wherein the animal is a mouse.

52. The animal of claim 50, wherein the promoter is tissue-specific.

53. The animal of claim 50, wherein the telomerase gene is any of the nucleic acid sequences presented in Figure 11.

54. A mouse, whose cells have an endogenous telomerase gene disrupted by homologous recombination with a nonfunctional telomerase gene, wherein the mouse is unable to express endogenous telomerase .

55. An inhibitor of vertebrate telomerase activity, wherein the inhibitor binds to telomerase and is not a nucleoside analogue.

56. The inhibitor of claim 55, wherein the vertebrate is a human.

57. The inhibitor of claim 55, wherein the inhibitor is antisense nucleic acid complementary to human telomerase mRNA.

58. The inhibitor of claim 57, wherein the antisense is complementary to region α , region β , region 2, region 3 or region X.

59. The inhibitor of claim 55, wherein the inhibitor is a ribozyme.

60. A method of treating cancer, comprising administering to a patient a therapeutically effective amount of an inhibitor according to claim 55.

61. A nucleic acid molecule comprising the sequence selected from the set consisting of sequences selected from region 1, region α , region β , region 2 or region 3 as presented in Figure 10 and variants thereof.

62. A method of identifying an effector of telomerase activity comprising:

(a) adding a candidate effector to a mixture of telomerase protein, RNA component and template, wherein the telomerase protein is encoded by an isolated nucleic acid molecule according to claim 1;

(b) detecting telomerase activity; and

(c) comparing the amount of activity in step (b) to the amount of activity in a control mixture without candidate effector, therefrom identifying an effector.

63. The method of claim 62, wherein the effector is an inhibitor.


64. the method of claim 62, wherein the nucleic acid molecule encodes human telomerase.

HUMAN TELOMERASE

ATGCCGCGCGCTCCCCGCTGCCGAGCCGTGCGCTCCCTGCTGCCGAGCCACTACCGCGAG	60
MetProArgAlaProArgCysArgAlaValArgSerLeuLeuArgSerHisTyrArgGlu	20
GTGCTGCCGCTGGCCACGTTCTGTCGGCGCCTGGGGCCCCAGGGCTGGCGGCTGGTGCAG	120
ValLeuProLeuAlaThrPheValArgArgLeuGlyProGlnGlyTrpArgLeuValGln	40
CGCGGGGACCCGGCGGCTTTCGCGCGCTGGTGGCCAGTGCCTGGTGTGCGTGCCCTGG	180
ArgGlyAspProAlaAlaPheArgAlaLeuValAlaGlnCysLeuValCysValProTrp	60
GACGCACGGCCGCCCCCGCGCCCCCTCCTCCGCCAGGTGTCCTGCCTGAAGGAGCTG	240
AspAlaArgProProProAlaAlaProSerPheArgGlnValSerCysLeuLysGluLeu	80
GTGGCCCGAGTGCTGCAGAGGCTGTGCGAGCGCGGCGGAAGAACGTGCTGGCCTTCGGC	300
ValAlaArgValLeuGlnArgLeuCysGluArgGlyAlaLysAsnValLeuAlaPheGly	100
TTCGCGCTGCTGGACGGGGCCGCGGGGGCCCCCGAGGCCTTCACCACCAGCGTGCGC	360
PheAlaLeuLeuAspGlyAlaArgGlyGlyProProGluAlaPheThrThrSerValArg	120
AGCTACCTGCCCAACACGGTGACCGACGCACTGCGGGGGAGCGGGGCGTGGGGGCTGCTG	420
SerTyrLeuProAsnThrValThrAspAlaLeuArgGlySerGlyAlaTrpGlyLeuLeu	140
TTGCGCCGCGTGGGCGACGACGTGCTGGTTACCTGCTGGCACGCTGCCGCTCTTTGTG	480
LeuArgArgValGlyAspAspValLeuValHisLeuLeuAlaArgCysAlaLeuPheVal	160
CTGGTGGCTCCAGCTGCGCCTACCAGGTGTGCGGGCCGCGCTGTACCAGCTCGGCGCT	540
LeuValAlaProSerCysAlaTyrGlnValCysGlyProProLeuTyrGlnLeuGlyAla	180
GCCACTCAGGCCCGGCCCGCCACACGCTAGTGGACCCGAAGGCGTCTGGGATGCGAA	600
AlaThrGlnAlaArgProProProHisAlaSerGlyProArgArgArgLeuGlyCysGlu	200
CGGGCCTGGAACCATAGCGTCAGGGAGGCCGGGTCCCCCTGGGCCTGCCAGCCCCGGT	660
ArgAlaTrpAsnHisSerValArgGluAlaGlyValProLeuGlyLeuProAlaProGly	220
GCGAGGAGGCGCGGGGCGAGTGCCAGCCGAAGTCTGCCGTTGCCAAGAGGCCAGGCGT	720
AlaArgArgArgGlyGlySerAlaSerArgSerLeuProLeuProLysArgProArgArg	240

Fig. 1A

12/68

*Fig. 7A*

Variants:	1	α	β	2	3
RT-PCR product	NO	+	+	NO	+ & -
PCR from LIM1215 lib.	-	+	-	+	NO
RT-PCR product	NO	-	+	NO	+
53.2 cDNA	-	-	-	-	NO

Fig. 7B

13/68

222
 Y 5'-CCAGGTG|ggcctc
 223
 gcagggtg|TCCTGCC-3'

1950
 1 5'-AAAGAGG|GTGGCTG.....AACAGAA|GCCGAGC-3'
 1952

2130
 α 5'-TGTCAAG|gtggatg.....ccccag|GACAGGC-3'
 2167

2286
 β 5'-GAGCCAC|gtctcta.....ggggcaa|GTCCTAC-3'
 2468

2843
 2 5'-ACTCCAG|GTGAGCG.....XXXXXXX|CTATGCC-3'
 2844

3157
 3 5'-AACGCAG|CCGAAGAAACATTTCTGTCGTGACTCCTGCGGTGCTTGGGTCGGGACAGCCAGAGATGG
 T A A E E N I L V V T P A V L G S G Q P E M E
 AGCCACCCCGCAGACCGTCGGGTGTGGGCAGCTTTCGGGTGTCTCCTGGGAGGGGAGTTG
 P P R R P S G V G S F P V S P G R G V G
 3158
 GGCTGGGCCTGTGACTCCTCAGCCTCTGTTTTCCCCCAG|GGATGTC-3'
 L G L *

Fig. 7C






Fig. 5

*Fig. 6*

*Fig. 3*




Fig. 4

Euplotes 1 -----MEVDVDNQADNHGHSALKTCCEEIKEAKTLYSWIQKVIRCR--NQSQSHYKDLEDIK
 HT1 1 RRLGPGQWRLVQRGDPAAFRALVAQCLVCVPWDAR-PPPAAPSFQVSCLELVARVLQRLCERGAKNVLAFGFALLDGA
 EST2 1 -----MKILFEFIQDKLDID--LQTNSTYKENLKCG

Euplotes 56 IFAQTNIVATPRDYNEEDFKVIARK-----EVFSTGLMIELIDKCLVELLSDDVSDRQKLCQCFGQKGMQ-LAK
 HT1 80 RGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAY---QVCGPPLYQLGAATQA
 EST2 30 HFNGLDEILT-FCALPNSRKIALP-----CLPGDLSHKAVIDHCIIYLLTGELYN---VLTFGYKIARWEDVNN

Euplotes 126 THLLTALSTQKQYFFQDEWQVRAMIGNELFRHLYTKYLIFQRTSEGLVQFCGMNVFDHLKVNDKFDKKQKGAADMNE
 HT1 157 RPPPHASGPRRLGGERAWHSHVREAGVPLGLPAGARRRGGSASRSLPLPKRPRGAAPPEPERTPVGGSSWAHPGRTRG
 EST2 97 SLFCHSANVNVTLLKGAWKMFHSLVGTYAFVDLLINYTVIQFNGQ-FFTQIVGNRCNEPHLPKWVQRSSS-----

Euplotes 206 PRCCSTCKYNVKNKDHFLVNI-----NVPNWNMKSRTIFCYTHFNRRNQFF
 HT1 237 PSDRGFCVVSAPRAEAEATSLLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTCPPVYAETKHFLYSSGDK--EQLR
 EST2 169 ----SATAAQIKQLTEPVTN-----KQFLHKLIN-SSSFF

Euplotes 255 KKHEFVSNKNNISAM-DRAQTIFTNI-----FRFNTRKKLKDVKIEKIAYMLEKVDFNFNYLTKSCPLPENWRE
 HT1 315 PSFLLSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRY-WQMRPLFLELLGNWAQCPYGVLLKTHCPRAAVTP
 EST2 200 PYSKILPSSSSIKKLTDLREAIFF-----TNLVKIPQLKVRINLTQKLLKRHKRLNYSILNSTCPPLEGT--

Telomerase domain

Euplotes 326 RK-----QKIENLINKTREEKS--KYEEELFSYTTDNKCITQFZINEFFYNILPKDFLTGR-NRKNFQKKVKYVELNKHE
 HT1 394 AAGVCAREKPGGSVAAPPEEDTDPRLVQLLRQHSSPWQVYGFVRACLRLVPPGLWGSRRHWERRFLNKKFISLGKHA
 EST2 268 -----VLDLSHLSRQ-----SPKERVLKFIVILQKLLPOEMFGSKKWKGIKVLNLLLSLPLNG

Euplotes 398 LIHKNLLEKINTREISWQVET-SAKHFYFDHENIYVLWKLRLWIFEDLVVSLIRCFFVYTEQKSYSKTYYYRKNIH
 HT1 474 KLSLQELTWKMSVRDCAWLRSPGVGCVPAAEHRLREEILAKFLHLMNSVYVVELLRFFVYTETTFQKNRLFFYRKSVW
 EST2 324 YLPFDSLLKKLRKDFRWFISD-IWFTKHNFENLN-QLAICFISHLFRQLPKIQTFFYCTEIS-STVTIVYFRHDTW

Motif 1 Motif2

Euplotes 477 DVIMKNSIADLKK-ETLAEVQEKEVEEWKSL-GFAPGKLRLIPKTT--FRPIMTFNKKIVNSDRK--TTKLTNTKLL
 HT1 554 SKLQSIGIROHLKRVOLRELSAEVROHREARALLSLRFIPKPDG--LRPIVNDYVVGARTFRREKRAERLTSRVK
 EST2 401 NKLITPFIVEYFK-TYLVENNVCNRHNHNSYLS-NFNHSMRIIPKKSNEFRIJAIPCRGADEEFT--IYKENHKNAIQ

Fig. 2A

Motif A

Euplotes 551 NSHMLKTLKN-RMFKDPFGFAVFNYDDVMKKYEEFVCKWKQVGQP-KLFFATMDIEKCYDSVNRKLSFLKTKLLSS
 HT1 632 ALFSLVNYERARR--PGLLGASVLGLDDIHRWRTFVLRVRAQDPPELYFVKVDVTGAYDTIPDRLTEVIAIIPON
 EST2 477 PTQKILEYLRMKRPTSFTKIYSPTQIADRIKEFKQRLKKFNNVLP-ELYFKFDYKSCYDSIPRMECMRILKDALKNEN

Euplotes 629 DFWIMTAQILKRKNIVIDSKWFRKKEMKDYFRQFKQIALEGGQYPTLFSVLENEQNDLNAKKTIVEAK-QRWYFKD
 HT1 710 TYCVRRYAVVQAAHGHVRKAFKSHVS-----TLTDLPYMRQFVAHLQETSPLRDAVVIEQSSSLWEASSG
 EST2 556 GFFVRSQYFFN-TNTGV/LKLFNVN-----A--SRVPKPYELYIDNVRTVHLSNQDVINVV-EMEIFKT-

Motif B Motif C

Euplotes 708 NLLQPVINICQYNYINFNGKFYKQTKGIPQGLCVSSILSSFYATLEESSLGFLRDESMNPENPNVLLMRLTDDYLLIT
 HT1 777 LFDVFLRFMCHAVRIR-GKSYVQCQGIQGSILSTLLCSLCYGMEN---KLFAIRRD-----GLLLRLVDDFLVLT
 EST2 616 --ALWVEDKCYIR-----EDGLFQGSLSAPIVDLVYDDLLEFYSEFKASPSOD-----TLILKLAODFLIIS

Motif D Motif E

Euplotes 788 TQENNAVLFEKLINVSRENGFKFAMKKLQTSFPLSPSKFAKYGMDSVEEQNIVQDYCDWIGISIDNKTALMPNIMLRI
 HT1 847 PHLTHAKTFLRTLVRGVPEYGCVMRLRKTVVNFPEDEALGG-TAFVQMPAHGLFPHCGLLDTRTLEVSQDYSSYAR--
 EST2 677 TDQQ-QVINIKKLAMG---GFQKYNAPANRDKILAVS-----SQSDDDTVIQFCAMHIFVKELEVWKHSSTMW---

Euplotes 868 EGILCTLNLNMOTKKASMLKKKLKSLMNNITHYFRKTITTEDFANKTLNKLFISSGYKYMCAKEY--KDHFKKMLAM
 HT1 924 TSIRASLTFRNGFKAGRNMRKLFGLVRLKCHSLFLDLQVNSLOTVCTNIYKILLQAYRFHACVLQLPFHQQVWKNPTF
 EST2 741 -----NFHIRSKSS---KGIFRSLIALFNTRISYKTIDTNLNSTNTVLMQIDHVKNISECYKSA--FKDLSIMVTQ

Euplotes 946 SSMIDLEVSKIIYSVTRAFFKYLCNINOTIFGEEHYDPDFLSTLKHFIETSTKKYIFNRVCMZLKAKEAKLKSDQCQS
 HT1 1004 FLRVISDTASLCYSTLKAKNAGMSLGAKGAAGPLPSEAVQMLC-HQAFLLKLTRHRVTYVPLLSLRTAQTLRKLPGT
 EST2 808 NMQFHSFLQRJIZMTVSG----CPITKCDPLIEYEV--FTI--LNGFLESLSNTSKF-KDNIIJLLRKEIQHLQAYIYI

Euplotes 1026 LQYDA-----
 HT1 1083 TLTALEAAANPALPSDFKTILD
 EST2 879 YIHIVN-----

Fig. 2B

AGCCACGTCTCTACCTTGACAGACCTCCAGCCGTACATGCGACAGTTCGTGGCTCACCTG SerHisValSerThrLeuThrAspLeuGlnProTyrMetArgGlnPheValAlaHisLeu	2340 780
CAGGAGACCAGCCCGCTGAGGGATGCCGTCGTCATCGAGCAGAGCTCCTCCCTGAATGAG GlnGluThrSerProLeuArgAspAlaValValIleGluGlnSerSerSerLeuAsnGlu	2400 800
GCCAGCAGTGGCCTCTTCGACGTCTTCTACGCTTCATGTGCCACCAGCCGTGCGCATC AlaSerSerGlyLeuPheAspValPheLeuArgPheMetCysHisHisAlaValArgIle	2460 820
AGGGGCAAGTCTACGTCCAGTGCCAGGGGATCCCGCAGGGCTCCATCCTCTCCACGCTG ArgGlyLysSerTyrValGlnCysGlnGlyIleProGlnGlySerIleLeuSerThrLeu	2520 840
CTCTGCAGCCTGTGCTACGGCGACATGGAGAACAAGCTGTTTGCGGGGATTGCGCGGGAC LeuCysSerLeuCysTyrGlyAspMetGluAsnLysLeuPheAlaGlyIleArgArgAsp	2580 860
GGGCTGCTCCTGCGTTTGGTGGATGATTTCTTGTGGTGACACCTCACCTCACCACGCG GlyLeuLeuLeuArgLeuValAspAspPheLeuLeuValThrProHisLeuThrHisAla	2640 880
AAAACCTTCTCAGGACCCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTG LysThrPheLeuArgThrLeuValArgGlyValProGluTyrGlyCysValValAsnLeu	2700 900
CGGAAGACAGTGGTGAACCTCCCTGTAGAAGACGAGGCCCTGGGTGGCACGGCTTTTGTT ArgLysThrValValAsnPheProValGluAspGluAlaLeuGlyGlyThrAlaPheVal	2760 920
CAGATGCCGGCCACGGCCTATCCCTGGTGCGGCCTGCTGCTGGATACCCGGACCCTG GlnMetProAlaHisGlyLeuPheProTrpCysGlyLeuLeuLeuAspThrArgThrLeu	2820 940
GAGGTGCAGAGCGACTACTCCAGCTATGCCCGGACCTCCATCAGAGCCAGTCTCACCTTC GluValGlnSerAspTyrSerSerTyrAlaArgThrSerIleArgAlaSerLeuThrPhe	2880 960
AACCGCGGCTTCAAGGCTGGGAGGAACATGCGTCGAAACTCTTTGGGGTCTTGCGGCTG AsnArgGlyPheLysAlaGlyArgAsnMetArgArgLysLeuPheGlyValLeuArgLeu	2940 980
AAGTGTACAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGACGGTGTGCACCAAC LysCysHisSerLeuPheLeuAspLeuGlnValAsnSerLeuGlnThrValCysThrAsn	3000 1000
ATCTACAAGATCCTCCTGCTGCAGGCGTACAGGTTTCACGCATGTGTGCTGCAGCTCCCA IleTyrLysIleLeuLeuLeuGlnAlaTyrArgPheHisAlaCysValLeuGlnLeuPro	3060 1020

Fig. 1D

TTTCATCAGCAAGTTTGAAGAAGCCACATTTTCTGCGCGTCATCTCTGACACGGCC	3120
PheHisGlnGlnValTrpLysAsnProThrPhePheLeuArgValIleSerAspThrAla	1040
TCCCTCTGCTACTCCATCCTGAAAGCCAAGACGCAGGGATGTCGCTGGGGGCCAAGGGC	3180
SerLeuCysTyrSerIleLeuLysAlaLysAsnAlaGlyMetSerLeuGlyAlaLysGly	1060
GCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCTGCTC	3240
AlaAlaGlyProLeuProSerGluAlaValGlnTrpLeuCysHisGlnAlaPheLeuLeu	1080
AAGCTGACTCGACACCGTGTACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAG	3300
LysLeuThrArgHisArgValThrTyrValProLeuLeuGlySerLeuArgThrAlaGln	1100
ACGCAGCTGAGTCGGAAGCTCCCGGGGACGACGCTGACTGCCCTGGAGCGCGCAGCCAAC	3360
ThrGlnLeuSerArgLysLeuProGlyThrThrLeuThrAlaLeuGluAlaAlaAlaAsn	1120
CCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACTgatggccacccgcccacagccag	3420
ProAlaLeuProSerAspPheLysThrIleLeuAsp	1132
Gccgagagcagacaccagcagccctgtcacgccgggctctacgtcccagggagggagggg	3480
Cggcccacacccaggcccgaccgctgggagctctgaggcctgagtgagtgtttggccgag	3540
gcctgcatgtccggctgaaggctgagtgtccggctgaggcctgagcgagtgtccagccaa	3600
gggctgagtgtccagcacacctgccgtcttcacttccccacaggctggcgctcggctcca	3660
ccccagggccagcttttcctcaccaggagcccggttccactccccacataggaatagtc	3720
catccccagattcgccattgttcacccctgccctgccctcctttgccttcacccccac	3780
catccaggtggagaccctgagaaggaccctgggagctctgggaatttgagtgaccaaag	3840
gtgtgccctgtacacaggcgaggaccctgcacctggatgggggtccctgtgggtcaaatt	3900
ggggggagggtgctgtgggagtaaaatactgaatatatgagttttcagttttgaaaaaa	3960
aaaa	3964

Fig. 1E

2 / 68

GGCGCTGCCCTGAGCCGGAGCGGACGCCCCTTGGGAGGGGTCTGGGCCACCCGGGC	780
GlyAlaAlaProGluProGluArgThrProValGlyGlnGlySerTrpAlaHisProGly	260
AGGACGCGTGGACCGAGTGACCGTGGTTTCTGTGTGGTGTACCTGCCAGACCCGCGAA	840
ArgThrArgGlyProSerAspArgGlyPheCysValValSerProAlaArgProAlaGlu	280
GAAGCCACCTCTTTGGAGGGTGGCTCTCTGGCAGCGCCACTCCCACCCATCCGTGGGC	900
GluAlaThrSerLeuGluGlyAlaLeuSerGlyThrArgHisSerHisProSerValGly	300
CGCCAGCACCGCGGGCCCCCATCCACATCGCGGCCACCAGTCCCTGGGACAGCCT	960
ArgGlnHisHisAlaGlyProProSerThrSerArgProProArgProTrpAspThrPro	320
TGTCCCCCGGTGTACGCCGAGACCAAGCACTTCTCTACTCCTCAGGCGACAAGGAGCAG	1020
CysProProValTyrAlaGluThrLysHisPheLeuTyrSerSerGlyAspLysGluGln	340
CTGCGGCCCTCTTCTACTCAGCTCTCTGAGGCCAGCCTGACTGGCGCTCGGAGGCTC	1080
LeuArgProSerPheLeuLeuSerSerLeuArgProSerLeuThrGlyAlaArgArgLeu	360
GTGGAGACCATCTTTCTGGGTTCCAGGCCCTGGATGCCAGGGACTCCCCGAGGTTGCC	1140
ValGluThrIlePheLeuGlySerArgProTrpMetProGlyThrProArgArgLeuPro	380
CGCCTGCCCCAGCGCTACTGGCAAATGCGGCCCTGTTTCTGGAGCTGCTTGGGAACCAC	1200
ArgLeuProGlnArgTyrTrpGlnMetArgProLeuPheLeuGluLeuLeuGlyAsnHis	400
GCGCAGTGCCCTACGGGGTGCTCCTCAAGACGCACTGCCCGCTGCGAGCTGCGGTACC	1260
AlaGlnCysProTyrGlyValLeuLeuLysThrHisCysProLeuArgAlaAlaValThr	420
CCAGCAGCCGGTGTCTGTGCCCGGAGAAGCCCCAGGGCTCTGTGGCGCCCCCGAGGAG	1320
ProAlaAlaGlyValCysAlaArgGluLysProGlnGlySerValAlaAlaProGluGlu	440
GAGGACACAGACCCCGTCGCTGGTGACGCTGCTCCGCCAGCACAGCAGCCCTGGCAG	1380
GluAspThrAspProArgArgLeuValGlnLeuLeuArgGlnHisSerSerProTrpGln	460
GTGTACGGCTTCGTGCGGGCCTGCCTGCGCGGCTGGTGCCCCAGGCCTCTGGGGCTCC	1440
ValTyrGlyPheValArgAlaCysLeuArgArgLeuValProProGlyLeuTrpGlySer	480
AGGCACAACGAACCGCTTCCTCAGGAACACCAAGAAGTTCATCTCCCTGGGAAGCAT	1500
ArgHisAsnGluArgArgPheLeuArgAsnThrLysLysPheIleSerLeuGlyLysHis	500

3 / 68

GCCAAGCTCTCGCTGCAGGAGCTGACGTGGAAGATGAGCGTGGGGGCTGCGCTTGGCTG	1560
AlaLysLeuSerLeuGlnGluLeuThrTrpLysMetSerValArgAspCysAlaTrpLeu	520
CGCAGGAGCCCAGGGGTTGGCTGTGTTCCGGCCGAGAGCACCGTCTGCGTGAGGAGATC	1620
ArgArgSerProGlyValGlyCysValProAlaAlaGluHisArgLeuArgGluGluIle	540
CTGGCCAAGTTCCTGCACTGGCTGATGAGTGTGTACGTCGTCGAGCTGCTCAGGTCTTTC	1680
LeuAlaLysPheLeuHisTrpLeuMetSerValTyrValValGluLeuLeuArgSerPhe	560
TTTTATGTCACGGAGACCAGTTCAAAAGAAGCAGGCTCTTTTCTACCGGAAGAGTGTG	1740
PheTyrValThrGluThrThrPheGlnLysAsnArgLeuPhePheTyrArgLysSerVal	580
TGGAGCAAGTTGCAAAGCATTGGAATCAGACAGCACTTGAAGAGGGTGAGCTGCGGGAG	1800
TrpSerLysLeuGlnSerIleGlyIleArgGlnHisLeuLysArgValGlnLeuArgGlu	600
CTGTCGGAAGCAGAGGTCAGGCAGCATCGGGAAGCCAGGCCCGCCCTGCTGACGTCCAGA	1860
LeuSerGluAlaGluValArgGlnHisArgGluAlaArgProAlaLeuLeuThrSerArg	620
CTCCGCTTCATCCCCAAGCCTGACGGGCTGCGGCCGATTGTGAACATGGACTACGTCGTG	1920
LeuArgPheIleProLysProAspGlyLeuArgProIleValAsnMetAspTyrValVal	640
GGAGCCAGAACGTTCCGCAGAGAAAAGAGGGCCGAGCGTCTCACCTCGAGGGTGAAGGCA	1980
GlyAlaArgThrPheArgArgGluLysArgAlaGluArgLeuThrSerArgValLysAla	660
CTGTTCAAGTGTCTCAACTACGAGCGGGCGGGCGCCCGGCTCCTGGGCGCCTCTGTG	2040
LeuPheSerValLeuAsnTyrGluArgAlaArgArgProGlyLeuLeuGlyAlaSerVal	680
CTGGGCCTGGACGATATCCACAGGGCCTGGCGCACCTTCGTGCTGCGTGTGCGGGCCAG	2100
LeuGlyLeuAspAspIleHisArgAlaTrpArgThrPheValLeuArgValArgAlaGln	700
GACCCGCCCGCTGAGCTGTACTTTGTCAAGGTGGATGTGACGGGCGCGTACGACACCATC	2160
AspProProProGluLeuTyrPheValLysValAspValThrGlyAlaTyrAspThrIle	720
CCCCAGGACAGGCTCACGGAGGTCATCGCCAGCATCATCAACCCAGAACACGTAAGTGC	2220
ProGlnAspArgLeuThrGluValIleAlaSerIleIleLysProGlnAsnThrTyrCys	740
GTGCGTCGGTATGCCGTGGTCCAGAAGGCCGCCCATGGGCACGTCCGCAAGGCCTTCAAG	2280
ValArgArgTyrAlaValValGlnLysAlaAlaHisGlyHisValArgLysAlaPheLys	760

Fig. 1C

14/68





Fig. 8

15/68

*Fig. 9*

16/68

sequence "Y" 104-105 bases

GGCCTCCCGGGGTCGGCGTCCGGCTGGGGTTGAGGGCGGCCGGGGGAACCAG
GlyLeuProGlyValGlyValArgLeuGlyLeuArgAlaAlaGlyGlyAsnGln
AlaSerProGlySerAlaSerGlyTrpGly * GlyArgProGlyGlyThrSer
ProProArgGlyArgArgProAlaGlyValGluGlyGlyArgGlyGluProAla

CGACATGCGGAGAGCAGCGCAGGCGACTCAGGGCGCTTCCCCGCAGGTG
ArgHisAlaGluSerSerAlaGlyAspSerGlyArgPheProArgArg
AspMetArgArgAlaAlaGlnAlaThrGlnGlyAlaSerProAlaGly
ThrCysGlyGluGlnArgArgArgLeuArgAlaLeuProProGlnVal

sequence "1" 38 bases

GTGGCTGTGCTTTGGTTTAACCTCCTTTTAAACCAGAA
ValAlaValLeuTrpPheAsnPheLeuPheAsnGlnLys

sequence "*" 36 bases

GTGGATGTGACGGGCGCGTACGACACCATCCCCAG
ValAspValThrGlyAlaTyrAspThrIleProGln

sequence "*" 182 bases

GTCTCTACCTTGACAGACCTCCAGCCGTACATGCGACAGTTCGTGGCTCACCTG
ValSerThrLeuThrAspLeuGlnProTyrMetArgGlnPheValAlaHisLeu

CAGGAGACCAGCCCGCTGAGGGATGCCGTGTCATCGAGCAGAGCTCCTCCCTG
GlnGluThrSerProLeuArgAspAlaValValIleGluGlnSerSerSerLeu

AATGAGGCCAGCAGTGGCCTCTTCGACGTCTTCCTACGCTTCATGTGCCACCAC
AsnGluAlaSerSerGlyLeuPheAspValPheLeuArgPheMetCysHisHis

GCCGTGCGCATCAGGGGCAA
AlaValArgIleArgGlyLys

partial sequence "2" unknown length

GTGAGCGCACCTGGCCGGAAGTGGAGCCTGTGCCCGGCTGGGGCAGGTGCTGCTGCAG
Ter

GGCCGTTGCGTCCACCTCTGCTTCCGTGTGGGCGAGGCGACTGCCAATCCAAAGGGT
CAGATGCCACAGGGGTGCCCTCGTCCCATCTGGGGCTGAGCACAAATGCATCTTTCTG
TGGGAGTGAGGGTGCCTCACAACGGGAGCAGTTTTCTGTGCTATTTTGGTAA...

Fig. 10A

17/68

sequence '3' 159 bases

CCGAAGAAAACATTTCTGTCGTGACTCCTGCCGTGCTTGGGTCGGGACAGCCAGAG
AlaGluGluAsnIleSerValValThrProAlaValLeuGlySerGlyGlnProGlu

ATGGAGCCACCCCGCAGACCGTCGGGTGTGGGCAGCTTCCGGTGTCTCCTGGGAGG
MetGluProProArgArgProSerGlyValGlySerPheProValSerProGlyArg

GGAGTTGGGCTGGGCCTGTGACTCCTCAGCCTCTGTTTTCCCCAG
GlyValGlyLeuGlyLeu *

sequence 'X' unknown length

_GACAGTCACCAGGGGGTTGACCGCCGACTGGGCGTCCCAGGGTTGACTATAGGA
CCAGGTGTCCAGGTGCCCTGCAAGTAGAGGGGCTCTCAGAGGCGTCTGGCTGGCATGG
GTGGACGTGGCCCCGGGCATGGCCTTCTGCGTGTGCTGCCGTGGGTGCCCTGAGCCCT
CACTGAGTCGGTGGGGGCTTGTGGCTTCCCGTGAGCTTCCCCTAGTCTGTTGTCTGG
CTGAGCAAGCCTCCTGAGGGGCTCTCTATTG

partial sequence of genomic intron (approximately 2.7 kb)
GTGGCTGTGCTTTGGTTAACTTCCTTTTAAACAGAAGTGCGTTTGAGCCCCACATT
TGGTATCAGCTTAGATGAAGGGCCCGAGGAGGGGCCACGGGACACAGCCAGGGCCAT
GGCACGGCGCCACCCATTTGTGCGCACAGTGAGGTGGCCGAGGTGCCGTGCCTCCA
GAAAAGCAGCGTGGGGGTGTAGGGGAGCTCCTGGGGCAGGGAC....

Fig. 10B

18/68

N-terminal truncated telomerase

ATGCCGCGGCTCCCGCTGCGAGCGCTGCGCTCCCTGCTGCGCAGCACTACCGCGAGGTGCTGCGCTGGCCAGTTCGTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGGCGCTGGGCCCCAGGGCTGGCGCTGGTGCAGCGGGGACCGCGGCTTTCCGCGCGCTGGTGGCCAGTGCCTGCTGCTGCTGCGCTGGGACGACCGCGCGCCCCCGCGCG
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

CCCTCCTTCGCGAGGTGCTCCTGCTGAAGAGCTGGTGGCCGAGTGTGCAGAGCTGTGCGAGCGGGGCGAAGAAGCTGCTGGCTTCGCGCTGCTGGACGGGGCGCG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGCGCGCCCCGAGGCTTCACACAGGTGCGAGTACCTGCCAACAGGTGACCGAGCACTGCGGGGAGCGGGGCTGGGGCTGCTGCTGCGCGCTGGGCGACGAGT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGTTCACTGCTGCGAGCTGGCGCTCTTGTGCTGGTGGCTCCAGCTGCGCTACAGGTGTGGGGCGCGGCTGTACAGCTGCGGCTGCGACTAGCGCGCGCGCGCGC
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACAGCTAGTGGACCCGAGGCTGTGGATGCGAACGGGCTGGAACCATAGCTCAGGGAGCGGGGCTCCCTGGGCTGCCAGCCCCGGGTGGGAGAGCGCGGGGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCGAAGTCTGCGTTGCCAAGAGCGCGAGGCTGGCTGCGCTGAGCGGAGCGAGCGCGCTGGGAGGGCTCTGGGCGACCGGGGAGGAGCGGTGACCGAGTGAACG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGGTTCTGTGTGTGTCACCTGCCAGACCGCGAAGAGCACTCTTGGAGGTCGCTCTGTGGAGCGCGCACTCCACCATCGTGGGCGCGAGCAGCAGCGGGCGCGCG
G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGCGCCACCACTGCTCCTGGGACAGGCTTGTCCCGGCTGTACCGAGAGCAAGCACTTCTCTACTCTCAGGCGACAAGAGCAGTGGCGCTCCTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTCTGAGCGCCAGGCTGACTGGCGCTCGGAGGCTGTGGAGACCATCTTCTGGGTTCCAGGCGCTGGATGCCAGGACTCCCGCAGGTTGCCCCCTGCCCCAGCTACTGGA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q

AATGCGGCGCTGTTCTGAGCTGCTTGGGAACACGCGAGTGGCTACGGGCTGCTCTCAAGACGCACTGCGCGCTGCGAGCTGCGGTGACCGCAGCGCGGTGTCTGTGCGG
W R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R

GGAGAAGCCAGGCTCTGTGGCGCGCGCGAGGAGGACACAGACCGCGCTGCGCTGTGCGAGTGTCTCGGCGACACAGCAGCGCTGGAGGTGTACGCTTCTGTGGGCGCTG
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CCTGCGCGGCTGTGCCCCAGGCTCTGGGCTCCAGGACACAGGCGCGCTTCTCAGGAACCAAGAAGTTCATCTCCTGGGGAAGCATGCCAGCTCTGCTGCAGGAGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

GAGTGGAGATGAGCGTGGGGAAGTGGCTTGGCTGCGCAGGAGCGCGGCTGGCTGTGTTCCGGCGCAGAGCAGCGTGTGCTGAGGAGATCTGCGCAAGTCTCTGCACTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

GATGAGTGTGTACGCTGAGCTGCTCAGTCTTTCTTTATGTACGAGAGCAGCTTTCAAAGAACAGGCTCTTTTCTACCGAAGAGTGTCTGGAGCAAGTGTCAAAGCATTGG
W S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G

AAT--NNN--GACAGTCAACAGGGGGTTGACGCGGAGTGGGCTGCCAGGTTGACTATAGGACAGGTGTCCAGGTGCGCTGCAAGTAGAGGGCTCTCAGAGGCTCTGGCTGG
CATGGGTGAGCTGGCGCGCGCATGGCTTGTGGTGTCTGCGGTGGTGGCTGAGCGCTCACTGAGTGGGTGGGGCTTGTGGCTTCCGCTGAGCTTCCCGTGTGTGTGTG

GCTGAGCAAGCTCTGAGGGCTCTCTATTG

Fig. 11A

19/68

Truncated protein 1

ATGCCGCGGCTCCCGCTGCCGAGCGGTGGGCTCCCTGCTGCGCAGCACTACCGGAGGTGCTGCCGTGCCACGTTCTGTG
 M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGCGGCTGGGCCCCAGGGCTGGCGGCTGGTGCAGCGGGGACCGGGGCTTTCCGCGCGCTGGTGGCCAGTGCCTGGTGTGGTGGCTGGGAGCAGCGGCCGCCCGCGC
 R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

CCGCTCTTCCGCGAGGTGTCTGCTGAAGGAGCTGGTGGCCGAGTCTGCAGAGGCTGTGCGAGCGGGCCGGAAGACGTGCTGGCTTCGGCTTCGCGCTGCTGGACGGGGCCG
 P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGCCCCCGAGGCTTCACCAACAGCGTGGCGAGCTACTGCCAACACGGTGACCGAGCACTGGGGGAGCGGGGCTGGGGCTGCTGCTGCCCGCGTGGCGACGAGT
 G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GGTGTTACCTGCTGGCAGGCTGGCGCTCTTTGTGCTGGTGGCTCCAGCTGGCTTACCAGGTGTGGGGCCGCGCTGTACCAGCTCGGCGTGGCTGAGCGCGCGCGCGC
 L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACAGCTAGTGGACCCGAGGGCTCTGGGATGCGAACGGGCTGGAACCATAGCTCAGGAGGCGGGGTCCCCTGGGCTGCCAGCCCCGGGTGGAGGAGCGGGGGGAGTGC
 H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCCGAGTCTGCGTTGCCAAGAGGCCAGGCGTGGCGCTGCCCTGAGCCGAGCGGACCGCGTTGGGAGGGGTCTGGGCCACCGGGGAGGAGCGGTGGACCGAGTGACG
 S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGGTTCTGTGTGTGCTGACCTGCCAGACCCCGAGAGCCACTCTTTGAGGGTGCGCTCTGTGCGACGCGCACTCCACCCATCGTGGGCGGACAGCAGCGGGGGCGCGC
 G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGCGCCACACGCTCCCTGGGACAGCTTGTCCCCGGTGTACCGGAGACCAAGCACTTCTCTACTCCTCAGCGACAAGGAGAGCTGGGCGCTCTCTCTACTCAG
 S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTCTGAGGCGCAGCTGACTGGCGCTCGGAGGCTCGTGGAGACCATCTTTCTGGSTTCAGGCGCTGGATGCCAGGACTCCCGCAGSTTGCCCCGCTGCCCGAGCTACTGCA
 S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q

AATGGGCGCTGTTCTGGAGCTGCTTGGGACCAAGCGGAGTGGCGCTACGGGCTGCTCTCAAGAGCACTGCGCGCTGGAGCTGCGGTCAACCCAGAGCGGGTGTCTGTGCCG
 M R P L F L E L L G N H A O C P Y G V L L K T H C P L R A A V T P A A G V C A R

GGAGAAGCCCCAGGCTCTGTGGCGGCCCCGAGGAGGAGACAGACCCCGTGGCTGGTGGAGCTGCTCGGCCAGCAGAGCGGCTGGCAGGTGTACGGCTTCTGTGGGCGCTG
 E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CTTGGCGGCTGTGCCCCAGGCTCTGGGCTCCAGGACACGAGCGCGCTTCTCAGGAACACGAAGTTCATCTCCCTGGGAAGCATGCCAAGCTCTGCTGAGGAGCT
 L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

GAGTGAAGATGAGCGTGGGAGCTGGCTTGGCTGGCAGGAGCCAGGGGTGGCTGTGTTCCGGCGCAGAGCACCGTCTGCTGAGGAGATCTGGCCAGGTCTCTGCACTGGCT
 T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

GATGAGTGTAGCTGCTGAGCTGCTCAGGTCTTTCTTTATGTACGAGACCAAGCTTTCAAAAGACAGGCTCTTTTCTACCGGAAGAGTGTCTGGAGCAAGTTGCAAGCATTTGG
 M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G

Fig. 11B

20/68

AATCAGACAGCACTTGAAGAGGTCAGCTGCGGAGCTGTGCGAAGCAGAGTCAGGCAGCATCGGGAAGCCAGGCCCGCCCTGCTGACGTCAGACTCCGCTTCATCCCCAAGCCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D

GTGGCTGTGCTTTGGTTAACTTCCTTTTAAACAGAA
V A V L W F T F L F N Q K

CGGGCTGCGCGGATTGTGAACATGGACTACGTCGTGGGAGCCAGAACGTTCCGAGAGAAAAGAGGCCGAGCGTCTCACCTCGAGGGTGAAGGCAGCTGTCAGCGCTCAACTACGA
G L R P I V N M D Y V V G A R T F R R E K R P S V S F R G *

Fig. 11C

Truncated protein 2

ATGCCGCGCGCTCCCGCTGCGAGCCGTGGGCTCCCTGCTGCGCAGCCACTACCGCAGGTGCTGCCGTGGCCAGCTTCGTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGGGCGCTGGGGCCCAAGGCTGGCGGCTGGTGACGCGGGGACCCGGGGCTTTCCGCGCGCTGGTGCCCACTGCTGGTGCTGGTGCCCTGGGACGACGCGCCGCCCGCCCGCG
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

CCCTCCTTCGCGCAGGTGTCTGCTGAAGAGCTGGTGCCCGAGTGTGTCAGAGGCTGTGCGAGCGCGGCGAAGAACGTGCTGGCTTCGCGCTGCTGGACGGGGCCG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCCCCCGAGGCTTCAACACAGCGTGCGCAGCTACCTGCCAACACGCTGACCGACGCACTGCGGGGGAGCGGGGCTGGGGGCTGCTGCTGCGCGCGTGCGCGACAGCT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGTTACCTGCTGCGAGCTGCGGCTCTTTGTGCTGGTCCAGCTGCGCTACAGGTGTGCGGGCGCGGCTGTACAGCTCGGCGCTGCACTCAGGCCCGCGCGCGC
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACAGCTAGTGGACCCCAAGGCTCTGGGATGCGAACGGCTTGAACCATAGGTCAGGAGGCGGGGCTCCCTGCGCTGCCAGCCCGGGTGGCAGGAGCGCGGGGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCGAAGTCTGCGTTGCCAAGAGGCCAGGCTGGCTGCGCTGAGCCGAGCGGACGCCGTTGGCAGGGGCTCTGGGCCACCGGGGAGGACGCTGGACGAGTGACCG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGGTTTCTGTGCTGTCACCTGCCAGACCGCGAAGAGCCACCTCTTTGAGGCTGCGCTCTCTGCGACGCGCACTCCACCCATCGTGGGCCCGCAGCAGCAGCGGGCCCCC
G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGCGGCCACAGCTCCCTGGGACAGCCTGTCCCCGGTGTACGCGAGACCAAGCACTTCCTCTACTCCTCAGGCGACAAGGAGCAGCTGCGGCCCTCCTCTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

Fig. 11D

21/68

CTCTCTGAGGCCAGCCTGACTGGCGCTCGGAGGCTGTGGAGACCATCTTTCTGGGTTCCAGGCCCTGATGCCAGGACTCCCGCAGGTTGCCCGCCTGCCCGAGCCTACTGGCA
 S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q
 AATCGCGCCCTGTTTCTGGAGTGTCTGGGAACACGCGCAGTGCCCTACGGGCTGCTCTCAAGACGACTGCCCGCTGGAGCTGCGGTCAACCCAGCAGCGGTGTCTGTGCCG
 M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R
 GGAGAAGCCCGAGGCTGTGTGGCGGCCCGGAGGAGGACAGACCCCGTCCGCTGTGCACTGCTCCGCCAGCAGCAGCCCTGGCAGGTGTACGGCTTGTGGGGCTG
 E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C
 CCTGCGCGGCTGTGTGCCCGAGCCTTGGGGCTCCAGGCACAACGAACCGCTTCTCAGGAACCAAGAAGTTTCATCTCCCTGGGAAGCATGCCAAGCTCTGCTGCAGGAGCT
 L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L
 GACGTGAAGATGAGCGTGGGACTGCGCTTGGCTGCGCAGGAGCCAGGGTTGGCTGTGTTCCGGCCGAGAGCAGCCTGTGCGTGAGGAGATCCTGGCAAGTTCTGCACTGCGT
 T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L
 GATGAGTGTGTACGTGCTCGAGTGTCTAGGTCTTTCTTTATGTACGAGAGCCAGCTTCAAAAGAACGGCTCTTTTCTACCGGAAGAGTGTCTGAGCAAGTTGCAAGCATTTGG
 M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
 AATCAGACGACTTGAAGAGGTGACGTGCGGAGCTGTGGAAGCAGAGGTGAGCAGCATCGGAAGCAGGCCCGCCTGCTGACGTCCAGACTCCGCTTCATCCCAAGCCTGA
 I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
 CGGGCTCGCGCGATTGTGAACATGGACTACGTGTGGGAGCCAGAACGTTCCGAGAGAAAAGAGGCCGAGCCTCTCACCTCGAGGTTGAAGGACTGTTGAGCGTCTCAACTACGA
 G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
 GCGGCGCGGCGCCCGGCTCTGTGGGCTGTGTGCTGGGCTGGAGATATCCACAGGGCTGGGCACTTCTGCTGCGTGTGGGCGCCAGGACCCCGGCTGAGCTGTACTT
 R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
 TGTCAAGTGGATGTGACGGGCGGTACGACCATCCCCAGGACAGGCTCAGGAGGTGATCGCCAGCATCAAAACCCAGAACGTAAGTGTGCGTGGTGGTATGCCGTGTGCA
 V K V D V T G A Y D T I P Q D R L T E V I A S I K P Q N T Y C V R R Y A V V Q
 GAAGCCGCCCATGGGACGTCCGCAAGGCTTCAAGAGCCAC
 K A A H G H V R K A F K S

GTCTACGTCCAGTG
 V L R P V

CCAGGGATCCCGAGGCTCCATCTCTCCAGCTGTCTGACGCTGTGCTACGGCGACATGGAGAACAAGCTGTTTGGGGATTGGCGGGACGGCTGTCTCGGTTTGTGGA
 P G D P A G L H P L H A A L Q P V L R R H G E Q A V C G D S A G R A A P A F V G
 TGATTTCTGTGTGACACCTACCTACCCACGCAAAACCTTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGGTGGTGAACCTTGGGAAGACAGTGGTGAACCTCCC

Fig. 11E

22/68

Reference protein

ATGCCGCGGCTCCCGCTGCCGAGCGTGCGCTCCCTGCTGCGCAGCCACTACCGCGAG	60
MetProArgAlaProArgCysArgAlaValArgSerLeuLeuArgSerHisTyrArgGlu	20
GTGCTGCGCTGGCCACGTTCTGCGCGCGCTGGGGCCCCAGGGCTGGCGGCTGGTGCA	120
ValLeuProLeuAlaThrPheValArgArgLeuGlyProGlnGlyTrpArgLeuValGln	40
CGCGGGGACCGCGCGCTTTCGCGCGCTGGTGCCAGTGCCCTGGTGTGCGTGCCCTGG	180
ArgGlyAspProAlaAlaPheArgAlaLeuValAlaGlnCysLeuValCysValProTrp	60
GACGACGGCGCGCCCCCGCGCGCCCTCTTCGCGCAGGTGCTGCTGAAGGAGCTG	240
AspAlaArgProProProAlaAlaProSerPheArgGlnValSerCysLeuLysGluLeu	80
GTGGCCGAGTGCTGCAGAGGCTGTGCGAGCGCGCGGAAGACGTGCTGGCTTCGGC	300
ValAlaArgValLeuGlnArgLeuCysGluArgGlyAlaLysAsnValLeuAlaPheGly	100
TTGCGCTGCTGGACGGGCGCGGGGGCCCCCGAGGGCTTCACCACGCGTGCGC	360
PheAlaLeuLeuAspGlyAlaArgGlyGlyProProGluAlaPheThrThrSerValArg	120
AGCTACCTGCCAACACGCTGACCGACGCACTGCGGGGAGCGGGCGTGGGGGCTGCTG	420
SerTyrLeuProAsnThrValThrAspAlaLeuArgGlySerGlyAlaTrpGlyLeuLeu	140
TTGGCCCGCTGGGCGACGCTGCTGGTTACCTGCTGGCAGGCTGCGCGCTCTTTGTG	480
LeuArgArgValGlyAspAspValLeuValHisLeuLeuAlaArgCysAlaLeuPheVal	160
CTGGTGGCTCCAGCTGCGCTACGAGTGTGCGGCGCGCGTGTACAGCTCGGCGCT	540
LeuValAlaProSerCysAlaTyrGlnValCysGlyProProLeuTyrGlnLeuGlyAla	180
GCCACTCAGGCGCGGCCCCCGCACGCTAGTGGACCCCGAAGGCGTCTGGGATGCGAA	600
AlaThrGlnAlaArgProProProHisAlaSerGlyProArgArgArgLeuGlyCysGlu	200
CGGGCTGGAACCATAGCGTCAGGGAGGCGGGGTCCCGCTGGGCTGCCAGCCCCGGT	660
ArgAlaTrpAsnHisSerValArgGluAlaGlyValProLeuGlyLeuProAlaProGly	220
GCGAGGAGCGCGGGGCGAGTGCCAGCGAAGTCTGCGTTGCCAAGAGGCGCAGCGT	720
AlaArgArgArgGlyGlySerAlaSerArgSerLeuProLeuProLysArgProArgArg	240
GGGCTGCCCTGAGCGGAGCGGACGCGGTGGGAGGGGTCTGGGCGCACCGGGG	780
GlyAlaAlaProGluProGluArgThrProValGlyGlnGlySerTrpAlaHisProGly	260
AGGACGCTGGACCGAGTGACCGTGGTTCTGTGTGTGTACCTGCCAGACCGCGAA	840
ArgThrArgGlyProSerAspArgGlyPheCysValValSerProAlaArgProAlaGlu	280
GAAGCCACCTCTTTGGAGGGTGCGCTCTCTGGCAGCGGCACTCCACCCATCCGTGGC	900
GluAlaThrSerLeuGluGlyAlaLeuSerGlyThrArgHisSerHisProSerValGly	300
CGCCAGCACGCGGGGCCCCCATCCACATCGGGCCACACGTCCCTGGGACACGCT	960
ArgGlnHisHisAlaGlyProProSerThrSerArgProProArgProTrpAspThrPro	320

Fig. 11F

23/68

TGTCCTCCGGGTACGCCGAGACCAAGCACTTCCTCTACTCCTCAGGCGACAAGGAGCAG	1020
CysProProValTyrAlaGluThrLysHisPheLeuTyrSerSerGlyAspLysGluGln	340
CTCGGGCCCTCCTTCTACTCAGCTCTCTGAGGCCAGCCTGACTGGCGCTCGGAGGCTC	1080
LeuArgProSerPheLeuLeuSerSerLeuArgProSerLeuThrGlyAlaArgArgLeu	360
GTGGAGACCATCTTTCTGGGTTCCAGGCCCTGGATGCCAGGACTCCCCGAGGTTGCC	1140
ValGluThrIlePheLeuGlySerArgProTrpMetProGlyThrProArgArgLeuPro	380
CGCTGCCCCAGCGTACTGGCAATGCGGCCCTGTTTCTGGAGCTGCTTGGGAACCAC	1200
ArgLeuProGlnArgTyrTrpGlnMetArgProLeuPheLeuGluLeuLeuGlyAsnHis	400
GCGCAGTGGCCCTACGGGGTGCTCTCAAGACGCACTGCCCGCTGCGAGCTGGGTACCC	1260
AlaGlnCysProTyrGlyValLeuLeuLysThrHisCysProLeuArgAlaAlaValThr	420
CCAGCAGCCGGTGTCTGTGCCCGGAGAACCCAGGGCTCTGTGGCGGGCCCGAGGAG	1320
ProAlaAlaGlyValCysAlaArgGluLysProGlnGlySerValAlaAlaProGluGlu	440
GAGGACACAGACCCCGTCGCCTGGTGACGTGCTCCGCCAGCACAGAGCCCTGGCAG	1380
GluAspThrAspProArgArgLeuValGlnLeuLeuArgGlnHisSerSerProTrpGln	460
GTGTACGGCTTCGTGGGGCTGCCTGGCGCGCTGGTGCCCCAGGCTCTGGGGCTCC	1440
ValTyrGlyPheValArgAlaCysLeuArgArgLeuValProProGlyLeuTrpGlySer	480
AGGCACAACGAACGCCGCTTCCTCAGGAACACCAAGAAGTTCATCTCCCTGGGAAGCAT	1500
ArgHisAsnGluArgArgPheLeuArgAsnThrLysLysPheIleSerLeuGlyLysHis	500
GCCAAGCTCTCGTCGAGAGCTGACGTGAAGATGAGCGTGGGGCTGCGCTTGCGTG	1560
AlaLysLeuSerLeuGlnGluLeuThrTrpLysMetSerValArgAspCysAlaTrpLeu	520
CGCAGGAGCCAGGGTTGGCTGTGTTCCGGCCGAGGACCGTCTGCGTGAGGAGATC	1620
ArgArgSerProGlyValGlyCysValProAlaAlaGluHisArgLeuArgGluGluIle	540
CTGGCCAAGTTCCTGCAGTGGCTGATGAGTGTACGTGTCGAGCTGCTCAGGTCTTTC	1680
LeuAlaLysPheLeuHisTrpLeuMetSerValTyrValValGluLeuLeuArgSerPhe	560
TTTTATGTCACGGAGACCAGTTTCAAAAGAACAGGCTCTTTTCTACCGGAAGAGTGC	1740
PheTyrValThrGluThrThrPheGlnLysAsnArgLeuPhePheTyrArgLysSerVal	580
TGGAGCAAGTTGCAAGCATTGGAATCAGACAGCACTTGAAGAGGTGCAGCTGCGGGAG	1800
TrpSerLysLeuGlnSerIleGlyIleArgGlnHisLeuLysArgValGlnLeuArgGlu	600
CTGTGGGAAGCAGAGGTGAGGAGCATCGGAAGCCAGGCCCGCCCTGCTGACGTCCAGA	1860
LeuSerGluAlaGluValArgGlnHisArgGluAlaArgProAlaLeuLeuThrSerArg	620
CTCGGCTTCATCCCAAGCCTGACGGGCTCGGGCGATTGTGAACATGGAAGTACGTGCTG	1920
LeuArgPheIleProLysProAspGlyLeuArgProIleValAsnMetAspTyrValVal	640

Fig. 11G

24/68

GGAGCCAGAACGTTCCGCAGAGAAAAGAGGGCCGAGCGTCTCACCTCGAGGGTGAAGGCA 1980
 GlyAlaArgThrPheArgArgGluLysArgAlaGluArgLeuThrSerArgValLysAla 660
 CTGTTACGCGTGCTCAACTACGAGCGGGCGGGCGCCCGGCTCCTGGGCGCTCTGTG 2040
 LeuPheSerValLeuAsnTyrGluArgAlaArgArgProGlyLeuLeuGlyAlaSerVal 680
 CTGGGCTGGACGATATCCAGGGCTGGCGCACCTTCGTGCTGCGTGTGCGGGCCAG 2100
 LeuGlyLeuAspIleHisArgAlaTrpArgThrPheValLeuArgValArgAlaGln 700
 GACCCGCGCTGAGCTGTACTTTGTCAAGGTGGATGTGACGGGCGGTACGACCATC 2160
 AspProProGluLeuTyrPheValLysValAspValThrGlyAlaTyrAspThrIle 720
 CCCAGGACAGGCTCAGGAGGTTCATCGCCAGCATCATCAACCCAGAACAGTACTGC 2220
 ProGlnAspArgLeuThrGluValIleAlaSerIleIleLysProGlnAsnThrTyrCys 740
 GTGGTGGTATGCCGTGGTCCAGAGGGCGCCATGGGCACGTCGGCAAGGCTTCAAG 2280
 ValArgArgTyrAlaValValGlnLysAlaAlaHisGlyHisValArgLysAlaPheLys 760
 AGCCACGTCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTCGTGGCTCACCTG 2340
 SerHisValSerThrLeuThrAspLeuGlnProTyrMetArgGlnPheValAlaHisLeu 780
 CAGGAGACAGCCCGCTGAGGATGCCGTGTCATCGAGCAGAGCTCCCTCGAATGAG 2400
 GlnGluThrSerProLeuArgAspAlaValValIleGluGlnSerSerSerLeuAsnGlu 800
 GCCAGCAGTGGCTCTTCGACGTCTTCTACGCTTCATGTGCCACACGCGTGCGCATC 2460
 AlaSerSerGlyLeuPheAspValPheLeuArgPheMetCysHisHisAlaValArgIle 820
 AGGGCAAGTCTACGTCCAGTGCCAGGGATCCCGCAGGGCTCCATCCTCCACGCTG 2520
 ArgGlyLysSerTyrValGlnCysGlnGlyIleProGlnGlySerIleLeuSerThrLeu 840
 CTCTGACGCTGTGCTACGGGACATGGAGAACAAGCTGTTTGGGGGATTGCGGGGAC 2580
 LeuCysSerLeuCysTyrGlyAspMetGluAsnLysLeuPheAlaGlyIleArgArgAsp 860
 GGGCTGCTCCTGCGTTTGGTGGATGTTCTTGTGGTGACACCTCACCTCAGCCACGG 2640
 GlyLeuLeuArgLeuValAspAspPheLeuLeuValThrProHisLeuThrHisAla 880
 AAAACCTTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTG 2700
 LysThrPheLeuArgThrLeuValArgGlyValProGluTyrGlyCysValValAsnLeu 900
 CGGAACAGTGGTGAACCTCCCTGTAGAAGACGAGCCCTGGGTGGCAGGCTTTTGT 2760
 ArgLysThrValValAsnPheProValGluAspGluAlaLeuGlyGlyThrAlaPheVal 920
 CAGATGCCGGCCACGGCTATCCCTGGTGGCGCTGCTGGATACCCGACCGCTG 2820
 GlnMetProAlaHisGlyLeuPheProTrpCysGlyLeuLeuLeuAspThrArgThrLeu 940
 GAGGTGCAGAGCACTACTCCAGCTATGCCCGACCTCCATCAGAGCCAGTCTCACCTTC 2880
 GluValGlnSerAspTyrSerSerTyrAlaArgThrSerIleArgAlaSerLeuThrPhe 960

Fig. 11H

25/68

AACCGCGGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGGTCTTGCGGCTG	2940
AsnArgGlyPheLysAlaGlyArgAsnMetArgArgLysLeuPheGlyValLeuArgLeu	980
AAGTGTACAGGCTGTTTCTGGATTTCAGGTGAACAGCCTCCAGACGGTGTGACCAAC	3000
LysCysHisSerLeuPheLeuAspLeuGlnValAsnSerLeuGlnThrValCysThrAsn	1000
ATGTACAAGATCCTCCTGCTGCAGGCGTACAGGTTTCAGGCATGTGTGCTGCAGTCCCA	3060
IleTyrLysIleLeuLeuLeuGlnAlaTyrArgPheHisAlaCysValLeuGlnLeuPro	1020
TTTCATCAGCAAGTTTGAAGAAGCCACATTTTCTGCGCGTCATCTCTGACACGGCC	3120
PheHisGlnGlnValTrpLysAsnProThrPhePheLeuArgValIleSerAspThrAla	1040
TCCCTCTGCTACTCCATCCTGAAAGCCAAGAAGCGAGGATGTCGCTGGGGGCCAAGGGC	3180
SerLeuCysTyrSerIleLeuLysAlaLysAsnAlaGlyMetSerLeuGlyAlaLysGly	1060
GCCGCGGGCCCTCTGCCCTCCAGGCGGTGCAGTGCTGTGCCACCAAGCATTCTGCTC	3240
AlaAlaGlyProLeuProSerGluAlaValGlnTrpLeuCysHisGlnAlaPheLeuLeu	1080
AAGCTGACTCGACACCGTGTACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCAG	3300
LysLeuThrArgHisArgValThrTyrValProLeuLeuGlySerLeuArgThrAlaGln	1100
ACGCAGCTGAGTCGGAAGCTCCCGGGGACGACGCTGACTGCCCTGGAGGCGCGCAAC	3360
ThrGlnLeuSerArgLysLeuProGlyThrThrLeuThrAlaLeuGluAlaAlaAlaAsn	1120
CGGCACTGCCCTCAGACTTCAAGACCATCCTGGAC	3420
ProAlaLeuProSerAspPheLysThrIleLeuAsp	1132

Fig. 11I

26/68

Truncated protein 3

ATGCGCGCGCTCCCGCTGCCGAGCGTGGCTCCCTGCTGCGCAGCCACTACCGGAGGTGCTGCCGTGGCCAGTTGCTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F Y

CGGCGCTGGGGCCAGGGCTGGCGCTGGTGACGCGGGGACCGCGGCTTTCCGCGCGCTGGTGGCCAGTGCCGTGTGCGTGCCCTGGGACGACGGCCGCCCCGGCCG
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

CCCCTCCTTCGCGAGGTGCTGCTGCTGAAGAGCTGTGGCCGAGTGTGACAGGGTGTGCGAGCGGGCGGAGAACGTGCTGGCCTTCGGCTTCGCGCTGTGGACGGGGCCG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCCCCCGAGGCTTACCACAGCGTGGCAGCTACCTGCCAACAGGTGACGACGACTGCGGGGAGCGGGGCTGGGGCTGCTGCTGCGCGCTGGGCGACGACGT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGTTACCTGCTGGCAGCTGCGCGCTCTTGTGCTGGTGGCTCCAGCTGCGCTACAGGTGTGCGGGCGCGCTGTACAGCTCGGCGCTGCCACTCAGGCCCCGGCCCCGCG
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACACGCTAGTGACCCCGAAGGCTGTGGATGCCAACGGGCTGGAACCATAGCGTCAGGAGCGGGGTCCCCCTGGGCTGCCAGCCCCGGGTGCGAGGAGCGGGGGCAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCGAGTCTGCGCTGCCAAGAGGCGCAGGCGTGGCGCTGCCCTGAGCGGAGCGGACGCGCTTGGGAGGGTCTGGGCGCACCGGGCAGGACGCGTGGACGAGTGACCG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGTTTCTGTGTGTGCTCACCTGCCAGACCGCGGAGAACGACCTCTTGGAGGGTGGCTCTCTGCGACGCGCCACTCCACCCATCGTGCGGCGCGCAGCACACGCGGGCCCCC
G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGCGCCACCACTGCTCCGCGGACGCTTGTCCCCGGGTGACCGGAGACCAAGCACTTCTCTACTCCTCAGGCSACAAGGAGCAGTGGCGGCTCCTTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTGAGGCGCAGCTGACTGGCGCTGGAGGCTGTGGAGACCATCTTCTGCTTCCAGGCGCTGGATGCCAGGACTCCCGCAGGTGGCCCGCTGCCCCAGCGCTACTGGCA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q

AATCGGCCCCCTGTTCTGAGCTGCTTGGGAACACGCGCAGTGGCCCTACGGGTGCTCTCAAGACGCACTGCCCCGTGCGAGCTGCGGTACCCGAGCAGCGGTGTCTGTGCGCG
M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R

GGAGAAGCCCCAGGGCTCTGTGGCGGCCCCGAGGAGGAGGACAGACCCCCGTGCGCTGGTGGAGCTGCTCCGCGAGCACAGCAGCCCCCTGGCAGGTGTACGGCTCTGTGCGGGCTG
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CCTGCGCGCGCTGGTGCCCCAGGCTCTGGGGCTCCAGGCACAACGAACGCGCTTCTCAGGAACACCAAGAATTCTCTCCTGGGAAGCATGCCAAGCTCTGCTGAGGAGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

GAGTGGAGATGACCGTGGGACTGCGCTTGGCTGGCAGGAGCCAGGGTGGCTGTGTTCCGGCGCAGAGCAGCTCTGCGTGAAGAGATCCTGGCAAGTCTCTGCTGAGGAGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

GATGAGTGTGTACGTGCTGAGCTGCTCAGGTCTTTCTTTATGTACGAGAGACAGCTTTCAAAGAACAGGCTCTTTTCTACCGGAAGAGTGTCTGGAGCAAGTGGAAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G

Fig. 11J

27/68

AATCAGACAGCACTTGAAGAGGTGAGCTGCGGAGCTGTGGAGCAGAGGTCAGGCAGCATCGGGAAGCCAGGCCCGCCCTGCTGACGTCCAGACTCCGCTTCATCCCCAAGCCTGA
 I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
 CGGGCTCGGGCGATTGTGAACATGGACTACCTGCTGGGAGCCAGAACGTTCCSCAGAGAAAAGGGCCGAGCGTCTCACCCTGAGGGTGAAGGCACTGTTCAAGCTGCTCAACTACGA
 G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
 GCGGGCGCGGCCCGCCCTGCTGGGCGCTGTGTGCTGGGCTGGACGATATCCACAGGGCTGGGCGACCTTCGTGCTGCGTGTGCGGGCCAGGACCCGCGCTGAGCTGTACTT
 R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
 TGTCAAGGTGGATGTGACGGGCGCTACGACACCATCCCCAGGACAGGCTCAGGAGGTGTCGCCAGCATCATCAACCCAGAACAGTACTGCGTGGCTGGTATGCCGTGGTCCA
 V K V D V T G A Y D T I P Q D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
 GAAGGCCGCCCATGGGACGTCGCCAAGGCTTCAAGAGCCAGTCTCTACCTTGACAGACCTCCAGCGGTACATGCGACAGTTCGTGGCTCACCTGAGGAGACCCAGGCCCTGAGGGA
 K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D
 TGGCTGCTCATCGAGCAGAGCTCCTCCGTAATGAGGCCAGAGTGGGCTCTTCGAGCTCTCCTACGCTTCATGTGCCACACGCGCTGCGCATCAGGGCAAGTCTACGTCCAGT
 A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C
 CCAGGGGATCCCGCAGGGCTCCATCCTCTCCACGCTGCTCTGACGCTGTGCTACGGGACATGGAGAACAGCTGTTTGGGGGATTGCGCGGACGGGCTGCTCCTGCTTTGGTGA
 Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D
 TGATTTCTGTTGGTGACACCTCACCTCACCCACGCGAAAACCTTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTGCGGAAGACAGTGGTGAACCTCCC
 D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P
 TGTAGAAGACGAGCCCTGGGTGGCAGGGCTTTTGTTCAGATGCCGGCCACGGCTATTCCCTGGTGGGCTGCTGCTGGATACCGGACCTGGAGGTGACAGGCACTACTCCAG
 V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S R
 GTGAGCGCACCTGCCCGAAGTGGAGCCTGTGCCCGCTGGGGCAGGTGCTGCTGAGGCGCGTTGGCTCCACCTCTGCTTCCGTGTGGGGCAGGCGACTGCCAATCCCAAGGGTCAGA
 *
 TGCCACAGGGTGCCCTCGTCCCATCTGGGGCTGAGCACAATGCATCTTTCTGTGGAGTGAGGGTGCCCTCACACGGGAGCAGTTTTCTGTGCTATTTTGTAA_

Fig. 11K

28/68

Altered C-terminus protein

ATGCGCGCGCTCCCGGCTGCGAGCGGTGCGCTCCCTGCTGCGCAGCCACTACCGCGAGGTGCTGCGCTGGCCACGTTCTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGCGCGCTGGGGCCAGGGCTGGCGGCTGGTGACGCGGGGACCGGGGCTTTCCGCGCTGGTGCGCCAGTGCCTGGTGTGCGTGCCCTGGGACGCAAGCGCGCGCGCGCGCGCG
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

CGCGCTCTCCGCGAGGTGCTGCTGAAGGAGCTGGTGCGCGAGTGCTGCGAGGCTGTGCGAGCGCGCGCGAAGAACGCTGGCTTCGGCTTCGGCTGCTGGACGGGCGCGG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCGCGCGAGGCTTCACACGAGCTGCGCAGCTACCTGCCAACAGGTGACCGACGCTGCGGGGAGCGGGGCTGGGGGCTGCTGCTGCGCGGCTGGGCGACGAGCT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGGTTCACCTGCTGGCAGCTGCGCGCTCTTTGTGCTGGTGGCTCCAGCTGGCGCTACAGGTGTGCGGGCGCGCGCTGTACGAGCTCGGCGCTGCCACTCAGGCGCGCGCGCGCG
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACAGCTAGTGGACCGCGAAGCGCTGTGGATGCGAAGCGCGCTGGAACCATAGGCTCAGGAGCGCGGGTCCCCCTGGGCTGCCAGCGCGGCTGCGAGGAGCGCGGGGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCGAAGCTGCGGTTGCCAAGAGCGCGAGGCTGGCGCTGCCCTGAGCGGAGCGGACCGCTTGGGAGGGTCTGCGGCCACCGGGCAGGACGCGTGGACCGAGTGACCG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGGTTTGTGTGTGTACCTGCCAGACCGCGGAGAGCCACCTCTTTGGAGGTCGCTCTCTGCGACGCGCACTCCACCCATCCGTGGGCGCGCAGCACCAGCGGGCGCGCG
G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGCGGCCACGCTCCCTGGGACAGCGCTTGTCCCCGCTGACGCGAGACCAAGCACTTCTCTACTCCTCAGCGACAGGAGCAGCTGCGCGCTCTCTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTGTAGGCGCGAGCTGAGTGGCGCTCGGAGGCTCGTGAGACCATCTTTCTGGGTTCCAGGCGCTGGATGCCAGGAGTCCCGCAGGTTGCCCGCGCTGCCGAGCGCTACTGGCA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q

AATGCGCGCGCTGTTCTGAGCTGCTTGGGAACACGCGAGTGCGCTACGCGGTGCTCTCAAGCGCACTGCGCGCTGCGAGCTGCGGTACCGCAGCAGCGGTGTCTGTGCGCG
M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R

GGAGAAGCGCGAGGCTGTGCGCGCGCGCGAGGAGGACACAGACCGCGCTGCGTGGTGACGCTGCTCCCGCAGCAGCAGCGCGTGGCAGGTGTACGCTTCTGTGCGCGCGT
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CCTGCGCGCGCTGCTGCGCGCGCGCTGCGGCTCAGGACACAGCGCGCTTCTCAGGACACCAAGAGTTATCTCCCTGGGGAAGCATGCCAAGCTCTGCTGCGAGGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

GACGTGAAGATGAGGTCGCGGACTGCGCTTGGCTGCGCAGGAGCGCGGCTTGGCTGTGTTCCGCGCGAGCAGCGCTGCGGTGAGGAGATCCTGCCAAGTTCTGCACTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

GATGAGTGTGTACGTGCGAGCTGCTCAGGCTCTTTTATGTACGAGAGCACGTTTCAAAAGACAGGCTCTTTTCTACCGGAAGAGTGTCTGAGCAAGTGTCAAAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G

AATCAGACGCACTTGAAGAGGTCAGCTGCGGAGCTGTGGAAGCAGAGGTGAGGAGCATCGGGAAGCAGCGCGCGCTGCTGACGTCCAGACTCCGCTTCATCCCCAAGCCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D

Fig. 11L

29/68

GGGGCTGGGGGATTGTGAACATGGACTACGTGCTGGGAGCCAGAACGTTCCGACAGAAAAGAGGGCCAGCGTCTCACCTGAGGGTGAAGGCAGTGTTCAGGTGCTCAACTACGA
 G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
 GGGGGGGGGGGGGGGGGGGCTCTGGGGGGCTCTGTGCTGGGGCTGGACGATATCCACAGGGGCTGGGGCACCCTTGGTGTGCTGTGGGGCCAGGACCCGGGGCTGAGCTGTACTT
 R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
 TGTCAAGGTGGATGTGACGGGGGGTACGACACCATCCCCAGGACAGGCTCAGGAGGTATGCCAGCATCATCAAACCCAGAACAGTACTGCGTGGGTATGCCGTGGTCCA
 V K V D V T G A Y D T I P Q D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
 GAAGGGGGGGGATGGGACGTCGCAAGGGCTTCAAGAGCCAGCTCTGTACCTTGACAGACCTCCAGCCGTACATGGACAGTTCGTGGCTCAGCTGCAGGACACAGCCGGCTGAGGA
 K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D
 TGGCGTGTATGAGGACAGCTCCTCCCTGAATGAGGCCAGGAGTGGCTCTTGCAGCTTCTTACGCTTATGTGCCACACGGCGTGGGATCAGGGGCAAGTCTACGTCCAGTG
 A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C
 CCAGGGGATCCCGCAGGGCTCCATCCTCTCCAGCGTGTCTGCAGCGTGTGCTACGGGACATGGAGAACAGCTGTTTGGGGGATTCCGGGGGACGGGGCTGCTCTGGGTTTGGTGA
 Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D
 TGATTCTTGTGTGTGACACCTCACCTCACCCAGCGGAAACCTTCTCAGGACCGTGGTCCGAGGTGTCCCTGAGTATGGCTGGGTGTGAATTCGGGAGACAGTGGTGAATTCGC
 D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P
 TGTAGAAGCAGAGGGCTGGGTGGCAGGGCTTTTGTTCAGATGCCGGCCACGGGCTATTCCCTGGTGGGGCTGCTGCTGGATACCGGACCTGGAGGTGCAGAGGACTACTCCAG
 V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S S
 CTATGCCGGACCTCCATCAGAGCAGTGTCACTTCAACCGGGCTTCAAGGCTGGGAGGAACATGGCTCGCAAACTCTTTGGGCTCTTGGGGTGAAGTGCACAGCGTGTCTTGTGGA
 Y A R T S I R A S L T F N R G F K A G R N M R R K L F G V L R L K C H S L F L D
 TTTGAGGTGAACAGCGCTCCAGAGGTGTGCACCAACATCTACAAGATCCTCCTGCTGAGGGCTACAGGTTTCAGCATGTGTGCTGAGCTCCCATTTTCAGCAAGTTTGAAGAA
 L Q V N S L Q T V C T N I Y K I L L L Q A Y R F H A C V L Q L P F H Q Q V W K N
 CCCCACATTTTCTGGCGGTATCTGTGACACGGGCTCCCTCTGCTACTCCATCCTGAAAGCCAAAGACGAGGATGTGCTGGGGGCAAGGGGCGGGGGCTCTGCGCTCCGA
 P T F F L R V I S D T A S L C Y S I L K A K N A E
 |
 CCGAAGAAAACATTTCTGTGCTGACTCCTGCGGTGCTTGGGTG
 E E N I L V V T P A V L G S
 GGAACGCCAGAGATGGAGCCACCCGAGACCGTGGGTGTGGGACGCTTCCGCTGTCTCTGGGAGGGGAGTTGGGCTGGGCTGTGACTCCTCAGCTCTGTTTCCCCAG
 G Q P E M E P P R R P S G V G S F P V S P G R G V G L G L *

Fig. 11M

30/68

Protein that lacks motif A

ATGCCGCGGCTCCCGGCTGCCGAGCGGTGGCTCCCTGCTGCGCAGGCACTACCGCGAGGTGCTGCCGTGGCCAGCTTCGTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGCGCGCTGGGGCCAGGGCTGGCGGCTGGTGACGCGGGGACCCGGCGGCTTTCCGGCGCTGGTGCCCACTGCTGGTGTGCGTGCCCTGGGACGACGCGCGCGCGCGCGC
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A
CCCTCCTTCGCGCAGGTGTCTGCTGAAGGAGCTGGTGCCCGAGTGCTGCAGAGGCTGTGCGAGCGCGCGGAGAAAGCTGGCTGGCTTCGCGCTTCGCGCTGGACGGGGCGG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R
CGGGGCGCGCGAGGCTTCACACCAAGGTGGCGAGCTACCTGCCCAACAGGCTGACCGACGCACTGCGGGGAGCGGGGCTGGGGGCTGCTGCTGCCCGCGGTGGGCGACGAGCT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V
GCTGGTTCACCTGCTGGCAGCTGGCGGCTCTTTGTGCTGGTGGCTCCAGCTGCGCTACAGGTGTGCGGGCGCGCGCTGTACAGCTCGGGCTGCGCTCAGGCGCGCGCGCGC
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P
ACAGCTAGTGGACCCGAAGGCTGTGGATGCGAAGCGGCTGGAACCATAGGCTCAGGAGGCGGGGTCCCGCTGGGCTGCCAGCGCGGGTGGGAGGCGCGGGGCGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A
CAGCGAAGTCTGCGTTCGCGAAGGCGCGAGGCTGGCGCTGCCCTGAGCGGAGCGGACCGCGTGGCGAGGGTCTGCGGCGACCGCGGAGGCGGTGGAACGAGTGACG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R
TGGTTCTGTGTGTGCTGCTGCGACCGCGCGAAGGCGAGCTCTTTGGAGGCTGGCTGCTGCGACGCGCACTCCACCCATCGGTGGGCGCGGAGCAGCAGCGGGCGCGCGC
G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P
ATCCACATCGCGGCGACCGCTCCCTGGGACAGGCTGTGTCGCGGCTGTACGCGGAGACCAAGCACTTCCTCTACTCCTCAGGCGACAGGAGCAGCTGCGGCGCTCCTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S
CTCTGAGGCGCGCTGCTGCTGCGGCTGGGAGGCTGTGCGACCATCTTTCTGGGTTCAGGCGCTGGATGCCAGGCACTCCCGCAGGTTGCCCGCGCTGCCAGCGCTACTGGCA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q
AATGCGCGCGCTGTTTCTGGAGCTGCTTGGGAACAGCGCAGTGCGGCTACGGGCTGCTCTCAAGACGCACTGCCCGCTGGGAGCTGCGGTACCGGAGCAGCGGTGTCTGTGCGCG
M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R
GGAGAAGCGCGAGGCTGTGTGCGGCGCGGAGGAGGACAGACCGCGCTGCGCTGGTGAGCTGCTCCGCGACAGCAGCGCGCTGGCAGGTGTACGCTTCGTGCGGCGCTG
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C
CCTGCGCGCGCTGGTGCGCGCGGCTCTGGGCTCCAGGACAAAGACCGGCTTCCTCAGGAACCAAGAGTTTCATCTCCCTGGGGAAGCATGCCAGCTCTGCTGCGAGGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L
GAGTGGAAGATGAGCGTGCGGCACTGCGCTTGGCTGCGCAGGAGCGGAGGTTGGCTGTGTTCCGGCGCAGAGCAGCGCTGTGCGTGAGGAGATCCTGGCAAGTTCTGCACTGCGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L
GATGAGTGTGTACGTGCTGAGCTGCTCAGGTCTTTCTTTATGTACGGAGACCACTTTCAAAGAACAGGCTCTTTTCTACCGGAAGAGTGTGTGAGCAAGTTGCAAGCAATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
AATCAGACAGCACTTGAAGGGGTGAGCTGCGGAGCTGTGCGAAGCAGAGGTGAGGAGCATCGGGAAGCAGCGCGCGCTGCTGAGTCCAGACTCCGCTTCATCCCAAGCGTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D

Fig. 11N

31/68

CGGGCTGGGCGGATTGTGAACATGACTACGTCTGGAGGCCAGAACGTTCCGCAGAGAAAAGAGGGCCGAGCGCTCACTCGAGGGTGAAGGCAGTGTTCAGCGTGTCAACTAGCA
G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E

GGGGCGCGGGCGCGGGCTCTGGGGCGCTCTGTGCTGGGGCTGGACGATATCCACAGGGCTGGGGACCTTCTGTGCTGGGTGGGGCCAGGACCGCGCGCTGAGCTGTACTT
R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F

TGTCAAG
V K

GACAGGCTCAGGAGTCAATCGCCAGTCAATCAAAACCCAGAACACTACTGCGTGGCTGGTATGCGGTGGTCCA
D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q

GAAGGGCGCCATGGGACGTCGCAAGGCTTCAAGAGCCAGCTCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTCGTGGCTCACCTCGAGGAGACCGCGCTGAGGGA
K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D

TGCGCTGCTCATCGAGCAGAGCTCTCCCTGAATGAGGCCAGAGTGGGCTCTTCCAGCTCTTCTACGCTTCATGTGCCACACCGCGTGGCATCAGGGCAAGTCTACGTCAGTG
A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C

CCAGGGGATCCCGCAGGGCTCCATCTCTCCAGCTGCTCTGCAGCTGTGCTACGGCGACATGGAGAACAGCTGTTTGGGGGATTCGGCGGACGGGCTGCTCTGCTTTGGTGA
Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D

TGATTTCTGTGTGTGACACCTCACTCAGGACCGGAAACCTTCTCAGGACCTGGTCCGAGGTGCTCCGTGAGTATGGCTGGGTGGTGAACCTTGGGAAGACAGTGGTGAACCTCC
D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P

TGTAGAAGACGAGCGCTGGGTGGCAGGCTTTGTTCAGATGCCGGCCACGGCTATTCCCTGGTGGGGCTGCTGCTGGATACCGGACCTGGAGGTGAGAGGAGTACTCCAG
V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S S

CTATGCCCCGACCTCCATCAGAGCAGTCTCACCTTCAACCGCGGCTTCAAGGCTGGGAGGAACATGCGTCCGAAACTCTTTGGGGTCTTGGGGTGAAGTGTACAGGCTGTTCTGGA
Y A R T S I R A S L T F N R G F K A G R N M R R K L F G V L R L K C H S L F L D

TTTGACAGTGAACAGCTCCAGAGGTTGACCAACATCTACAAGATCTCTGCTGACGGGTACAGGTTTACGCAATGTGTGCTGAGCTCCCATTTTCAGCAAGTTTGAAGAA
L Q V N S L Q T V C T N I Y K I L L L Q A Y R F H A C V L Q L P F H Q Q V W K N

CCCCACATTTTCTGGCGTCTATCTGACACGGCTCCCTCTGCTACTCCATCTCTGAAAGCCAGAACGAGGATGTGCTGGGGGCAAGGGCGCGCGGCTCTGCGCTCCGA
P T F F L R V I S D T A S L C Y S I L K A K N A G M S L G A K G A A G P L P S E

GGCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCAAGCTGACTCGACACGGTGTCACTACGTGCCACTCTGGGGTCACTCAGGACAGCCAGACGAGTGAAGTGGAGTCCC
A V Q W L C H Q A F L L K L T R H R V T Y V P L L G S L R T A Q T Q L S R K L P

GGGACGACGCTGACTGCCCTGGAGGCGGAGCCACCCGGCACTGCCCTCAGACTTCAAGACCATCTGAGTGTGCGACCGGCCACAGCCAGGCGAGAGCAGACACGAGAGCC
G T T L T A L E A A A N P A L P S D F K T I L D

CTGTCAAGCGGGCTCTACGTCCAGGGAGGGAGGGGCGGCCACACCCAGGCGCGACCGCTGGGAGTCTGAGGCTGAGTGAAGTGTGGCGAGGCTGCATGTGGGTGAAGGCT
GAGTGTCCGGCTGAGGCTGAGCGAGTGTCCAGGCAAGGGCTGAGTGTCCAGCAGACCTGCCGTCTTCACTTCCACAGGCTGGCGCTGGCTCCACCCAGGGCGAGCTTTTCTCAC
CAGGAGCCCGGCTTCCACTCCACATAGGAATAGTCCATCCAGATTCGCCATGTTTCAACCCCTGGCCCTGCCCTCTTTGGCTTCCACCCCCACCATCCAGGTGGAGACCTGAGAA
GGACCTGGGAGCTCTGGGAATTTGAGTGACCAAGGTGTGCCCTGTACACAGGCGAGGACCTGCACCTGGATGGGGTCCCTGTGGGTCAAAATTTGGGGGAGGTGTGTGGGAGTAA
AAACTGAATATAGATTTTTAGTTTTGA

Fig. 11 O

32/68

Truncated protein that lacks motif A

ATGCCGCGCGCTCCCGCTGCCGAGCGGTGGGTCCCTGCTGGCGACCCACTACCGCGAGGTGCTGCCGTGGCCAGTTGGTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGCGCCTGGGGCCCAAGGCTGGCGGCTGTCAGCGCGGGGACCCGGCGGCTTTCGCGCGCTGGTGGCCAGTGCCCTGCTGTGCGTGCCCTGGGACGACGGCCGGCCCCGGCCG
RRLGPGQGWRLVQRGDPAAFRALVAQCCLVCVPWDARPPPA
CCCTCCTTCGCGCAGGTGCTGCTGAAGGAGCTGCTGGCCGAGTGCTGACAGGCTGTGCGAGCCGGCGCGAAGACGTGCTGGCCTTCGGCTTCGCGCTGTGACGGGGCCG
PSFRQVVSCLKELVARVLQRLCERGAKNVLAFFGFAALLDGAR
CGGGGGCCCCCGAGGCTTCACACACAGCTGCGAGCTACCTGCCAACACGGTGACGACGCACTGCGGGGAGCGGGGCTGGGGCTGCTGCTGCGCCGCTGGGCGACGACGT
GGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGGDDV
GCTGGTTCACCTGCTGGCAGCTGCGCGCTCTTTGTGCTGCTGCCAGCTGCGGCTACAGGTGTGCGGGCGCGCTGTACAGCTCGGCGTGCCACTAGGCCGGGCCCCGGC
LVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPP
ACACGCTAGTGGACCCCGAAGCGCTGGGATGCGAACGGGCTGGAACATAGGCTCAGGAGGGCGGGGTCCCCCTGGGCTGCCACCCCGGGTGGAGGAGCGGGGGAGTG
HASGPRRRRLGGERAWNHSVREAGVPLGLPAPGARRRRGSA
CAGCGAAGTCTGCCGTTGCCAAGAGGCCAGCGTGGCGCTGCCCTGAGCCGAGCGGACGCCGTTGGGAGGGGTCTGGGCCCACCGGGGAGGACGCGTGGACCGAGTGACG
SRSLLPLPKRPRRGAAPPEPERTPVGGQGSWAHPGRTRGPSDR
TGSTTCTGTGTGTGTACCTGCCAGACCCCGAAGAGCCACTCTTTGAGGGTGGCTCTCTGACCGGCCACTCCACCCATCGTGGGCGCCAGCAGCGCGGGCCCCC
GFCVVSPPARPAEEATSLEGA LSGTRHSHPSVGRQHHA GPP
ATCAGCATCGCGCCACACGCTCCCTGGGACACGCTTGTCCCCGGGTGACGCGAGACCAAGCACTTCTCTACTCTCTCAGCGACAGGAGCAGCTGGGCGCTCTCTCTACTAG
STSRPPRPWDTPCPPVYAETKHFLYS S G D K E Q L R P S F L L S
CTCTCTGAGGCCAGCCTGACTGGCGCTCGGAGGCTGCTGGAGACCATCTTTCTGGGTTCCAGGCCCTGGATGCCAGGACTCCCCGAGGTTGCCCGCTGCCCGAGCCTACTGGCA
SLRPSLTGARRLVETIFLGSRPWMPGTTPRRLPLRLPQRYWQ
AATGGGCCCCGTGTTTCTGAGCTGCTTGGGAACACGCGAGTGCCCTACGGGTGCTCTCTAAGACGACTGCCGCTGCGAGCTGCGGTACCCCGAGCAGCGGCTGTCTGTGCCG
MRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCA
GGAGAAGCCCAAGGCTCTGTGGCGGCCCGGAGGAGGACACACACCCCGTGCGCTGGTGCACTGCTCCCGAGCAGCAGCCCTGGCAGGTGTACGCTTGTGCGGCGCTG
EKPGGSVAAP E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C
CCTGCGCGGCTGGTCCCCAGGCTCTGGGGCTCAGGACACAAGACGCGCTTCTCAGGAACACCAAGTTCATCTCCCTGGGAAGCATGCCAGCTCTCGCTGAGGAGCT
LRRLLVPPGLWGSRHNERRFLRNTKKFISLGKHA K L S L Q E L
GACGTGGAAGATGAGCGTGGGACTGCGCTGCGCTGCGCAGGAGGCCAGGGTGGCTGTGTTCCGGCGCGCAGAGCACCGCTGCGGTGAGGAGATCTGGCCAGTCTCTGACTGCT
TWKMSVVRDCAWLR R S P G V G C V P A A E H R L R E E I L A K F L H W L
GATGAGTGTGTACGCTGCTGAGCTGCTCAGGCTTTCTTTATGTACGGAGACACGTTTCAAAGAACAGGCTCTTTTCTACCGGAAGAGTGTCTGAGCAAGTGTCAAAGCATGG
MSVYVVELLRSFFYVTE T T F Q K N R L F F Y R K S V W S K L Q S I G
AATCAGACAGCACTTGAAGAGGTGACGCTGCGGAGCTGTGGAAGCAGAGGTACGGCAGCATCGGAAGCCAGGCCCCGCTGCTGACGCTCCAGACTCCGCTTCATCCCAAGCGCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D

Fig. 11P

33/68

CCGGCTGCGGCGATTGTGAACATGGACTACGTGCTGGGAGCCAGAACGTTCCGAGAGAAAAGGGCCGAGCGTCTCACCCTGAGGGTGAAGGCACGTGTTGAGCGTCTCAACTACGA
 G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
 GGGGCGCGGCGCCCGGCTCCTGGGCGCTCTGTGCTGGGCTGAGCATATCCAGGGGCTGGGCGACCTTCGTGCTGCGTGTGCGGGCCAGGACCCCGGCTGAGCTGTACTT
 R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
 TGTCAG GACAGGCTCAGGAGTTCATCGCCAGCATCATCAACCCAGAACGTAAGTGGTGGTGGTATGGCGTGGTCCA
 V K D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
 GAAGGCGCGCATGGGACGTCGCAAGGCTTCAAGAGCCAGCTCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTGCTGGCTCACCTGAGGAGACCGCCGCTGAGGGA
 K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D
 TGGCTGCTCATCGAGCAGAGCTCCTCCCTGAATGAGGCGAGTGGCTCTTCCAGCTCTTCTACGCTTCATGTGCCACACGCGTGGCATCAGGGCAAGTCTACGTCAGTG
 A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C
 CCAGGGATCCGCGAGGCTCCATCCTCTCCAGCTGCTCTGAGCTGTGCTACGGGACATGGAGAACAAGCTGTTTGGGGGATTGCGGGGACGGGCTGCTCCTGCGTTTGGTGA
 Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D
 TGATTTCTTGTGGTGACACCTCACCTCACCCACGCAAAACCTTCTCAGGACCTGGTCCGAGGTGCTCCGTGAGTATGGCTGCGTGGTGAACCTGCGGAAGACAGTGGTGAACCTCCC
 D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P
 TGTAGAAGACGAGGCTGGGTGGCAGGCTTTTGTTCAGATGCCGGCCACGGCTATTCCCTGCTGGGCGCTGCTGCTGATACCGGACCTGGAGTGCAGAGGACTACTCCAG
 V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S R
 GTGAGCGACCTGGCCGGAAGTGAGCCTGTGCCCGCTGGGCGAGTGTGCTGCGAGGCGGTTGCGTCCACCTCTGCTTCGCTGTTGGGCGAGGCGACTGCCAATCCCAAGGGTCAGA
 TGGCACAGGTTGCCCCCTGCTCCATCTGGGCTGAGCACAATGCATCTTCTGTGGAGTGAGGTCCTCACAACGGGAGCAGTTTCTGTGCTATTTTGTAA

Fig. 11Q

34/68

Lacks motif A and altered C-terminus

ATGCCGCGCGCTCCCGCTGCCAGCGGTGCGCTCCCTGCTGCGCAGCCACTACGCGAGGTGCTGCCGCTGGCCACGTTGCTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGCGCGCTGGGGCCCCAGGGCTGGCGGCTGGTGACGCGGGGACCCGGCGGCTTTCGCGCGCTGGTGGCCAGTGCTGCTGGTGGCTGGGACGCGACGGCGCCCCCGCGCGC
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

CCCCCTCCTTCGCGCAGGTGCTGCTGAAGGAGCTGGTGCGCGGAGTGTGCGAGGCTGTGCGAGCGCGGCGGAAGAGTGCTGGCGTTGCGCTTCGCGCTGCTGAGCGGGGCGCG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCCCCCGAGGCTTCACCACGCGTGGCGAGCTACCTGCCCAACAGGTAACGACGCACTGCGGGGAGCGGGGCGTGGGGGCTGCTGCTGCGCGCGTGGGCGACGAGCT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGGTTACCTGCTGGCAGCTGCGCGCTCTTTGTGCTGGTGGCTCCAGCTGCGCCTACCAGGTGTGCGGGCGCGCTGTACAGCTCGGCGCTGCCACTCAGGCCGGCCCCCGCGC
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACAGCTAGTGGACCCGAAGCGTCTGGGATGCGAACGGCTGGAACCATAGCGTCAGGAGCGCGGGTCCCTTGGGCTGCCAGCCCCGGGTGCGAGGAGGCGCGGGGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCCGAAGTCTGCGGTGCCCAAGAGCGCCAGGCTGGCGCTGCCCTGAGCGGAGCGGACGCGGCTTGGGAGGGGCTCTGGGCCCCCGGGGAGGAGCGCTGGACCGAGTGACCG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGTTTCTGTGTGTGTGCTGCTGCCAGACCGCGCGAAGAGCCACCTCTTTGAGGGGTGCGCTCTCTGCGCAGCGCGCACTCCGACCATCGGTGGGCGCGCAGCACCAGCGGGCCCCC
G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGGGCCACCAGCTCCCTGGGACAGCTTGTCCCCGGGTGACGCGAGACCAAGCACTTCTCTACTCTCAGGCGACAAGGAGCAGCTGCGGCGCTCTCTCTACTCAG
S T S R P P R P N D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTCTGAGGCGCAGCTGACTGCGGCTCGGAGGCTCTGGAGACCATTCTTCTGGTTCAGGCGCTGGATGCCAGGGAATCCCGCAGGTGCCCCGCTGCCAGGCTACTGGCA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q

AATGCGGCGCTGTTTCTGAGAGTGTGTTGGGAACACGCGAGTGCCCTACGGGTGCTCTCAAGACGCACTGCGCGCTGCGAGCTGCGGTACCCCCAGCAGCGGCTGTGTGCCG
M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R

GGAGAAGCCCCAGGCTCTGTGGGCGCCCCGAGGAGGAGACAGACCGCGTGCCTGGTGACGTGCTCCGCGCAGCAGAGCGCTGGCAGGTGTACGGCTGTGTGGGGCTG
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CCTGCGCGGCTGGTGGCCCCAGGCTCTGGGGTCCAGGCGACAACGAAGCGGCTTCTCAGGAACCAAGAGTTATCTCCCTGGGAAGCATGCCAAGCTCTCGCTGACAGAGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

GACGTGGAAGATGAGGTGCGGGAAGTGGCTTGGCTGCGCAGGAGCCAGGGGTGGCTGTGTTCCGCGCGCAGACCGCTGCGTGAGGAGATCCTGGCCAAGTCTCTGCACTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

GATGAGTGTGTACGTGCTGAGCTGCTCAGGTCTTTCTTTTATGTACGGAGACCAGGTTTCAAAAGAACAGGCTCTTTTCTACCGGAAGAGTGTGTGGAGCAAGTTGCAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G

AATCAGACAGCACTTGAGAGGGTGCAGTGGCGAGCTGTGGAAGCAGAGGTGAGGAGCATCGGAAGCCAGGCCCCGCTGCTGACGTCCAGACTCCGCTTCATCCCCAAGCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D

Fig. 11R

35/68

CCGGCTGCGGCGATTGTGAACATGGACTACGTGCTGGGAGCCAGAACSTTCGACAGAGAAAGAGGCGGAGCGTCTCACCTCGAGGGTGAAGGCACGTTCAGCGTGTCAACTACGA
 GLRPVIVNWDYVVGARTFRREKRAERLTSRVKALFSVLN YE
 GCGGGCGCGGCGCGCGCTCCTGGGCGCTCTGTGCTGGGCTGGACGATATCCAGGGCTTGGCGACCTTCGTGCTGCGTGTGCGGGCCAGGACCGCGCGCTGAGCTGTACTT
 RARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPELYF
 TGTCAAG
 V K
 GACAGGCTCAGGAGGTATGCCAGCATCATCAAAACCCAGAACAGTACTGCGTGCCTGCGTATGCCGTGGTCCA
 DRLTEVIAASIIKPONTYCVRRYAVVQ
 GAAGCGCCCATGGGACGTCGCAAGGCTTCAAGAGCCAGCTCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTGCTGGCTCACCTGCAGGAGACCGCGCTGAGGGA
 KAAHGHVVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRD
 TGGCTGCTCATGAGCAGAGCTCCTCCCTGAATGAGGCCAGCAGTGGCTCTTCCAGCTCTCTACGCTTCATGTGCCACCGCGCTGGCATCAGGGGCAAGTCTACGTCAGTG
 AVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQC
 CCAGGGATCCCGAGGGCTCCATCCTCTCCAGCTGCTCTGCAGGCTGTGCTACGGCAGCATGGAGAACAGCTGTTGCGGGATTCCGGGAGCGGCTGCTCTGCGTTTGGTGA
 QGIPQGSILSTLLCSLCYGD MENKLFAGIRRDGLLLRLVD
 TGATTTCTGTGGTGAACCTCACCTCACCCACGCGAAACCTTCTCAGGACCTGCTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTTCCGGAAGACAGTGGTGAACCTCC
 DFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNL RKT VVNFP
 TGTAGAAGACGAGGCGCTGGGTGGCAGGCTTTTGTTCAGATGCCGGCCACGGCTATTCCCTGGTGGGCTGCTGCTGGATACCGGACCTGGAGTGCAGAGGACTACTCCAG
 VED EALGGTA FVQMPAHGLFPWCGLLLDTRTLEVS DYSS
 CTATGCCGGACCTCCATCAGAGCCAGTCTCACCTCAACCGCGGCTTCAAGGCTGGGAGGAACATGCTGCGAAACTCTTTGGGCTCTTGGGCTGAAGTGTACAGCTGTTCTGGA
 YARTSIRASLTFRNGFKAGRNMRRKLFGVLRRLKCHSLFLD
 TTTGAGGTGAACAGCTCCAGAGGTGTGCACCAACATCTACAAGATCCTCTGCTGCGAGGCTACAGGTTTCAGCATGTGTGCTGCAGCTCCCATTTTCATCAGCAAGTTTGAAGAA
 LQVNSLQTVCTNIYKILLLOAYRFHACVLQLPFHQQVWKH
 CCCCACATTTTCTGCGCGTATCTGTGACACGGCTCCCTCTGCTACTCCATCCTGAAAGCCAGAACCGGATGTGCTGGGGCCAGGGCGCGCGCGGCTCTGCGCTCCGA
 PTFFLRVISDTASLCYSILKAKNAE
 |
 CCGAAGAAACATTTCTGTGCTGACTCCTGCGGTGCTGGGTC
 EENILVVTPAVLGS
 GGGACAGCCAGAGATGGAGCCACCCGAGACCTCGGGTGTGGGAGCTTTCCGGTGTCTCTGGAGGGAGTTGGGCTGGGCTGTGACTCCTCAGCCTGTGTTTCCCGGAG
 GQPEMEPPRRPSGVGSFPVSPGRGVGLGL*

Fig. 11S

N-terminal truncated telomerase (ver. 2)

Fig. 11T

37/68

CATGAGTGTGTACGTGTCGAGCTGCTCAGGTCTTTCTTTATGTACGGAGACCACTTTCAAAGAAGAGGCTCTTTTCTACCGAAGAGTGTCTGGAGCAAGTTGCAAAGCATTGG
 W S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
 AAT--NNN--GACAGTCACCAGGGGGTTGACCGCCGACTGGGGCTCCCGAGGGTTGACTATAGGACAGGTGTCCAGGTGCCCTGCAAGTAGAGGGGCTCTCAGAGGGCTCTGGCTGG
 CATGGGTGGAGTGGCCCCGGCATGGCCTTCTGCGTGTGCTGGGTGGCTGCCCTGAGCCCTCACTGAGTGGGTGGGGGCTTGTGGCTTCCGCTGAGCTTCCCGTAGTCTGTTGTCTG
 GCTGAGCAAGCTCTGAGGGGCTCTCTATTG

Fig. 11U

Truncated protein 1 (ver. 2)

ATGCCGCGGCTCCCGCTGCCGAGCGGTGGCTCCCTGCTGCGCAGCCACTACCGGAGGTGCTGCCGTGGCAGCTTGGT
 M P R A P R C R A V R S L L R S H T R E V L P L A T F V
 CCGCGCTGGGGCCCGAGGGCTGGCGGCTGCTGAGCGCGGGACCGCGGGCTTTCGCGCGCTGGTGGCCAGTGCCTGGTGTGCTGCGCTGGGACGACGGCGCGCGCGCGCG
 R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A
 GGCCTCCCGGGGTGGGCTCCGGCTGGGGTTGAGGGCGGGCGGGGGAACAGCGACATGCGGAGAGCAGGCGAGCGAGTCAAGGGGCTTCCCGCGAGGTG
 G L P G V G V R L G L R A A G G N Q R H A E S S A G D S G R F P R R
 A S P G S A S G W G * G R P G G T S D M R R A A Q A T Q G A S P A G
 P P R G R R P A G V E G G R G E P A T C G E Q R R R L R A L P P Q V
 CCGCTCTCCCGAGGTGTCTGCTGAAGGAGCTGGTGGCCGAGTGTGACAGGCTGTGCGAGCGCGCGGGAAGAACGTGCTGGCTTGGGCTTGGGCTGCTGGACGGGGCCG
 P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R
 CCGGGGCCCCCGAGGGCTTCAACACAGCGTGGCAGCTACTGCCCCAACAGGTGACCGACGCACTGCGGGGAGCGGGGCTGGGGGCTGCTGCGCGCGGTGGGCGACAGCT
 G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V
 GCTGTTACCTGCTGGCAGCTGCGCGCTCTTTGTGCTGGTGGCTCCAGCTGGGCTACAGGTGTGCGGGCGCGCTGTACAGCTGCGGCTGCGACTCAGGCCCCCGCGCG
 L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P
 ACAGCTAGTGGACCCGAAGCGTCTGGATGCGAACGGGCTGGAACATAGCGTCAAGGAGGCGGGGTCCCGCTGGGCTGCCAGCCCGGGTGGAGGAGCGCGGGGAGTGG
 H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A
 CAGCGAAGTCTGCCGTTGCCAAGAGGGCCAGGCGTGGCGCTGCCCTGAGCGGAGCGGACCGCGGTTGGGAGGGGTCTGGGCGCACCGGGCAGGACCGGTGACCGAGTGAACG
 S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R
 TGGTTCTGTGTGTGTCACCTGCCAGACCCCGGAAGAGCCACCTCTTTGAGGGTGGCTCTCTGCGACGGGCACTCCACCCATCGTGGGGCGGACGACACCGGGGCCCCC
 G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q R H A G P P

Fig. 11V

38/68

ATGCGCGCGCTCCCGCTGCCAGCGGTGCGCTCCCTGCTGCGCAGCCACTACCGCGAGGTGCTGCGCTGCCAGCTTCGTG
 W P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGCGCGCTGGGGCCAGGGCTGGCGGCTGGTGAGCGCGGGGACCGCGCGCTTTCCGCGCGCTGGTGCGCCAGTGCGCTGGTGCGSTGCCCTGGAGCGACCGCGCGCGCGCGCGCG
 R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

GGCGTCCCGGGGTGCGCGTCCGCGTGGGGTTGAGGGCGGCGGGGGGAACAGCGACATGCGGAGAGCGCGCAGGCGACTCAGGGCGCTTCCCGCGCAGGTG
 G L P G V G V R L G L R A A G G N Q R H A E S S A G D S G R F P R R
 A S P G S A S G W G * G R P G G T S D M R R A A Q A T Q G A S P A G
 P P R G R R P A G V E G G R G E P A T C G E Q R R R L R A L P P Q V

CCGCTCCTTCGCGCAGGTGCTGCTGCTGAAGGAGCTGGTGCGCGAGTGCTGCGAGGCTGTGCGAGCGCGCGGAAGAAGCTGCTGGCTTCGGCTTCGCGCTGCTGGACGGGGCGCG
 P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCGCGCGAGGCTTCACCAACAGCGTGGCGAGCTACCTGCCCAACAGGTGACCGAGCACTGCGGGGAGCGGGGCTGGGGCTGCTGCTGCCCGCGSTGGGCGACGAGT
 G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGGTTCACCTGCTGGCAGCTGCGCGCTCTTTGTGCTGGTGGCTCCAGCTGCGCTACAGGTGTGCGGGCGCGCGCTGTACAGCTGCGCGCTGCCACTCAGCGCGCGCGCGCGCG
 L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACACGCTAGTGGACCCGAAGCGCTTGGGATGCGAACGGGCTGGAACATAGCGTCAGGGAGGCGGGGCTCCCGCTGGCGCTGCCAGCGCGGGTGCGAGGAGCGCGGGGCGAGTGC
 H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCGGAAGTTCGCGTTGCCAAGAGGCGCGAGGCTGGCGCTGCCCTGAGCGGAGCGGACGCCGTTGGGAGGGGCTCTGGGCGCACCGCGGAGGCGGAGTGCAGCG
 S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGGTTTCTGTGGTGTACCTGCCAGACCGCGGAAGAAGCCACTCTTTGGAGGGTGCGCTCTGCGACGCGCACTCCACCCATCGTGGGCGCGCAGCAGCAGCGGGCGCGCGCG
 G F C V V S P A R P A E E A T S L E G A L S G T R H S H P S V G R Q H H A G P P

ATCCACATCGCGGCGACCGCTCCCTGGGACAGCGCTGTCCCGCGGTGACCGGAGACCAAGCACTTCCCTACTCCTCAGGCGACAAGGAGAGCTGGGCGCTCCTTCTACTCAG
 S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

Fig. 11W

Truncated protein 2 (ver.2)

ATGCCGCGGCTCCCGCTGCCAGCGGTGCGCTCCCTGCTGCCAGCCACTACCGGAGGTGCTGCCGCTGCCACGTTCTG
M P R A P R C R A V R S L L R S H T R E V L P L A T F V

CGGCGCTCGGGCCCCAGGGCTGGCGCTGGTGACGCGCGGACCCGGCGCTTTCCGCGCGCTGGTGCCAGTGCCCTGGTGCGTGCCCTGGGACGACGGCGCCCGCCCGCGC
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

GGCTCCCGGGGTGGCGTCCGGTGGGTTGAGGGCGCGCGGGGAACAGCGACATCGGAGAGCAGCGAGGCGACTCAGGGCGCTTCCCGCGAGTG
G L P G V G V R L G L R A A G G N O R H A E S S A G D S G R F P R R
A S P G S A S G W G * G R P G G T S D M R R A A Q A T Q G A S P A G
P P R G R R P A G V E G G R G E P A T C G E Q R R R L R A L P P Q V

CCCCCTCTCCCGAGGTCTCTGCTGAAGGAGCTGGTGGCGGAGTGCTGACAGGCTGTGCGAGCGCGCGGGAAGACGTGCTGGCTTCGGCTTCGCGCTGCTGAGGGGGCGG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCCCCCGAGGGCTTACCACAGCGTGCGCAGCTACCTGCCCAACCGGTGACGACGCACTGCGGGGAGCGGGGCTGGGGCTGCTGCTGCGCGCGTGGGCGACAGCT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGTTACCTGCTGGCAGCTGCGCGCTCTTTGTGCTGGTGGCTCCAGCTGCGCTACAGGTGTGCGGGCGCGCGTGTACAGCTCGGGCTGCCACTCAGGCGCGCGCGCGC
L V H L L A R C A L F V L V A P S C A Y Q V C G P P L Y Q L G A A T Q A R P P P

ACAGCTAGTGGACCCGAGGGCTCTGGGATGCGAACGGCTTGAACATAGCTCAGGAGGGCGGGGTCCCGCTGGGCTGCCAGCCCGGGTGCGAGGAGCGCGGGCGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCCGAAGTCTGCGTTGCCAAGAGGGCCAGCGTGGCGCTGCCCTGAGCGGAGCGGACCGCGTTGGGAGGGGTCTGGGCCACCGGGCAGGACCGTGGACCGAGTGACG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGTTTCTGTGTGTGTCACCTGCCAGACCCCGAAGAAGCACCTCTTTGAGGGTGGCTCTCTGGCAGCGGCACTCCACCCATCCGTGGCGCGCAGCACCGCGGGCGCGC
G F C V V S P A R P A E E A T S L E G A L S G T R H S K P S V G R Q H H A G P P

ATCCACATCGCGCCACCACTCCCTGGGACAGCTTGTCCCGGGTGTACGCGAGACCAAGCACTTCTCTACTCTCAGGCGACAAGGAGCAGCTGGCGCGCTCTCTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTGAGGGCCAGCTGACTGGCGCTGGAGGCTGTGGAGACCATCTTTCTGGTTCCAGGCGCTGATGCCAGGCACTCCCGCAGGTTGCCCGGCTGCCAGCGCTACTGGCA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L P R L P Q R Y W Q

AATCGGCCCCGTGTTCTGGAGCTGCTTGGGAACACGGCAGTGCCCTACGGGTGCTCTCAAGACGCACTGCCGCTGCGAGCTGCGGTCACCAGCAGCGGTGTCTGTGCGCG
M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R

GGAGAAGCCCCAGGGCTCTGTGGCGGGCCCCGAGGAGGACACAGACCCCGTGGCTGGTGCAGCTGCTCGCCAGCAGCAGCGCGCTGGCAGGTGTACGGCTCTGTGGGGCGTG
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CCTGCGCGGTGGTGGCCCCAGGGCTCTGGGGCTCAGGCAACGAACCGCGCTTCTCAGGAACCAAGAAGTTCATCTCCCTGGGGAAGCATGCCAAGCTCTGCTGAGGAGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

Fig. 11X

40/68

GACGTGGAAGATGAGCGTGGGACTGCGCTTGCTGCGCAGGAGCCAGGGGTTGGCTGTGTTCCGGCCGACAGCACCGCTGCGTGAGGAGATCCTGGCCAAGTTCTGCACGTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L
GATGAGTGTGTACGTGCTCGAGCTGCTCAGGTCTTTCTTTATGTACAGGAGACAGCTTTCAAAGAACAGGCTCTTTTCTACGGAAGAGTGTCTGAGCAAGTTGCAAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
AATCAGACAGCACTTGAAGAGGGTGACGTGCGGAGCTGTGGAAGCAGAGGTCAAGCAGCATCGGAAGCCAGGCCCGCCCTGCTGACGTCCAGACTCCGCTTCATCCCAAGCCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
CGGGCTGCGCGGATTGTGAACATGGACTACGTGCTGGAGCCAGAACGTTCCGACAGAAAAGAGGGCCGAGCTCTCACCTCGAGGTTGAAGGCACGTTCAGCCTGCTCAACTAGCA
G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
GCGGGCGCGCGCCCGCCCTCTGCTGGCGCCTGTGCTGGGCTGGACGATATCCACAGGGCTGGCGCACCTTGCTGCTGCTGCGGGCCAGGACCGCGCCCTGAGCTGTACTT
R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
TGTCAAGGTGGATGTGACGGGCGGTACGACACCATCCCCAGGACAGGCTCACGGAGGTCACTGCCAGCATCATAAACCCAGAACAGTACTGCGTGGCTGGGTATGCCGTGGTCCA
V K V D V T G A Y D T I P Q D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
GAAGGCCGCCCATGGGCACGTCCGCAAGGCCCTTCAAGAGCCAC
K A A H G H V R K A F K S H

GTCTACSTCCAGTG
V L R P V

CCAGGGGATCCGSCAGGGCTCCATCCTCTCCACGTGCTCTGCAGCCTGTGCTACGGCSACATGGAGAACAAGCTGTTTCCGGGATTCCGGGGGACGGGCTGCTCCTGCGTTTGGTGA
P G D P A G L H P L H A A L Q P V L R R H G E Q A V C G D S A G R A A P A F V G
TGATTCTTGTGTTGACACTCACCTCACCCACGGGAAACCTTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTTCCGGAAGACAGTGGTGAACCTTCCC

Fig. 11Y

41/68

Reference protein (ver. 2)

ATGCCGCGGCTCCCGCTGCCGAGCCGTGCGCTCCCTGCTGCGCAGCCACTACCGGAG 60
 MetProArgAlaProArgCysArgAlaValArgSerLeuLeuArgSerHisTyrArgGlu 20
 GTGCTGCCGCTGGCCAGTTCTGTCGGCGCTGGGGCCAGGGCTGGCGGCTGGTCAG 120
 ValLeuProLeuAlaThrPheValArgArgLeuGlyProGlnGlyTrpArgLeuValGln 40
 CCGGGGACCCGGCGCTTTCCGCGCGCTGGTGGCCAGTGCCTGGTGTGCGTGCCCTGG 180
 ArgGlyAspProAlaAlaPheArgAlaLeuValAlaGlnCysLeuValCysValProTrp 60
 GACGACGGCGCCCGCGCGCGCGCGCTCCCTCCGCGAGGTG
 AspAlaArgProProProAlaAlaProSerPheArgGlnVal
 GGCCTCCCGGGGTGGGCTCCGGTGGGTTGAGGGCGCGGGGGGAACGAGACATCCGAGAGCAGGGCAGGCGACTCAGGGCGCTTCCCGCGAGGTG
 G L P G V G V R L G L R A A G G N Q R H A E S S A G D S G R F P R R
 A S P G S A S G W G * G R P G G T S D M R R A A Q A T Q G A S P A G
 P P R G R R P A G V E G G R G E P A T C G E Q R R R L R A L P P Q V
 TCCTGCCCTGAAGGAGCTG 240
 SerCysLeuLysGluLeu 80
 GTGGCCCGAGTGTGTCAGAGCTGTGCGAGCGCGCGGAGAAGCGTGTGGCCTTCGGC 300
 ValAlaArgValLeuGlnArgLeuCysGluArgGlyAlaLysAsnValLeuAlaPheGly 100
 TTGCGCTGCTGGACGGGGCCCGGGGGCCCCCGAGGCTTCACACAGCGTGGCG 360
 PheAlaLeuLeuAspGlyAlaArgGlyGlyProProGluAlaPheThrThrSerValArg 120
 AGCTACCTGGCCAAACAGGTGACCGACCGACTGCGGGGAGCGGGGCTGGGGCTGCTG 420
 SerTyrLeuProAsnThrValThrAspAlaLeuArgGlySerGlyAlaTrpGlyLeuLeu 140
 TTGCGCGGCTGGCGACGACGTGCTGTTACCTGCTGSCACGCTGCGCGCTCTTTGTG 480
 LeuArgArgValGlyAspAspValLeuValHisLeuLeuAlaArgCysAlaLeuPheVal 160
 CTGTTGGCTCCAGCTGCGCTACCAGGTGTGGGGCGCGCTGTACCAGCTGGCGCT 540
 LeuValAlaProSerCysAlaTyrGlnValCysGlyProProLeuTyrGlnLeuGlyAla 180
 GGCCTCAGCGCGCGCGCGCGCACAGCTAGTGGACCCGAGGGGTCTGGGATGCGAA 600
 AlaThrGlnAlaArgProProHisAlaSerGlyProArgArgArgLeuGlyCysGlu 200
 CGGGCTGGAACCATAGCTCAGGAGGCGGGGTCCCCCTGGGCTGCCAGCCCGGGT 660
 ArgAlaTrpAsnHisSerValArgGluAlaGlyValProLeuGlyLeuProAlaProGly 220
 GCGAGGAGGCGCGGGCAGTGCCAGCGAAGTCTGCGTTGCCAAGAGCCAGGCGT 720
 AlaArgArgArgGlyGlySerAlaSerArgSerLeuProLeuProLysArgProArgArg 240
 GCGCTGCCCTGAGCGGAGCGGACGCGCTTGGGAGGGGTCTGGGCGCCACCGGGC 780
 GlyAlaAlaProGluProGluArgThrProValGlyGlnGlySerTrpAlaHisProGly 260

Fig. 11Z

AGGACGCGTGACCGAGTGACCGTGGTTTCTGTGTGGTGTACCTGCCAGACCGCCGAA	840
ArgThrArgGlyProSerAspArgGlyPheCysValValSerProAlaArgProAlaGlu	280
GAAGCACCTCTTTGGAGGGTGGCTCTCTGGCAGCGCCACTCCCACCCATCCGTGGGC	900
GluAlaThrSerLeuGluGlyAlaLeuSerGlyThrArgHisSerHisProSerValGly	300
CGCCAGCACACGCGGGCCCCCATCCACATCGCGGCCACACGTCCCTGGGACAGCCT	960
ArgGlnHisHisAlaGlyProProSerThrSerArgProProArgProTrpAspThrPro	320
TGTCCCCCGGTGTACCGGAGACCAAGCACTTCCTCTACTCCTCAGGCGACAAGGAGCAG	1020
CysProProValTyrAlaGluThrLysHisPheLeuTyrSerSerGlyAspLysGluGln	340
CTGGGGCCCTCCTTCTACTCAGCTCTCTGAGGCCAGCCTGACTGGCGCTCGAGGCTC	1080
LeuArgProSerPheLeuLeuSerSerLeuArgProSerLeuThrGlyAlaArgArgLeu	360
GTGGAGACCATCTTTCTGGGTTCCAGGCCCTGGATGCCAGGGACTCCCGCAGGTTGCC	1140
ValGluThrIlePheLeuGlySerArgProTrpMetProGlyThrProArgArgLeuPro	380
CGCCTGCCCGAGCGCTACTGGCAAATGCGGCCCTGTTTCTGGAGCTGCTTGGGAACCAC	1200
ArgLeuProGlnArgTyrTrpGlnMetArgProLeuPheLeuGluLeuGlyAsnHis	400
GCGCAGTGCCCTACGGGGTGCTCCTCAAGACGCACTGCCCGCTGCGAGCTGCGGTACC	1260
AlaGlnCysProTyrGlyValLeuLeuLysThrHisCysProLeuArgAlaAlaValThr	420
CCAGCAGCGGTGTGTGTGCCCGGGAAGCCCCAGGGCTCTGTGGCGGGCCCCGAGGAG	1320
ProAlaAlaGlyValCysAlaArgGluLysProGlnGlySerValAlaAlaProGluGlu	440
GAGGACACAGACCCCGCTGCGCTGGTGCAGCTGCTCCGCCAGCAGCAGCCCTGGCAG	1380
GluAspThrAspProArgArgLeuValGlnLeuLeuArgGlnHisSerSerProTrpGln	460
GTGTACGGCTTGTGCGGGCTGCTGCGCCGGCTGTGCCCCAGGCCTCTGGGGCTCC	1440
ValTyrGlyPheValArgAlaCysLeuArgArgLeuValProProGlyLeuTrpGlySer	480
AGGCACAACGAACGCGCTTCTCAGGAACACCAAGAAGTTCATCTCCCTGGGAAGCAT	1500
ArgHisAsnGluArgArgPheLeuArgAsnThrLysLysPheIleSerLeuGlyLysHis	500
GCCAGCTCTCGCTGCAGGAGCTGACGTGGAAGATGAGCGTGGGGCTGCGCTTGSGTG	1560
AlaLysLeuSerLeuGlnGluLeuThrTrpLysMetSerValArgAspCysAlaTrpLeu	520
CGCAGGAGCCAGGGGTTGGCTGTGTTCCGGCCGAGAGCACCGTCTGCGTGAGGAGATC	1620
ArgArgSerProGlyValGlyCysValProAlaAlaGluHisArgLeuArgGluGluIle	540
CTGCCAAGTTCTGCACTGGCTGATGAGTGTGTACGTGCTGAGCTGCTCAGGTCTTTC	1680
LeuAlaLysPheLeuHisTrpLeuMetSerValTyrValValGluLeuLeuArgSerPhe	560
TTTTATGTCACGGAGACCGTTTCAAAGAACAGGCTCTTTTCTACCGGAAGAGTGTG	1740
PheTyrValThrGluThrThrPheGlnLysAsnArgLeuPhePheTyrArgLysSerVal	580

Fig. 11AA

43/68

TGSAGCAAGTTGCAAGCATTGGAATCAGACAGCACTTGAAGAGGTGCAGCTGCGGGAG	1800
TrpSerLysLeuGlnSerIleGlyIleArgGlnHisLeuLysArgValGlnLeuArgGlu	600
CTGTGGAAGCAGAGGTGAGGAGCATCGGAAGCCAGGCCGCCCTGCTGACGTCCAGA	1860
LeuSerGluAlaGluValArgGlnHisArgGluAlaArgProAlaLeuLeuThrSerArg	620
CTCCGCTTCATCCCAAGCCTGACGGGCTGCGGCCATTGTGAACATGGAAGTACGTCTGTG	1920
LeuArgPheIleProLysProAspGlyLeuArgProIleValAsnMetAspTyrValVal	640
GGAGCCAGAACGTTCCGAGAGAAAAGAGGGCCGAGCGTCTCACCTGAGGGTGAAGGCA	1980
GlyAlaArgThrPheArgArgGluLysArgAlaGluArgLeuThrSerArgValLysAla	660
CTGTTACGCGTGTCAACTACGAGCGGGCGGGCGGCCCGGCTCTGCGCGCTCTGTG	2040
LeuPheSerValLeuAsnTyrGluArgAlaArgArgProGlyLeuLeuGlyAlaSerVal	680
CTGGGCTGGAGATATCCACAGGGCTGGGGACCTTCGTCTGCGTGTGCGGGCCAG	2100
LeuGlyLeuAspAspIleHisArgAlaTrpArgThrPheValLeuArgValArgAlaGln	700
GACCCCGCGCTGAGCTGTACTTTGTCAAGGTGGATGTGACGGCGCGTACGACACCATC	2160
AspProProProGluLeuTyrPheValLysValAspValThrGlyAlaTyrAspThrIle	720
CCCCAGGACAGGCTCAGGAGGTGATCGCCAGCATCATCAACCCAGAACGTAAGTGC	2220
ProGlnAspArgLeuThrGluValIleAlaSerIleIleLysProGlnAsnThrTyrCys	740
GTGCGTCGGTATGCGGTGTCAGAGGGCGGCCATGGGCACGTCCGCAAGGCCTCAAG	2280
ValArgArgTyrAlaValValGlnLysAlaAlaHisGlyHisValArgLysAlaPheLys	760
AGCCAGCTCTCTACCTTGACAGACCTCAGCGTACATGGGACAGTTCGTGGCTCACCTG	2340
SerHisValSerThrLeuThrAspLeuGlnProTyrMetArgGlnPheValAlaHisLeu	780
CAGGAGACAGCCCGCTGAGGGATGCGGTGTCATGAGCAGAGCTCCTCCCTGAATGAG	2400
GlnGluThrSerProLeuArgAspAlaValValIleGluGlnSerSerSerLeuAsnGlu	800
GCCAGCAGTGCGCTCTCGACGCTCTCTACGCTTCATGTGCCACCACGCGTGCACATC	2460
AlaSerSerGlyLeuPheAspValPheLeuArgPheMetCysHisHisAlaValArgIle	820
AGGGCAAGTCTACGTCCAGTGCCAGGGATCCCGCAGGGCTCCATCCTCTCCAGGCTG	2520
ArgGlyLysSerTyrValGlnCysGlnGlyIleProGlnGlySerIleLeuSerThrLeu	840
CTCTGACCGCTGTGCTACGGGACATGGAGAACAGCTGTTTGGGGGATTGGGGGAC	2580
LeuCysSerLeuCysTyrGlyAspMetGluAsnLysLeuPheAlaGlyIleArgArgAsp	860
GGGCTGCTCCTGCGTTTGGTGGATGATTTCTTGTGTGTGACAGCTCACCTCACCACGGG	2640
GlyLeuLeuLeuArgLeuValAspPheLeuLeuValThrProHisLeuThrHisAla	880
AAAACCTTCCTCAGGACCTGGTCCGAGGTGTCCTGAGTATGGCTGCGTGGTGAAGTGG	2700
LysThrPheLeuArgThrLeuValArgGlyValProGluTyrGlyCysValValAsnLeu	900

Fig. 11AB

44/68

CGGAAGACAGTGGTGAACCTCCCTGTAGAAGACGAGGCCCTGGGTGGACGGCTTTTGTT	2760
ArgLysThrValValAsnPheProValGluAspGluAlaLeuGlyGlyThrAlaPheVal	920
CAGATGCCGGCCACGGCCTATCCCTGGTGGCCCTGCTGCTGSATACCGGACCCTG	2820
GlnMetProAlaHisGlyLeuPheProTrpCysGlyLeuLeuLeuAspThrArgThrLeu	940
GAGGTGCAGAGCCTACTCCAGCTATGCCGGACCTCCATCAGAGCCAGTCTCACCTTC	2880
GluValGlnSerAspTyrSerSerTyrAlaArgThrSerIleArgAlaSerLeuThrPhe	960
AACCGCGGCTTCAAGGTGGGAGGAACATGCGTCGCAAACTCTTTGGGCTCTGGCGCTG	2940
AsnArgGlyPheLysAlaGlyArgAsnMetArgArgLysLeuPheGlyValLeuArgLeu	980
AAGTGTACAGCCTGTTTCTGGATTGTCAGGTGAACAGCCTCCAGACGGTGTGCACCAAC	3000
LysCysHisSerLeuPheLeuAspLeuGlnValAsnSerLeuGlnThrValCysThrAsn	1000
ATCTACAAGATCCTCCTGCTGCAGGGTACAGGTTTCACGCATGTGTGCTGCAGCTCCA	3060
IleTyrLysIleLeuLeuGlnAlaTyrArgPheHisAlaCysValLeuGlnLeuPro	1020
TTTCATCAGCAAGTTTGAAGAAGCCACATTTTCTGCGCGTCATCTCTGACAGGCC	3120
PheHisGlnGlnValTrpLysAsnProThrPhePheLeuArgValIleSerAspThrAla	1040
TCCCTGCTACTCCTCATCTGAAAGCCAGAACGCGAGGATGTCGCTGGGGGCCAAGGGC	3180
SerLeuCysTyrSerIleLeuLysAlaLysAsnAlaGlyMetSerLeuGlyAlaLysGly	1060
GCGCGCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCTGCTC	3240
AlaAlaGlyProLeuProSerGluAlaValGlnTrpLeuCysHisGlnAlaPheLeuLeu	1080
AAGCTGACTCGACACCGTGTCACTACGTGCCACTCCTGGGGTCACTCAGGACAGCCAG	3300
LysLeuThrArgHisArgValThrTyrValProLeuLeuGlySerLeuArgThrAlaGln	1100
ACGCAGCTGASTCGGAAGCTCCCGGGGACGACGCTGACTGCCCTGGAGGCCGACGCAAC	3360
ThrGlnLeuSerArgLysLeuProGlyThrThrLeuThrAlaLeuGluAlaAlaAlaAsn	1120
CGGGCACTGCCCTCAGACTTCAAGACCATCCTGGAC	3420
ProAlaLeuProSerAspPheLysThrIleLeuAsp	1132

Fig. 11AC

Truncated protein 3 (ver. 2)

CTTGCGCCGGTGGTGCCTCCAGGCGCTCTGGGGTCCAGGCACAAGGAAGCGCGCTTCCTCAGGAACACCAAGAAGTTCATCTCCCTGGGAAGCATGCCAAGCTCTGGTGCAGGAGCT
 L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

Fig. 11AD

46/68

GACGTGAAGATGAGCGTGCAGGACTGCGCTTGGCTGCCAGGAGCCAGGGGTTGGCTGTGTTCCGGCCGAGAGCACCCTGCGGTGAGGAGATCCTGGCCAAGTTCCTGCACGTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

GATGAGTGTGTACGTGCTCGAGCTGCTCAGGTCTTTCTTTATGTACAGGAGACCAGTTTCAAAGAACAGGCTCTTTTCTACCGGAAGAGTGTCTGGAGCAAGTTGCAAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G

AATCAGACAGCACTTGAAGAGGGTGCAGCTGCGGAGCTGTGGGAAGCAGAGGTGAGGAGCATCGGGAAGCCAGGCCCGCCCTGCTGACGTCCAGACTCCGCTTCATCCCAAGCCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D

CGGGCTGCGGCGATTGTGAACATGGACTACGTGCTGGGAGCCAGAACGTTCCGAGAGAAAAGAGGGCCGAGGCTCTCACCTCGAGGTGAAGGCACTGTTACGCTGCTCACTACGA
G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E

GCGGGCGCGGCCCGCCGCTCTGGGCGCTCTGTGCTGGGCTGGACGATATCCAGAGGCTGCGGACCTTCGTGCTGCGTGTGCGGGCCAGGACCCGCGCTGAGCTGTACTT
R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F

TGTCAAGGTGGATGTGACGGGCGGTACGACACCATCCCCAGGACAGGCTCACGGAGGTGATCGCCAGCATCATCAAAACCCAGAACAGTACTGCGTGCCTGGTATGCCGTGGTCCA
V K V D V T G A Y D T I P Q D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q

GAAGGCCCGCATGGGCACGTCCCAAGGCCTTCAAGAGCCAGGTCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTCGTGGCTCACCTGCAGGAGACAGCCGCTGAGGGA
K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D

TGCCGTGTCATCGAGCAGAGCTCCTCCCTGAATGAGGCCAGCAGTGGCTCTTCGAGCTCTTCTACGCTTCATGTGCCACCGCGGTGGCATCAGGGCAAGTCTACGTCCAGTG
A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C

CCAGGGGATCCCGCAGGCTCCATCCTCTCCAGCTGCTCTGACGCTGTGCTACGGCGACATGGAGAACAAGCTGTTTGCGGGATTCCGGGGGACGGGCTGCTCCTGCCGTTTGGTGA
Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D

TGATTTCTTGTGGTGACACCTCACCTCACCCAGCGAAAACCTTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTTGGGAAGACAGTGGTGAACCTCCC
D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P

TGTAGAAGCAGAGGCCCTGGGTGGCAGGCTTTTGTTCAGATGCCGGCCACGGCCTATTCCCTGGTGGGCTGCTGCTGATACCCGACCTGGAGGTGCAGAGCAGTACTCCAG
V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S R

GTGAGGCACTTGGCCGAAGTGGAGCTGTGCCGCTGGGCAAGTGTCTGTCAGGGCGTTGCGTCCACCTCTGCTTCGTTGTGGGGCAGGCGACTGCCAATCCCAAGGGTCAGA
*

TGCCACAGGGTGCCCTCGTCCATCTGGGCTGAGCACAATGCATCTTCTGTGGAGTGAGGGTGCCTCACAACGGGAGCAGTTTCTGTGCTATTTTGGTAA

Fig. 11AE

47/68

Altered C-terminus protein (ver. 2)

[illegible]

Fig. 11AF

48/68

GACGTGAAGATGAGCGTGGGGACTGCGCTTGGCTGCGCAGGAGCCAGGGGTGGCTGTGTTCCGGCCGACAGCACCCTGCGGTGAGGAGATCCTGGCAAGTCTGCACTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L
GATGAGTGTGTACGTGCTGAGCTGCTCAGGTCTTTCTTTATGTACGGAGACCAGTTCAAAGAAGAGGCTCTTTTCTACGGGAAGAGTGTCTGGAGCAAGTTCGAAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
AATCAGACAGCATTGAAGAGGGTGCAGCTGCGGGAGCTGTGGAAGCAGAGGTGAGCAGCATCGGGAAGCCAGGCCCGCCCTGCTGACGTCCAGACTCCGCTTCATCCCCAAGCCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
CGGGCTGCGGCCGATTGTGAACATGGAAGTGTGAGGAGCCAGAACGTTCCGACAGAAAAGAGGGCCGAGCGTCTCACCTCGAGGGTGAAGGCACTGTCAGCGTGTCAACTACGA
G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
GCGGGCGGGCCCGCCGCTCTGCTGGGCGCTGTGCTGGGCTGGAAGATCCAGAGGCTTGGCGCACCTTCTGCTGCGGTGCGGGCCAGGACCCCGCCCTGAGCTGTACTT
R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
TGTCAAGTGGATGTGACGGGCGGTACGACACCATCCCCAGGACAGGCTCAGGAGGTATCGCCAGCATCATCAAAACCCAGAACAGTACTGCGTGCCTGCGTATGCCGTGGTCCA
V K V D V T G A Y D T I P Q D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
GAAGCCCGCCCATGGGACGTCCGCAAGGCTTCAAGAGCCAGCTCTTACCTTGACAGACCTCCAGCCGTACATGCGACAGTTGGTGGCTCACTGCGAGAGACAGCCCGCTGAGGA
K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D
TGCGTGTGTCAGCAGAGCTCCTCCCTGAATGAGGCCAGCAGTGGCTCTTCCAGCTTCTCTAGGCTTCTATGTCGCCACCAAGCCGTGGCATCAGGGCAAGTCTACGTCCAGTG
A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C
CCAGGGATCCCGCAGGGCTCATCTCTCCAGCTGCTCTGAGCTGTGTACGGCAGATGGAGAACAGCTGTTTGGGGGATTGGGGGGACGGCTGCTCTGCGTTTGGTGA
Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D
TGATTTCTGTGTGTGACAGCTCACTCACCACCGGAAACCTTCTCAGGACCTGCTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTGCCGAAGACAGTGGTGAATCCG
D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P
TGTAAGACGAGGCCCTGGGTGGCAGGCTTTTGTTCAGATGCCGGCCACGGCTATTCCCTGGTGGGCTGCTGCTGGATACCGGACCTGGAGGTGCAGAGCAGTACTCCAG
V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S S
CTATGCCCGACCTCCATCAGAGCAGTCTCACCTTCAACCGCGGCTTCAAGGCTGGGAGAACATGCTCGCAACTCTTTGGGGTCTTGGGCTGAAGTGTACAGCCTGTTTCTGGA
Y A R T S I R A S L T F N R G F K A G R N M R R K L F G V L R L K C H S L F L D
TTTGAGGTGAACAGCCTCCAGAGGTGTGCACCAACATCTACAAGATCCTCTGCTGAGGCTACAGGTTTCAGCATGTGTGCTGAGCTCCATTTCATCAGCAAGTTTGAAGAA
L Q V N S L Q T V C T N I Y K I L L L Q A Y R F H A C V L Q L P F H Q Q V W K N
CCCCACATTTTCTGCGGTATCTCTGACAGGCTCCTCTGCTACTCCATCTGAAAGCCAGAACGAGGGATGTGCTGGGGGCCAAGGGCGCCCGGCGCTCTGCCCTCCGA
P T F F L R V I S D T A S L C Y S I L K A K N A E

CCGAAGAAAACATTTCTGTGCTGACTCTGCGGTGCTTGGGTC
E E N I L V V T P A V L G S

GGGACAGCCAGAGATGGAGCCACCCGACAGCCTCGGGTGTGGGAGCTTTCGGTGTCTCTGGGAGGGAGTTGGGCTGGGCTGTGACTCCTCAGCCTCTGTTTTCCCCAG
G Q P E M E P P R R P S G V G S F P V S P G R G V G L G L *

Fig. 11AG

Protein that lacks motif A (ver. 2)

Fig. 11AH

GACGTGGAAGATGACGCTGCGGGACTGCGCTTGGCTGCGCAGGAGCCAGGGGTGGCTGTGTTCCGGCCGACAGACACGCTGCGGTGAGGAGATCCTGCCAAGTCTCTGCACTGGCT
 T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L
 GATGAGTGTGTACGTCGTCGAGCTGCTCAGGTCTTTCTTTATGTACCGAGACCACGTTTCAAAGAACAGGCTCTTTTTCTACCGAAGAGTGTCTGGAGCAAGTGCAAAGCATTGG
 M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
 AATCAGACAGCACTTGAAGAGGGTGACGCTGCGGGAGCTGTGGAAGCAGAGGTACGGCAGCATCGGGAAGCCAGGCCCGCCTGCTGACGTCAGACTCCGCTTCATCCCCAAGCCTGA
 I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
 CGGGCTCGGGCSATTGTGAACATGGACTACGTCGTGGGAGCCAGAACGTTCCGACAGAAAAAGAGGGCCGAGGCTCTCACCTCGAGGAGTGAAGGCACTGTTACGCGTGTCAACTACGA
 G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
 GCGGGCGGGGCCCGCGGCTCTGCTGGGCGCTGTGCTGGGCGCTGGACGATATCCACAGGGCCTGGGCGACCTTCGTGCTGCGTGTGGGGGCCAGGACCGCGCGCTGAGCTGTACTT
 R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
 TGTCAAG
 V K
 GACAGGCTCACGAGGTCATCGCCAGCATCATCAAAAGCCAGAACGCTACTGCGTGGTGGTATGCCGTGGTCCA
 D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
 GAAGGCCGCCCATGGGACGTCGCAAGGCTTCAAGAGCCAGCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTCGTGGCTCACCTGCAGGAGACCAGCCGCTGAGGGA
 K A A H G H V R K A F K S H V S T L T D L O P Y M R Q F V A H L Q E T S P L R D
 TGGCTGTCATCGACAGAGCTCCTCCCTGAATGAGGCCAGCAGTGGCTCTTCGACGCTCTCTACGCTTCATGTGCCACCAAGCGCTGCCATCAGGGCAAGTCTACGTCAGTG
 A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C
 CCAGGGGATCCCGCAGGCTCCATCCTCTCCAGCTGCTCTGCAGCCTGTGCTACGGGACATGAGAGAACAAGCTGTTTCCGGGGATTCCGGGGACGGGCTGCTCCTGGTGTGGTGA
 Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D
 TGATTTCTGTGTGACACCTCACCTCACCCAGCGAAAAACCTTCTCAGGACCTGGTCCGAGGTGCTCCTGAGTATGGCTGGCTGGTGAAGTTCGCGAAGACAGTGGTGAAGTCCC
 D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P
 TGTAGAAGAGAGGCGCTGGGTGGCAGGCTTTTGTTCAGATGCGGGCCACGGCTATTCCCTGGTGGCGCTGCTGCTGGATACCCGACCTGGAGGTGCAGAGCGACTACTCCAG
 V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S S
 CTATGCGCGGACCTCCATCAGAGCCAGTCTCACCTTCAACCGGGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGCTCTTGGGCTGAAGTGTACAGCCTGTTTCTGGA
 Y A R T S I R A S L T F N R G F K A G R N M R R K L F G V L R L K C H S L F L D
 TTTGAGGTGAACAGCCTCCAGAGGTTGTGACCAACATCTACAAGATCCTCTGCTGCAGGCGTACAGGTTTCAGGCATGTGTGCTGCAGCTCCCATTTTCATCAGCAAGTTTGAAGAA
 L Q V N S L Q T V C T N I Y K I L L L Q A Y R F H A C V L Q L P F H Q Q V W K N
 CCCACATTTTCTGCGGTCATCTCTGACAGGCTCCTCTGCTACTCCATCCTGAAAGCCAAGAACGACAGGATGTGCTGGGGGCCAAGGGCGCGCGGCCCTCTGCCCTCCGA
 P T F F L R V I S D T A S L C Y S I L K A K N A G M S L G A K G A A G P L P S E
 GGGCTGCGAGTGGCTGTGCCACCAAGCATTCTGCTCAAGCTGACTCGACACCGTGTACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCAGGACGAGTGTGAGTGGAGGCTCCC
 A V Q W L C H Q A F L L K L T R H R V T Y V P I L G S I R T A Q T Q L S R K L P

Fig. 11AI

51/68

GGGAGGACGCTGACTGCCCTGGAGGCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACTGATGGCCACCCGCCACAGCCAGGCCAGAGCAGACACCAGCAGCC
G T T L T A L E A A N P A L P S D F K T I L D

CTGTCAACGCGGCTCTACSTCCAGGGAGGGAGGGGCGGCCACACCCAGGCCCGCACCGCTGGGAGTCTGAGGCTGAGTGAGTGTTTGGCCGAGGCCGTCATGTCCGGCTGAGGCT
GAGTGTCGGCTGAGGCTGAGGCTGAGTGTCAGCCAAGGCTGAGTGTCAGCACACCTGCCGTCTTCACTTCCCACAGGCTGGCGCTGGGCTCCACCCAGGGCCAGCTTTTCTCAG
CAGGAGCCCGCTTCCACTCCCACATAGGAATAGTCCATCCGAGATTGCCATTGTTACCCCTCGCCCTGCCCTCCTTTGCTTCCACCCCCACCATCCAGGTGGAGACCTGAGAA
GGACCTGGGAGCTCTGGGAATTTGGAGTGACCAAGGTGTGCCCTGTACACAGGCGAGGACCTGCACCTGGATGGGGTCCCTGTGGGTCAAATTGGGGGAGGTCTGTGGGAGTAA
AATACTGAATATATGAGTTTTTCAGTTTTGA

Fig. 11AJ

Truncated protein that lacks motif A (ver. 2)

CGGGGCGCTGGGGCCCGCAGGGGTGGGGGGTGGTGCAGGCCGGGGACCGGGCGGCTTTCCGGGCGCTGGTGGGCCAGTGCCTGGTGTGGCTGGCCCTGGGACGCACGGCGGGCCCCCGGGCGC
R R L G P Q G W R L V Q R G D P A A F R A L V A Q C L V C V P W D A R P P P A A

GGCCCTCCCCGGGTGCGCGTCCGGCTGGGGTTGAGGGCGCCGGGGGGAACAGCGACATGCGGAGAGCAGCGCAGGCGACTCAGGCGGCTTCCCCGCGAGGTG
G L P G V G V R L G L R A A G G N Q R H A E S S A G G C A G G F R P R R
A S P G S A S G W G * G R P G G T S D M R R A A Q A T O G A S P A G
P P R G R R P A G V E G G R G E P A T C G E Q R R R L R A L P P Q V

CCGCTCCTTCCGCGAGGTGCTGCTGCTGAAGGAGCTGGTGGCCGAGTGCTGCAGAGCTGTGGAGCGGGGGCGAAGAACGTGCTGGCTTCGGCTTCGCGCTGCTGGACGGGGCCCG
P S F R Q V S C L K E L V A R V L Q R L C E R G A K N V L A F G F A L L D G A R

CGGGGGCCCCCGAGGGCTTCACCAACAGCGTGGGCAGCTACCTGCCCAACACGGTGACCGACGCACTGGGGGGAGCGGGGCGTGGGGGCTGCTGCTGGCCCGGTGGGGCAGCAGT
G G P P E A F T T S V R S Y L P N T V T D A L R G S G A W G L L L R R V G D D V

GCTGTTACACTGCTGGCACCGCTGGCGCTCTTTGTGCTGGTGGCTCCACAGTGGCGCTACCAAGTGTGGGGCGCGCTGTACCAAGTCCGGCTGGCACTCAGGCCGGCGCGCGCC
LVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARP

ACACGCTAGTGGACCCCGAAGGGCTCTGGGATGCCAACGGGCTGGAAACCATAGGCTCAGGAGGCGGGGTCCCCCTGGGCTGCCAGCCCCGGGTGGAGGAGGCGGGGGGAGTGC
H A S G P R R R L G C E R A W N H S V R E A G V P L G L P A P G A R R R G G S A

CAGCCGGAAGTCTGCCGTTGCCCAAGAGGCCCGAGGGGTGGCGCTGCCCGCTGAGCCGGAGCGGACGCCGTTGGGACAGGGGTCCTGGGGCCACCGGGGAGGACGCTGGACCGAGTGAACG
S R S L P L P K R P R R G A A P E P E R T P V G Q G S W A H P G R T R G P S D R

TGGTTTCTGTGTGTGTACCTGCCAGACCCGCCAAGAACCCACTCTTTGGAGGGTGGGTCTCTGGCAGCGGCCACTCCACCCATCCGTGGGCGGCCAGCACCGCGGGCCCCC
GFCVVSPPARPAEEATSLGALSGLTRHSHPSVGRQHHAGPP

ATCCACATCCGGGGACCAAGTCCCTGGGACAGCCTTGTCCCGGTTACGGGAGACCAAGCACTTCTCTACTCCTCAGGGACAGGAGCAGCTGGGGCCTCCTTCTACTCAG
S T S R P P R P W D T P C P P V Y A E T K H F L Y S S G D K E Q L R P S F L L S

CTCTCTGAGGCCAGGCTGACTGGCGCTCGGAGGCTCGTGGAGACATCTTTCTGGGTTCCAGGCGCTGGATGCCAGGACTCCCGCAGGTTGCCCGCCCTGCCGAGCGTACTGGCA
S L R P S L T G A R R L V E T I F L G S R P W M P G T P R R L L P R L P Q R Y W Q

AATGGGGCCCTGTTTCTGGAGCTGCTTGGGAACCAAGGGCAGTGGCCCTACGGGCTGCTCTCAAGAGGCACTGCCCGCTGGGAGCTGGGGTCAACCCAGCAGCCGGTGTCTGTGGCGG
M R P L F L E L L G N H A Q C P Y G V L L K T H C P L R A A V T P A A G V C A R

CGAGAAGCCCCAGGGCTCTGTGGGGGCCCCGAGGAGGAGGACACAGACCCCGTGCCTGGTGCAGCTGCTCCGCCAGCAGCAGCCCGCTGCCAGGTGTACGGCTTCGTGGGGGCTG
E K P Q G S V A A P E E E D T D P R R L V Q L L R Q H S S P W Q V Y G F V R A C

CCTGCCCGCGCTGTGCCCCAGGCGCTCTGGGGCTCAGGCACAACGAACGCGGTTCTCAGGAACACCAAGAAGTTCATCTCCCTGGGGAAGCATGCCAAGCTCTCCTGCAGGAGCT
L R R L V P P G L W G S R H N E R R F L R N T K K F I S L G K H A K L S L Q E L

GAGGTGGAGATGAGGCTGCGGGACTGCGCTTGGCTGCCAGGAGCCAGGGGTTGGCTGTGTTCCGGCCGAGAGCACCGTCTCGCTGAGGAGATCTCTGCCCAAGTTCTGCACTGGCT
T W K M S V R D C A W L R R S P G V G C V P A A E H R L R E E I L A K F L H W L

Fig. 11AK

53/68

GATGAGTGTGTACGTGCTGAGCTGCTCAGGTCTTTCTTTATGTACGAGACCACTTTCAAAGAAGAGGCTCTTTTCTACCGAAGAGTGTCTGAGCAAGTGTCAAAGCATTGG
 M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
 AATCAGACGCACTTGAAGAGGTTGAGCTGCGGAGCTGTGGAAGCAGAGGTGAGGAGCATCGGAAGCCAGGCCCGCTGCTGACGTCCAGACTCCGCTTCATCCCAAGCCTGA
 I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
 CCGGCTGCGGCGATTGTGAACATGSACTACGTGCTGGGAGCCAGAACSTTCCGAGAGAAAAGAGGCCGAGGCTCTACCTCGAGGTAAGGCACTGTTCAAGGTGCTCAACTACGA
 G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
 GCGGCGCGGCGCCCGGCTCCTGGGCGCTCTGTGCTGGGCTGAGGATATCCAGAGGCTGCGGCACTTCTGCTGCGTGTGCGGCGCAGGACCGCGGCTGAGCTGTACTT
 R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
 TGTCAAG
 V K
 GACAGGCTCAGGAGGTCATCGCCAGCATCATCAAAACCCAGAACAGTACTGGTGGCTGGTATGCGGTGTGCA
 D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q
 GAAGCGCGCCATGGGCACTGCGCAAGGCTTCAAGAGCCAGCTCTCTACCTTGACAGACCTCCAGCGTACATGCGAGAGTCTGGCTCACCTCGAGGAGACCGCGGCTGAGGA
 K A A H G H V R K A F K S H V S T L T D L Q P Y M R Q F V A H L Q E T S P L R D
 TGCCGTGTCATCGAGCAGAGCTCCTCCCTGAATGAGGCCAGAGTGGCTCTTCCAGCTCTTCTACGCTTATGTGCCACACCGCTGCGCATCAGGGCAAGTCTTACCTCCAGT
 A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C
 CCAGGGATCCCGAGGGCTCCATCCTCTCCAGCTGCTCTGAGCTGTGCTACGGCAGCATGGAGAACAAGCTGTTTGGCGGATTCCGCGGACGGGCTGCTCCTGGCTTTGGTGA
 Q G I P Q G S I L S T L L C S L C Y G D M E N K L F A G I R R D G L L L R L V D
 TGATTCTGTGTGTGACACCTCACCTCACCCACGCAAAACCTTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTTGGGAAGACAGTGGTGAACCTCCC
 D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P
 TGTAGAAGACGAGGCGCTGGGTGGCAGGCTTTTGTTCAGATGCGGCGCCAGGCTATTCCCTGGTGGGCGCTGCTGCTGGATACCGGACCCCTGGAGGTGAGAGGCACTACTCCAG
 V E D E A L G G T A F V Q M P A H G L F P W C G L L L D T R T L E V Q S D Y S R
 GTGAGCGACCTGGCGGAAGTGGAGCCTGTGCCCGCTGGGCAAGTGTGCTGAGGGCGGTGGCTCCACCTCTGCTTCGCTGTGGGCAAGGCACTGCCAATCCAAAGGCTCAGA
 TGCCACAGGTTGCCCTCCTCCATCTGGGCTGAGCACAATGCATCTTCTGTGGAGTGAGGGTGCTCACAACGGGAGCAGTTTCTGTGCTATTTTGTAA

Fig. 11AL

Lacks motif A and altered C-terminus (ver. 2)

Fig. 11AM

55/68

GATGAGTGTGTACGTGTCGAGCTGCTCAGGTCCTTTCTTTATGTCAAGGAGACACGTTTCAAAAGAACAGCCTCTTTTCTACCGAAGAGTGTCTGGAGCAAGTGTCAAAGCATTGG
M S V Y V V E L L R S F F Y V T E T T F Q K N R L F F Y R K S V W S K L Q S I G
AATCAGACAGCACTTGAAGAGGGTGCAGCTGCGGGAGCTGTGCGAAGCAGAGGTCAAGCAGCATCGGGAGCCAGGCCCGCCCTGCTGAGCTCCAGACTCCGGTTTCATCCCCAAGCCTGA
I R Q H L K R V Q L R E L S E A E V R Q H R E A R P A L L T S R L R F I P K P D
CGGGCTCGGGCCGATTGTGAACATGGACTACGTGTCGGAGCCAGAAGCTTCGCGAGAGAAAAGGGCCGAGCGTCTCACCTCGAGGGTGAAAGCACTGTTCCAGGTGCTCAACTACGA
G L R P I V N M D Y V V G A R T F R R E K R A E R L T S R V K A L F S V L N Y E
GGGGGGCGGGCCCCCGGCTCTCTGGGGGCTCTGTGCTGGGGCTGGACGATATCCACAGGGCTGGCGCAGCTTGTGCTGTGGTGTGCGGGGCCAGGACCCGCGCTGAGCTGTACTT
R A R R P G L L G A S V L G L D D I H R A W R T F V L R V R A Q D P P P E L Y F
TGTCAGG
V K
GACAGGCTCACGAGGTTCATCGCCAGCATCATCAAAACCCAGAACAGTACTGGTGTGCTGGSTATCGGTGTGTCA
D R L T E V I A S I I K P Q N T Y C V R R Y A V V Q

GAAGCGCGCCCATGGGCAGCTCGCAAGGCCTTCAAGAGCCAGCTCTCTACCTTGACAGACCTCCAGCGTACATGCGACAGTTGCTGGCTCACCTGCAGGAGACCAGCCCGCTGAGGGA
K A A H G H V R K A F K S H V S T L T D L Q P Y W R Q F V A H L Q E T S P L R D

TGGCGTGGTCATCGAGCAGAGCTCTCCCTGAATGAGGCAGCAGTGGCCTCTTCCAGCTTCTCTACGCTTCAATGTCACCAAGCGCGTGGCGATCAGGGGCAAGTCTCTACGCTCCAGTG
A V V I E Q S S S L N E A S S G L F D V F L R F M C H H A V R I R G K S Y V Q C

CCAGGGGATCCCGCAGGGCTCCATCCTCTCCACGCTGCTCTGCAGCTGTGCTADGGGACATGGAGAACAAGCTGTTTCGGGGGATTGGGGGACGGGGCTGCTCTGGGTTTGSTGA
Q G I P Q G S I L S T L L C S L C Y G D H E N K L F A G I R R D G L L L R L V D

TGATTTCTGTTGGTGACACCTCACCTCACCCACGCCAAAACCTTCTCTCAGGACCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACCTGCGGAAGACAGTGGTGAATTCCC
 D F L L V T P H L T H A K T F L R T L V R G V P E Y G C V V N L R K T V V N F P

TGTAGAAGACGAGGCCCTGGTGGCAGGGCTTTGTTCAGATGCCGGCCACGGCTATTCCTCGTGGGCTGCTGCTGGATACCCGACCGCTGGAGGTGCAGAGCGACTACTCCAG
VEDEALGGTA FVQMPAHGLFPWCGLLLDTRTLEVS DYSS

CTATGCCCGGACCTCCATCAGAGCCAGTCTCACCCTTCAACCGCGGCTTCAAGGCTGGGAGGAACATCGGTGCAAACTCTTTGGGGTCTTGGGGCTGAAGTGTACAGCCTGTTTCTGGA
Y A R T S I R A S L T F N R G F K A G R N M R R K L F G V L R L K C H S L F L D

TTTGCAGGTGAACAGCCTCCAGACGGTGTGCACCAACATCTACAAGATCCTCCTGCTGCAGCGGTACAGGTTTCAGGCATGTGTGCTGCAGTCCCAATTCATCAGCAAGTTTGAAGAA
LQVNSLQTVCTNIYKILLQAYRFHACVLQLPFHQQVWKN

CCCCACATTTTCTGCGCGTCATCTCTGACACGGCTCCCTCTGCTACTCCATCCTGAAAGCCAGAAGCAGGGATGTCCTGGGGGCCAAGGCGGCCCGCGCCCTCTGCCCTCGGA
PTFFFLRVISDTASLCYSILKAKNAE


CCGAAGAAAAACATTTCTGTCGTGACTCCTCGGTCGCTTGGGTC
E E N I L V V T P A V L G S

GGGACAGCCAGAGATGGAGCCACCCCGACAGCCGTCGGGTGTGGGCAGCTTTCGGTGTCTCTGGGAGGGAGTTGGGCTGGGGCTGTGACTCTCAGCCTCTGTTTTCCCGCAG
G O P E W E P P R R P S G V G S F P V S P G R G V G L G L *

Fig. 11AN

56/68

HeLa									
GM847	p44								
1:10		+ phTC51							
1:100									
GM847	P68			+ phTC51					
1:10									
1:100									
GM847	P68			(-)					
1:10				vec					
1:100									
SUSM-1	p18			+ phTC51					
1:10									
1:100									
RKF-T/A6	p40			+ phTC51					
1:10									
1:100									
lysis buffer									



23/10/97
5 day exposure
2:6

Fig. 12

57/68




Fig. 13A

58/68

LOCUS pAKI28.4 7615 bp dsDNA Circular
 DEFINITION Human telomerase clone with exon beta spliced out

```

1 tgcacctgca ggcattgcaag cttggcactg gccgtcgttt tacaacgtcg tgactgggaa
61 aaccttgccg ttacccaact taatcgccct gcagcacatc cccctttcgc cagctggcgt
121 aatagcgaag agggccgcac cgaatcgccct tccaacagt tgcgcagcct gaatggcgaa
181 tggcgccctga tgcgggtattt tctccttacg catctgtgcg gtatttcaca ccgcataaat
241 tccctgtttt ggcggatgag agaagatttt cagcctgata cagattaaat cagaacgcag
301 aagcggctcg ataaaacaga atttgcctgg cggcagtagc gcggtggtcc cacttgaccc
361 catgccgaac tcagaagtga aacgccgtag cgcgatggt agtggtgggt ctccccatgc
421 gagagtaggg aactgccagg catcaaataa aacgaaaggc tcagtcgaaa gactgggcct
481 ttcgttttat ctgtgtttg tccgtgaacg ctctcctgag taggacaaat ccgcccggag
541 cggatttgaa cgttgcgaag caacggcccg gaggggtggc ggacggacgc ccgccataaa
601 ctgccaggca tcaaattaag cagaaggcca tcctgacgga tggccttttt gcgtttctac
661 aaactcttcc tgtgctcata tctacaagcc atccccccac agatacggta aactagcctc
721 gtttttgcag caggaaagca gggaaatttt ggtgcactct cagtacaatc tgctctgatg
781 ccgcatagtt aagccagccc cgacacccgc caacacccgc tgacgcgccc tgacgggctt
841 gtcgtctccc ggcattccgt tacagacaag ctgtgaccgt ctccgggagc tgcattgttc
901 agagggtttc accgtcatca ccgaaacgcg cgagacgaaa gggcctctgt atacgcctat
961 ttttataggt taatgtcatg ataataatgg tttcttagac gtgaggttct gtaccgcaca
1021 ccattcgaatg gtgcaaaacc tttcgcggtg tggcatgata gcgcccggaa gagagtcaat
1081 tcagggtggt gaattgtgaa ccagtaacgt tatacagatg cgcagagtat gccggtgtct
1141 cttatcagac cgtttccgcg gtggtgaacc aggccagcca cgtttctgcy aaaaacgcggg
1201 aaaaagtgga agcggcgatg gcggagctga attacattcc caaccgcgtg gcacaacaac
1261 tggcgggcaa acagtcgttg ctgattggcg ttgccacctc cagtctggcc ctgcacgcgc
1321 cgtcgcaaat tgcgcggcg attaaatctc gcgcgatca actgggtgcc agcgtgggtg
1381 tgcgatggt agaacgaagc ggcgtcgaag cctgtaaagc ggcggtgcac aatcttctcg
1441 cgaacgcgt cagtgggctg atcattaact atccgctgga tgaccaggat gccattgtctg
1501 tggaaactgc ctgcactaat gttccggcgt tatttcttga tgcctctgac cagacaccca
1561 tcaacagtat tattttctcc catgaagacg gtacgcgact ggcggtggag catctggctg
1621 cattgggtca ccagcaaatc gcgctgttag cgggccatt aagtctgtc tcggcgctc
1681 tgcgtctggc tggctggcat aaatatctca ctgcgaatca aattcagccg atagcggaa
1741 gggaaggcga ctggagtgcc atgtccggtt ttcaacaaac catgcaaatg ctgaatgagg
1801 gcattcgtcc cactgcgatg ctggttgcca acgatcagat ggcgctgggc gcaatgcgcg
1861 ccattaccga gtccgggctg cgcgttggtg cgatatctc ggtagtggga tacgacgata
1921 ccgaagacag ctcatgttat atcccgccgt taaccaccat caaacaggat tttcgccctg
1981 tggggcaaac cagcgtggac cgcttctgac aactctctca gggccaggcg gtgaaggcca
2041 atcagctgtt gccgctctca ctggtgaaaa gaaaaaccac cctggcgccc aatacgcaaa
2101 ccgctctccc ccgcgcgttg gccgattcat taatgcagct ggcacgacag gtttcccgac
2161 tggaaagcgg gcagtgcgca caacgcaatt aatgtaagt agtcactca ttaggcaccc
2221 caggctttac actttatgct tccgacctgc aagaacctca cgtcaggtg cacttttcgg
2281 ggaaatgtgc gcggaacccc tattgttta ttttctaaa tacattcaaa tatgtatccg
2341 ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa gagtatgagt
2401 attcaacatt tccgtgtcgc cttattccc tttttgcgg cattttgcct tctgttttt
2461 gctcaccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg tgcacgagtg
2521 ggttacatcg agaactggat ctcaacagcg gtaagatcct tgagagtttt cgcgccgaag
2581 aacgttttcc aatgatgagc acttttaaag ttctgtatg tggcgcggtg ttatcccgta
2641 ttgacgccgg gcaagagcaa ctccgtcgcc gcatacacta ttctcagaat gacttggtg

```

Fig. 13B

```

2701 agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca
2761 gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca acgatcggag
2821 gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact cgccttgatc
2881 gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc acgatgcctg
2941 tagcaatggc aacaacgttg cgcaaaactat taactggcga actacttact ctagcttccc
3001 ggcaacaatt aatagactgg atggaggcgg ataaagttgc aggaccactt ctgcgtcgg
3061 cccttcgggc tggctggtt attgctgata aatctggagc cggtgagcgt gggctcgcg
3121 gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagt atctacacga
3181 cggggagtcg ggcaactatg gatgaacgaa atagacagat cgctgagata ggtgcctcac
3241 tgattaagca ttgtaactg tcagaccaag ttactcata tatactttag attgatttaa
3301 aacttcattt ttaatttaaa aggatctagg tgaagatcct tttgataat ctcatgacca
3361 aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa aagatcaaag
3421 gatcttcttg agatcccttt tttctgcgcg taatctgctg cttgcaaaca aaaaaaccac
3481 cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactctttt ccgaaggtaa
3541 ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg tagttaggcc
3601 accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaate ctgttaccag
3661 tggctgtgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga cgatagttac
3721 cggataaggc gcagcggctg ggtgaacgg ggggttcgtg cacacagccc agcttgaggc
3781 gaacgaccta caccgaactg agatacctac agcgtgagca ttgagaaagc gccacgcttc
3841 ccgaaggag aaaggcggac aggtatccgg taagcggcag ggtcggaaaca ggagagcgca
3901 cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg tttcgccacc
3961 tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg
4021 ccagcaacgc ggccttttta cgttctctgg ccttttgctg gccttttgct cacatgttct
4081 ttctgtcgtt atccctgat tctgtggata accgtattac cgcctttgag tgagctgata
4141 ccgctcgcgg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc
4201 gcccaatacg caaacgcct ctcgccgcgc gttggccgat tcattaatgc agaattaatt
4261 ctcatgtttg acagcttate atcgactgca cggtgaccca atgcttctgg cgtcaggcag
4321 ccatcggaag ctgtggtatg gctgtgcagg tcgtaaatca ctgcataatt cgtgtcgtc
4381 aaggcgcact cccgttcttg ataattgttt ttgcgcggac atcataacgg ttctggcaaa
4441 tattctgaaa tgagctgttg acaattaate atcggtcgt ataattgttg gaattgtgag
4501 cggataacaa ttccacacag gaaacagcga tgaattcaga tctcaccatg aaggagctgg
4561 tggcccaggt gctgcagagg ctgtgcgagc gcggcgcgaa gaacgtgctg gccttcggct
4621 tcgcgctgct ggacggggcc cgggggggccc ccccgaggc cttcaccacc agcgtgcgca
4681 gctacctgcc caacacggtg accgacgcac tgcgggggag cggggcggtg gggctgctgc
4741 tgcgccgcgt gggcgacgac gtgctggttc acctgctggc acgctgcgcg ctctttgtgc
4801 tgggtggctcc cagctgcgcc taccagggtg gcgggcccgc gctgtaccag ctcggcgctg
4861 ccactcaggc ccggcccccg ccacacgcta gtggaccccg aaggcgtctg ggatgcgaac
4921 gggcctggaa ccatagctc agggaggccg gggccccct gggcctgcca gccccgggtg
4981 cgaggaggcg cgggggcagt gccagccgaa gtctgccgtt gccaagagg cccaggcgtg
5041 gcgctgcccc tgagcgggag cggacgcccg ttgggcaggg gtccctgggc caccggggca
5101 ggacgcgtgg accgagtac cgtggtttct gtgtggtgtc acctgccaga cccgccgaag
5161 aagccacctc ttggagggt gcgtctctg gcacgcgcca ctcccacca tccgtgggccc
5221 gccagacca cgcggggccc ccatccacat cgcggccacc acgtccctgg gacacgcctt
5281 gtccccgggt gtacgcccag accaagcact tcctctactc ctccaggcagc aaggagcagc
5341 tgcggccctc ctctctactc agctctctga gggccagcct gactggcgct cggaggctcg
5401 tggagaccat ctttctgggt tccaggccct ggatgccagg gactccccgc aggttgcccc
5461 gcctgccccg gcgtactgg caaatgcgc ccctgtttct ggagctgctt gggaaccacg
5521 cgcagtcccc ctacgggggtg ctccctaaga cgcactgccc gctgcgagct gcggtcacc

```

Fig. 13C

60/68

5581 cagcagccgg tgtctgtgcc cgggagaagc cccagggctc tgtggcggcc cccgaggagg
5641 aggacacaga ccccgctcgc ctggtgcagc tgctccgcca gcacagcagc ccctggcagg
5701 tgtacggctt cgtgcggggc tgccctgcgc ggctgggtgc cccagggctc tggggctcca
5761 ggcacaacga acgcccgttc ctcaggaaca ccaagaagt catctccctg gggaagcatg
5821 ccaagctctc gctgcaggag ctgacgtgga agatgagcgt gcgggactgc gcttggctgc
5881 gcaggagccc aggggttggc tgtgttcgg ccgcagagca ccgtctgctg gaggagatcc
5941 tggccaagt cctgcactgg ctgatgagt tgtacgtcgt cgagctgctc aggtctttct
6001 tttatgtcac ggagaccacg tttcaaaaga acaggctctt tttctaccgg aagagtgtct
6061 ggagcaagt gcaaagcatt ggaatcagac agcacttgaa gaggggtcag ctgcccggagc
6121 tgtcggagc agaggtcagg cagcatcggg aagccaggcc cggcctgtg acgtccagac
6181 tccgcttcat cccaagcct gacgggctgc ggccgattgt gaacatggac tacgtcgtgg
6241 gagccagaac gttccgcaga gaaaagagg ccgagcgtct cacctcgagg gtgaaggcac
6301 tgttcagcgt gctcaactac gaggcggcgc ggcccccgg cctcctgggc gcctctgtgc
6361 tgggcctgga cgatatccac agggcctggc gcacctcgt gctgcgtgtg cggggccagg
6421 acccgccgcc tgagctgtac tttgtcaagg tggatgtgac gggcgcgtag gacaccatcc
6481 cccaggacag gtcacggag gtcacgcca gcatcatcaa accccagaac acgtactgcg
6541 tgcgtcggta tgcgtggtc cagaaggccg cccatgggca cgtccgcaag gcctcaaga
6601 gccacgtcct acgtccagt ccaggggatc ccgcagggt ccctccttc cacgctgtc
6661 tgcagcctgt gctacggcga catggagaac aagctgtttg cggggattcg gcgggacggg
6721 ctgctcctgc gtttgggtga tgatttctt ttggtgacac ctcacctcac ccacgcgaaa
6781 acttcctcag gacctggtcc gaagtgtcct gagtatggct gcgtggtgaa cttgcggaag
6841 acagtgtgta acttcctgt agaagacgaa gccctgggtg gcacggcttt tgttcagatg
6901 ccggcccacg gcctattccc ctggtgcggc ctgctgctgg ataccggac cctggagggtg
6961 cagagcgact actccagcta tgcccggacc tccatcagag ccagtctcac cttcaaccgc
7021 ggcttcaagg ctgggaggaa catgcgtcgc aaactctttg gggctttgag gctgaagtgt
7081 cacagcctgt ttctggattt gcaggtgaa agcctccaga cgggtgtcac caacatctac
7141 aagatcctcc tgctgcaggc gtacagggtt cagcgtgtg tgctgcagct cccatttcat
7201 cagcaagttt ggaagaacct cacattttt ctgcgcgtca tctctgacac ggctccctc
7261 tgctactcca tctgaaagc caagaacgca gccgaagaaa acatttctgt cgtgactcct
7321 gcggtgcttg ggtcgggaca gccagagatg gagccacccc gcagaccgtc ggggtgtggc
7381 agctttccgg tgtctcctgg gaggggagtt gggctgggccc tgtgactcct cagcctctgt
7441 tttccccag ggtgtcgtc gggggccaag ggcgcgcgc gccctctgcc ctccgaggcc
7501 gtgcagtggc tgtgccacca agcattcctg ctcaagctga ctcgacaccg tgtcacctac
7561 gtgccactcc tggggtcact caggacaggc aagtgtgggt ggaggccagt gcggg

Fig. 13D

61/68




Fig. 14A

62/68

LOCUS pAKI28.7 7797 bp dsDNA Circular
 DEFINITION Human telomerase clone with alternative C-terminus

```

1  tgcacctgca ggcattgcaag ctgtggcactg gccgtcggtt tacaacgtcg tgactgggaa
61  aaccttgagg ttacccaact taatcgccct gcagcacatc cccctttcgc cagctggcgt
121 aatagcgaag aggcccgcac cgatcgccct tcccaacagt tgcgcagcct gaatggcgaa
181 tggcgccctga tgcggtattt tctccttacg catctgtgcg gtatttcaca ccgcataaat
241 tccctgtttt ggccgatgag agaagatttt cagcctgata cagattaaat cagaacgcag
301 aagcggctcg ataaaacaga atttgccctg cggcagtagc gccgtgggtc cacctgaccc
361 catgccgaac tcagaagtga aacgccgtag cgccgatggt agtgtgggtt ctccccatgc
421 gagagtaggg aactgccagg catcaataaa aacgaaaggc tcagtcgaaa gactgggcct
481 ttcgttttat ctgttgtttg tcggtgaacg ctctcctgag taggacaaat ccgccgggag
541 cggatttgaa cgttgcaag caacggcccg gagggtggcg ggcaggacgc ccgcataaa
601 ctgccaggca tcaaattaag cagaaggcca tcctgacgga tggcctttt gcgtttctac
661 aaactcttcc tgtcgtcata tctacaagcc atccccccac agatacggta aactagcctc
721 gtttttgcag caggaaagca gggaatttat ggtgcactct cagtacaatc tgctctgatg
781 ccgcatagtt aagccagccc cgacacccgc caacacccgc tgacgcgcc tgacgggctt
841 gtctgtctcc ggcattccgt tacagacaag ctgtgaccgt ctccgggagc tgcattgttc
901 agagggtttc accgtcatca ccgaaacgcg cgagacgaaa gggcctcgtg ataccgctat
961 ttttataggt taatgtcatg ataataatgg tttcttagac gtgaggttct gtaccgaca
1021 ccatcgaaat gtgcaaaacc tttcgcggtg tggcatgata gcgccgggaa gagagtcaat
1081 tcagggtggt gaattgtgaa ccagtaacgt tatacgtatg cgcagagtat gccggtgtct
1141 cttatcagac cgtttccgcg gtggtgaacc aggccagcca cgtttctgcg aaaacgcggg
1201 aaaaagtggg agcggcgatg gcggagctga attacattcc caaccgcgtg gcacaacaac
1261 tggcgggcaa acagtcgttg ctgattggcg ttgccacctc cagtctggcc ctgcacgcgc
1321 cgtcgcaaat tgcgcggcg attaaatctc gcgccgatca actgggtgcc agcgtggtgg
1381 tgtcgatggt agaacgaagc ggcgtcgaag cctgtaaagc ggcggtgcac aatcttctcg
1441 cgcaacgcgt cagtgggctg atcattaact atccgctgga tgaccaggat gccattgctg
1501 tggaaagctg ctgcactaat gttccggcgt tatttcttga tgtctctgac cagacaccca
1561 tcaacagtat tattttctcc catgaagacg gtacgcgact gggcgtggag catctggtcg
1621 cattgggtca ccagcaaatc gcgctgttag cgggccattt aagtctgtc tcggcgcgtc
1681 tgcgtctggc tggctggcat aaatatctca ctgcgaatca aattcagccg atagcggaac
1741 gggaaggcga ctggagtgcc atgtccggtt ttcaacaaac catgcaaatg ctgaatgagg
1801 gcatcggtcc cactgcgatg ctggttgcca acgatcagat ggcgtgggca gcaatgcgcg
1861 ccattaccga gtccgggctg cgcggttggt cggtatctc ggtagtgga tacgacgata
1921 ccgaagacag ctcatgttat atcccgccgt taaccacat caaacaggat tttcgccctg
1981 tggggcaaac cagcgtggac cgcttgctgc aactctctca gggccaggcg gtgaagggca
2041 atcagctgtt gccgctctca ctggtgaaaa gaaaaaccac cctggcgccc aatacgcaaa
2101 ccgcctctcc ccgcgcgttg gccgattcat taatgcagct ggcacgacag gtttccgcac
2161 tggaaagcgg gcagtgaagc caacgcaatt aatgtaagtt agctcactca ttaggcaccc
2221 caggctttac actttatgct tccgacctgc aagaacctca cgtcagggtg cacttttcgg
2281 ggaaatgtgc gcggaacccc tatttgttta tttttctaaa tacattcaaa tatgtatccg
2341 ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa gagtatgagt
2401 attcaacatt tccgtgtcgc ccttattccc ttttttgccg cattttgcct tcctgtttt
2461 gtcaccccag aaacgctggt gaaagtaaaa gatgtgaag atcagttggg tgcacgagtg
2521 ggttacatcg agaactggat ctcaacagcg gtaagatcct tgagagtttt cggcccgagg
2581 aacgttttcc aatgatgagc acttttaaaag ttctgctatg tggcgcggtg ttatcccgta
2641 ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat gacttggtg

```

Fig. 14B

2701 agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca
2761 gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca acgatcggag
2821 gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact cgccttgatc
2881 gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc acgatgcctg
2941 tagcaatggc aacaacgttg cgcaaaactat taactggcga actacttact ctagcttccc
3001 ggcaacaatt aatagactgg atggaggcgg ataaagtgtc aggaccactt ctgcgtcgg
3061 cccctccggc tggctggttt attgctgata aatctggagc cggtagcgt gggctcgcg
3121 gtatcattgc agcactggg ccagatggta agccctccc tatcgtagt atctacacga
3181 cggggagtc ggcaactatg gatgaacgaa atagacagat cgctgagata ggtgcctcac
3241 tgattaagca ttggttaactg tcagaccaag ttactcata tatactttag attgatttaa
3301 aacttcattt ttaatttaa aggatctagg tgaagatcct tttgataat ctcatgacca
3361 aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa aagatcaaaag
3421 gatcttcttg agatcctttt tttctgcgag taatctgctg cttgcaaaca aaaaaaccac
3481 cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactctttt ccgaaggtaa
3541 ctggcttcag cagagcgcag ataccaaata ctgtccttct agttagccg tagttaggcc
3601 accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaata ctgttaccag
3661 tggctgctgc cagtggcgat aagtcgtgct ttaccgggtt ggactcaaga cgatagttac
3721 cggataaggc gcagcgtcg ggtgaacgg ggggttcgtg cacacagccc agcttgagc
3781 gaacgaccta caccgaactg agatacctac agcgtgagca ttgagaaagc gccacgcttc
3841 ccgaaggag aaaggcgac aggtatccgg taagcggcag ggtcggaca ggagagcgca
3901 cgaggagct tccagggga aacgcctggt atctttatag tcctgtcggg ttccgccacc
3961 tctgacttga gcgtcgattt ttgtgatgct cgtcagggg gcggagccta tggaaaaacg
4021 ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgc cactgttct
4081 ttctgtcgtt atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata
4141 ccgctcgcg cagccgaacg accgagcgca gcgagtcagt gagcaggaa gcggaagagc
4201 gcccaatacg caaacgcct ctccccgcg gttggccgat tcattaatgc agaattaatt
4261 ctcatgtttg acagcttatc atcgactgca cggtgacca atgcttctg cgtcaggcag
4321 ccatcggaag ctgtggtatg gctgtgcagg tcgtaaatca ctgcataatt cgtgtcgtc
4381 aaggcgcact ccggttctg ataattgttt ttgcccgcac atcataacgg ttctggcaaa
4441 tattctgaaa tgagctgttg acaattaatc atcggctcgt ataattgttg gaattgtgag
4501 cggataacaa ttacacacag gaaacagcga tgaattcaga tctaccatg aaggagctgg
4561 tggcccaggt gctgcagagg ctgtgcgagc gcggcgcaa gaacgtgctg gccttcggt
4621 tcgctgctg ggacggggcc cgccggggcc ccccgaggc cttaccacc agcgtgcgca
4681 gctacctgcc caacacgggt accgacgcac tgcgggggag cggggcggtg gggtgctgc
4741 tgcgccgct gggcgacgac gtgctggtt accctgctgc acgctgcgc ctctttgtgc
4801 tgggtgctcc cagctgcgc taccaggtgt gcgggccgc gctgtaccag ctccggcgtg
4861 ccactcaggc ccggccccc ccacacgcta gtggacccg aaggcgtctg ggatgcgaac
4921 gggcctgga ccatagcgtc agggaggccg gggccccct gggcctgcca gccccgggtg
4981 cgaggaggcg cgggggcagt gccagccgaa gtctgccgtt gcccagagg cccaggcgtg
5041 gcgtgcccc tgagccggag cggacggccg ttgggcagg gtccctgggc caccgggca
5101 ggacgcgtg accgagtgc cgtggtttct gtgtggtgt acctgccaga cccgccgaag
5161 aagccacctc tttggagggt gcgtctctg gcacgcgcca ctcccacca tccgtgggccc
5221 gccagacca cgcgggcccc ccatccacat cgcggccacc acgtccctgg gacacgcctt
5281 gtcccccggt gtacgccgag accaagcact tcctctactc ctcaggcgac aaggagcagc
5341 tgcggccctc cttctactc agctctctga ggccagcct gactggcgt cggaggctcg
5401 tggagaccat ctttctgggt tccaggccct ggatgccagg gaactcccgc aggttgcgcc
5461 gcctgcccc ggcgtactgg caaatgcggc ccctgtttct ggagctgctt gggaaccacg
5521 cgcagtgcgc ctacggggtg ctctcaaga cgcactgccc gctgcgagct gcggtcacc

64/68

5581 cagcagccgg tgtctgtgcc cgggagaagc cccagggctc tgtggcggcc cccgaggagg
5641 aggacacaga ccccgcgcg cttggtgcagc tgctccgcca gcacagcagc ccctggcagg
5701 tgtacggctt cgtgcgggccc tgccctgcgccc ggctgggtgcc cccaggccctc tggggctcca
5761 ggcacaacga acgccgcttc ctcaggaaca ccaagaagtt catctccctg gggaaagcatg
5821 ccaagctctc gctgcaggag ctgacgtgga agatgagcgt gcgggactgc gcttggctgc
5881 gcaggagccc aggggttggc tgtgttccgg ccgcagagca ccgtctgcgt gaggagatcc
5941 tggccaagtt cctgcactgg ctgatgagtg tgtacgtcgt cgagctgctc aggtctttct
6001 tttatgtcac ggagaccacg tttcaaaaaga acaggctctt tttctaccgg aagagtgtct
6061 ggagcaagtt gcaaagcatt ggaatcagac agcacttgaa gagggtgcag ctgcgggagc
6121 tgtcggaagc agaggtcagg cagcatcggg aagccaggcc cgccctgctg acgtccagac
6181 tccgcttcat cccaagcct gacgggctgc ggccgattgt gaacatggac tacgtcgtgg
6241 gagccagaac gtccgcaga gaaaagaggg ccgagcgtct caccctgagg gtgaaggcac
6301 tgttcagcgt gctcaactac gagcgggcgc ggccgcccgg cctcctgggc gcctctgtgc
6361 tgggcctgga cgatatccac agggcctggc gcaccttctg gctgcgtgtg cgggcccagg
6421 acccgccgcc tgagctgtac ttgttcaagg tggatgtgac gggcgcgtag gacaccatcc
6481 cccaggacag gtcacggag gtcacgcca gcatcatcaa acccagaac acgtactgcg
6541 tgcgtcggta tgccgtggtc cagaaggccg cccatgggca cgtccgcaag gccttcaaga
6601 gccacgtctc taccttgaca gacctccagc cgtacatgcg acagttcgtg gctcacctgc
6661 aggagaccag cccgctgagg gatgccgtcg tcatcgagca gagctcctcc ctgaatgagg
6721 ccagcagtgg cctcttcgac gtcttcctac gcttcattgt ccaccacgcc gtgcgcatca
6781 ggggcaagtc ctacgtccag tgccagggga tcccgcaggg ctccatcctc tccacgctgc
6841 tctgcagcct gtgtacggc gacatggaga acaagctgtt tgccgggatt cggcgggacg
6901 ggctgtcctc gcgtttggtg gatgatttct tgttggtgac acctcacctc acccagcga
6961 aaacttcctc aggacctggt ccgaagtgtc ctgagtatgg ctgcgtgggt aacttgcgga
7021 agacagtggg gaacttccct gtagaagacg aagccctggg tggcacggct tttgttcaga
7081 tgccggccca cggcctatc ccttggtgcg gcctgctgct ggatacccgg accttgagg
7141 tgcagagcga ctactccagc tatgcccgga cctccatcag agccagtctc acctcaacc
7201 gcggcttcaa ggctgggagg aacatgcgtc gcaaactctt tggggtcttg cggctgaagt
7261 gtcacagcct gtttctggat ttgcaggta acagcctcca gacggtgtgc accaactct
7321 acaagatcct cctgctgcag gcgtacagg ttcacgcatg tgtgtgcag ctcccatttc
7381 atcagcaagt ttggaagaac cccacatttt tcctgcgct catctctgac acggcctccc
7441 tctgtactc catcctgaaa gccaaagacg cagccgaaga aaacatttct gtcgtgactc
7501 ctgcgggtgct tgggtcggga cagccagaga tggagccacc ccgcagaccg tcgggtgtgg
7561 gcagctttcc ggtgtctcct gggaggggag ttgggctggg cctgtgactc ctcagcctct
7621 gttttccccc agggatgtcg ctgggggcca agggcgccgc cggccctctg ccctccgagg
7681 ccgtgcagtg gctgtgccac caagcattcc tgctcaagct gactcgacac cgtgtcacct
7741 acgtgccact cctgggggtca ctcaggacag gcaagtgtgg gtggaggcca gtgcggg

Fig. 14D

65/68




Fig. 15A

LOCUS pAKI28.14 7688 bp dsDNA Circular
DEFINITION Human telomerase clone with exon alpha spliced out

```
1 tgcacctgca ggcattgcaag ctgggactg gccgtcggtt tacaacgtcg tgactgggaa
61 aaccctggcg ttacccaact taatcgccct gcagcacatc cccctttcgc cagctggcgt
121 aatagcgaag aggcccgcac cgatcgccct tcccaacagt tgcgcagcct gaatggcgaa
181 tggcgccctga tgcggtatct tctccttacg catctgtgcg gtatttcaca ccgcataaat
241 tccctgtttt ggcggatgag agaagatttt cagcctgata cagattaaat cagaacgcag
301 aagcggctctg ataaaacaga atttgcctgg cggcagtagc gcggtgggtc cacctgacct
361 catgccgaac tcagaagtga aacgccgtag cgccgatggt agtgtggggt ctccccatgc
421 gagagtaggg aactgccagg catcaaataa aacgaaaggc tcagtcgaaa gactgggcct
481 ttcgttttat ctgttgtttg tcggtgaacg ctctcctgag taggacaaat ccgcggggag
541 cggatttgaa cgttgcaag caacggcccg gaggtggcg ggcaggacgc ccgcataaa
601 ctgccaggca tcaaattaag cagaaggcca tcctgacgga tggccttttt gcgtttctac
661 aaactcttcc tgcgtcata tctacaagcc atccccccac agatacggta aactagcctc
721 gtttttgcag caggaaagca gggaatttat ggtgactctc cagtacaatc tgctctgatg
781 ccgcatagtt aagccagccc cgacaccgcg caacaccgcg tgacgcgccc tgacgggctt
841 gtctgctccc ggcattcgct tacagacaag ctgtgaccgt ctccgggagc tgcattgtgc
901 agaggttttc accgtcatca ccgaaacgcg cgagacgaaa gggcctcgtg atacgcctat
961 ttttataggt taatgtcatg ataataatgg tttcttagac gtgaggttct gtacccgaca
1021 ccatcgaatg gtgcaaaacc tttcgcggta tggcatgata gcgcccgaa gagagtcaat
1081 tcagggtggt gaattgaaa ccagtaacgt tatacgtatg cgcagagtat gccggtgtct
1141 ctatcagac cgttcccgcg gtgtgaacc aggccagcca cgtttctgcg aaaacgcggg
1201 aaaaagtgga agcggcgatg gcggagctga attacattcc caaccgcgtg gcacaacaac
1261 tggcgggcaa acagtcgttg ctgattggcg ttgccacctc cagtctggcc ctgcacgcgc
1321 cgtcgcaaat tgcgcggcg attaaatctc gcgccgatca actgggtgcc agcgtggtgg
1381 tgcgatggt agaacgaagc ggcgtcgaag cctgtaaagc ggcgtgac aatcttctcg
1441 cgcaacgcgt cagtgggctg atcattaact atccgctgga tgaccaggat gccattgctg
1501 tggagctgc ctgcactaat gttccggcgt tatttcttga tgtctctgac cagacacca
1561 tcaacagtat tattttctcc catgaagacg gtacgcgact ggcgtggag catctggtcg
1621 cattgggtca ccagcaaatc gcgtgttag cgggccatt agttctgtc tcggcgctc
1681 tgcgtctggc tggctggcat aaatatctca ctgcgaatca aattcagccg atagcggaa
1741 gggagggcga ctggagtgc atgtccggtt ttcaacaac catgcaaatg ctgaatgagg
1801 gcatcgttc cactgcgatg ctggttgcca acgatcagat ggcgtggc gcaatgcgcg
1861 ccattaccga gtccgggtg cgcttggtg cgatatctc ggtagtggga tacgacgata
1921 ccgaagacag ctcatgttat atcccgccgt taaccaccat caaacaggat tttcgctgc
1981 tggggcaaac cagcgtggac cgcttgcgc aactctctca gggccaggcg gtgaagggca
2041 atcagctgtt gccgctctca ctggtgaaaa gaaaaaccac cctggcgccc aatacgcaaa
2101 ccgcctctcc ccgcgcgttg gccgattcat taatgcagct ggcacgacag gtttcccgac
2161 tggaaagcgg gcagttagcg caacgcaatt aatgtaagt agctcactca ttaggcaccc
2221 caggctttac actttatgct tccgacctgc aagaacctca cgtcaggtg cacttttcgg
2281 ggaaatgtgc gcggaacccc tatttgttta ttttctaaa tacattcaaa tatgtatccg
2341 ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa gagtatgagt
2401 attcaacatt tccgtgtcgc cttattccc ttttttcgg cattttgcct tctgttttt
2461 gctcaccag aaacgtggt gaaagtaaaa gatgctgaag atcagttggg tgcacgagtg
2521 ggttacatcg agaactggat ctcaacagcg gtaagatcct tgagagtttt cggcccgaa
2581 aacgttttcc aatgatgagc acttttaaaag ttctgctatg tggcgcggtt ttatcccgta
2641 ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat gacttggtg
```

2701 agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca
 2761 gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca acgatcggag
 2821 gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact cgccttgatc
 2881 gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc acgatgcctg
 2941 tagcaatggc aacaacgttg cgcaaaactat taactggcga actacttact ctgacttccc
 3001 ggcaacaatt aatagactgg atggaggcgg ataaagtgc aggaccactt ctgcgctcgg
 3061 cccttcgggc tggctgggtt attgctgata aatctggagc cggtgagcgt gggctcgcg
 3121 gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagt atctacacga
 3181 cggggagtcg ggcaactatg gatgaacgaa atagacagat cgctgagata ggtgcctcac
 3241 tgattaagca ttggttaactg tcagaccaag ttactcata tatactttag attgatttaa
 3301 aacttcattt ttaatttaaa aggatctagg tgaagatcct tttgataat ctcatgacca
 3361 aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa aagatcaaaq
 3421 gatcttcttg agatcccttt tttctgcgcg taatctgctg cttgcaaaca aaaaaaccac
 3481 cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactctttt ccgaaggtaa
 3541 ctggcttcag cagagcgagc ataccaaata ctgtccttct agtgtagccg tagttaggcc
 3601 accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaate ctgttaccag
 3661 tggctgctgc cagtggcgat aagtcgtgct ttaccgggtt ggactcaaga cgatagttac
 3721 cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc agcttgagc
 3781 gaacgaccta caccgaactg agatacctac agcgtgagca ttgagaaagc gccacgcttc
 3841 ccgaaggag aaaggcgagc aggtatccgg taagcggcag ggtcggaaca ggagagcgca
 3901 cgaggagct tccaggggga aacgcctggt atctttatag tcctgtcggg tttcgccacc
 3961 tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg
 4021 ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct cacatgttct
 4081 ttcctgcgtt atccctgat tctgtggata accgtattac cgcttttgag tgagctgata
 4141 ccgctcggc cagccgaacg accgagcgca gcgagtcagt gacgagaggaa gcggaagagc
 4201 gcccaatacg caaacgcctt cccccggc gttggccgat tcattaatgc agaattaatt
 4261 ctcatgtttg acagcttate atcgactgca cgggtgacca atgcttctgg cgtcaggcag
 4321 ccatcggaag ctgtggtatg gctgtgcagg tcgtaataca ctgcataatt cgtgtcgtc
 4381 aaggcgact cccgttctgg ataattgttt ttgcggcgac atcataacgg ttctggcaaa
 4441 tattctgaaa tgagctgttg acaattaatc atcggctcgt ataattgttg gaattgtgag
 4501 cggataacaa ttccacacag gaaacagcga tgaattcaga tctcaccatg aaggagctgg
 4561 tggcccgagt gctgcagagg ctgtgcgagc gcggcgcgaa gaacgtgctg gccttcggct
 4621 tcgctgctgct ggacggggcc cgcgggggcc ccccgaggc cttaccacc agcgtgcgca
 4681 gctacctgcc caacacgggtg accgacgcac tgcgggggag cggggcgctg gggctgctgc
 4741 tgcgcgcgt gggcgacgac gtgctggtt acctgctggc acgtgcgcg ctctttgtgc
 4801 tgggtggctc cagctgcgc taccaggtgt gcggggcgcc gctgtaccag ctcggcgctg
 4861 ccactcaggc cggggccccc ccacacgcta gtggaccccg aaggcgtctg ggatgcgaac
 4921 gggcctggaa ccatagcgtc agggaggccg ggggtccctt gggcctgcca gcccgggtg
 4981 cgaggaggcg cgggggcagt gccagccgaa gtctgccgtt gcccagagg cccaggcgtg
 5041 gcgctgcccc tgagccggag cggacgcccg ttgggcaggg gtccctgggccc caccgggca
 5101 ggacgcgtgg accgagtgc cgtggtttct gtgtggtgac acctgccaga cccgcccgaag
 5161 aagccacctc ttggagggt gcgtctctg gcacgcgcca ctcccacca tccgtgggccc
 5221 gccagcacca cgcgggcccc ccatccacat cgcgccacc acgtccctgg gacacgcctt
 5281 gtccccgggt gtacgcccag accaagcact tcctctactc ctcaggcgac aaggagcagc
 5341 tgcggccctc ctctctact agctctctga ggcccagcct gactggcgct cggaggctcg
 5401 tggagaccat ctttctgggt tccaggccct ggatgccagg gaetccccgc aggttgcgcc
 5461 gcctgcccc ggcgtactgg caaatgcggc ccctgtttct ggagctgctt gggaaccacg
 5521 cgcagtgcgc ctacgggggt ctctcaaga cgcactgccc gctgcgagct gcggtcacc

Fig. 15C

68/68

5581 cagcagccgg tgtctgtgcc cgggagaagc cccagggctc tgtggcgggc cccgaggagg
5641 aggacacaga cccccgtcgc ctggtgcagc tgetccgcca gcacagcagc ccctggcagg
5701 tgtacggctt cgtgcggggc tgcttgcgcc ggctgggtgcc cccaggcctc tggggctcca
5761 ggacacaaga acgccgcttc ctcaggaaca ccaagaagtt catctccctg gggaaagcatg
5821 ccaagctctc gctgcaggag ctgacgtgga agatgagcgt gcgggactgc gcttggctgc
5881 gcaggagccc aggggttggc tgtgttccgg ccgcagagca ccgtctgcgt gaggagatcc
5941 tggccaagtt cctgcactgg ctgatgagtg tgtacgtcgt cgagctgctc aggtctttct
6001 tttatgtcac ggagaccacg ttcaaaaaga acaggctctt tttctaccgg aagagtgtct
6061 ggagcaagtt gcaaagcatt ggaatcagac agcacttgaa gagggtgcag ctgcgggagc
6121 tgtcggaaagc agaggtcagg cagcatcggg aagccaggcc cgccttctg acgtccagac
6181 tccgcttcat cccaagcct gacgggctgc ggccgattgt gaacatggac tacgtcgtgg
6241 gagccagaac gtccgcaga gaaaagagg ccgagcgtct cacttcgagg gtgaaggac
6301 tggtcagcgt gctcaactac gagcgggcgc ggcgccccgg cctcctgggc gcctctgtgc
6361 tgggcctgga cgatatccac agggcctggc gcaccttcgt gctgcgtgtg cgggcccagg
6421 acccgccgcc tgagctgtac ttgtcaagg acaggctcac ggaggtcatc gccagcatca
6481 tcaaaccag aacacgtact gcgtgcgtcg gtatgccgtg gtccagaagg ccgccatgg
6541 gcacgtccgc aaggccttca agagccacgt ctctacctg acagacctcc agccgtacat
6601 gcgacagtgc gtggctcacc tgcaggagac cagcccgtg agggatgccg tcgtcatcga
6661 gcagagctcc tcctgaatg aggcagcag tggcctctc gacgtcttcc tacgttcat
6721 gtgccaccac gccgtgcgca tcaggggcaa gtccctacgc cagtgcagg ggtcccga
6781 gggtccatc ctctccagc tgctctgcag cctgtgtac ggcgacatgg agaacaagct
6841 gtttgccggg attcgccggg acgggctgct cctgcgttg gtggatgatt tctgttgg
6901 gacacctcac ctcaccacg cgaaaacct cctcaggacc ctggtccgag gtgtccctga
6961 gtatggctgc gtggtgaact tgcggaagac agtgggtgaa ttccctgtg aagacgaggc
7021 cctgggtggc acggcttttg ttcagatgcc ggcccacggc ctattcccct ggtgcggcct
7081 gctgctggat acccggaacc tggaggtgca gagcgactac tccagctatg cccggacctc
7141 catcagagcc agtctcacct tcaaccgagg cttaaggct gggaggaaca tgcgtcgcaa
7201 actctttggg gtcttgccgc tgaagtgtca cagcctgtt ctggatttgc aggtgaacag
7261 cctccagacg gtgtgcacca acatctacaa gatcctcctg ctgcaggcgt acaggtttca
7321 cgcagtgtgt ctgcagctcc catttcatca gcaagtttg aagaacccca catttttct
7381 gcgcgtcatc tctgacacgg cctccctctg ctactccatc ctgaaagcca agaacgcagg
7441 gatgtcgtg ggggccaagg gcgcgcgg ccctctgccc tccgaggccg tgcagtggct
7501 gtgccaccaa gcattcctgc tcaagctgac tcgacaccgt gtcacctacg tggcactcct
7561 ggggtcactc aggcagccc agacgcagct gagtcggaag ctcccgggga cgacgtgac
7621 tgccctggag gccgcagcca acccggcact gccctcagac ttcaagacca tcctggactg
7681 atctagag

Fig. 15D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/13835

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/54 C12N9/12 A61K38/45 C07K16/40 C12Q1/68
C12Q1/48 C12N15/11 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 01835 A (ANDREWS WILLIAM H ;VILLEPONTEAU BRYANT (US); FUNK WALTER (US); FEN) 25 January 1996 see page 9, line 31 - page 14, line 5 see page 55, line 22 - page 59, line 3 see page 62, line 3 - page 67, line 8 ---	1,2,11, 13,16, 17, 55-57, 59,60, 62-64
X	WO 96 19580 A (COLD SPRING HARBOR LAB ;GREIDER CAROL (US); COLLINS KATHLEEN (US);) 27 June 1996 cited in the application see examples 8-10	1,2,11, 13,16, 17,23, 27-29,32
A	see claims ---	1-63

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 December 1998

Date of mailing of the international search report

22/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

Int l Application No

PCT/US 98/13835

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAYAMA, J.-I. ET AL.: "TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family" CELL, vol. 88, 21 March 1997, pages 875-884, XP002087001 see the whole document ---	1,11, 13-16, 23,32
X	ADAMS, M. ET AL.: "EST12462 uterus tumor I Homo sapiens cDNA 5'end" EMBL DATABASE ENTRY HSZZ05016; ACCESSION NUMBER AA299878, 18 April 1997, XP002087002 cited in the application see abstract & ADAMS, M. ET AL.: "initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence" NATURE, vol. 377, 1995, pages 3-174, ---	3,6,27
A	LINGNER ET AL: "Reverse transcriptase motifs in the catalytic subunit of telomerase" SCIENCE, XP002080419 cited in the application see the whole document ---	32-40, 46-48
A	WO 95 13382 A (GERON CORP ;UNIV CALIFORNIA (US); UNIV TEXAS (US)) 18 May 1995 see the whole document ---	23-64
P,X	WO 98 14593 A (ANDREWS WILLIAM H ;CECH THOMAS R (US); MORIN GREGG B (US); NAKAMUR) 9 April 1998 cited in the application see examples see SEQ IDs 1,2,117,119,140 and 613 see claims ---	1-63
P,X	KILIAN, A. ET AL.: "Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types." HUMAN MOLECULAR GENETICS., vol. 6, 12 November 1997, pages 2011-2019, XP002086926 OXFORD GB cited in the application see the whole document ---	1-22, 27-49

-/--

INTERNATIONAL SEARCH REPORT

Int ernational Application No

PCT/US 98/13835

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	MEYERSON M ET AL: "HEST2, THE PUTATIVE HUMAN TELOMERASE CATALYTIC SUBUNIT GENE, IS UP-REGULATED IN TUMOR CELLS AND DURING IMMORTALIZATION" CELL, vol. 90, no. 4, 22 August 1997, pages 785-795, XP002056804 cited in the application see the whole document ---	1-11, 13-18, 27-29, 31-34, 41,42
P, X	NAKAMURA T M ET AL: "TELOMERASE CATALYTIC SUBUNIT HOMOLOGS FROM FISSION YEAST AND HUMAN" SCIENCE, vol. 277, 15 August 1997, pages 955-959, XP002056803 cited in the application see the whole document ---	1-11, 13-18, 27-29, 31-34, 41,42
P, X	WO 98 21343 A (AMGEN CANADA INC ;AMGEN INC (US)) 22 May 1998 see figure 9 see page 68, line 32 - page 95, line 5 see claims ---	1-35, 38-43, 46-49
E	WO 98 37181 A (COUNTER CHRISTOPHER M ;WEINBERG ROBERT A (US); WHITEHEAD BIOMEDICA) 27 August 1998 see page 37, line 22 - page 58, line 16 see figure 2 -----	1-63

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 13835

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 60
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13835

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9601835 A	25-01-1996	US 5583016 A	10-12-1996
		US 5776679 A	07-07-1998
		AU 696702 B	17-09-1998
		AU 2964795 A	09-02-1996
		AU 3095095 A	09-02-1996
		BG 101103 A	31-10-1997
		BR 9508254 A	23-12-1997
		CA 2194393 A	25-01-1996
		CN 1158617 A	03-09-1997
		CN 1168696 A	24-12-1997
		CZ 9700034 A	15-10-1997
		EP 0778842 A	18-06-1997
		EP 0793719 A	10-09-1997
		FI 970026 A	03-03-1997
		JP 10505488 T	02-06-1998
		JP 10507067 T	14-07-1998
		NO 970041 A	06-03-1997
		PL 318169 A	26-05-1997
		WO 9601614 A	25-01-1998
		US 5837857 A	17-11-1998
WO 9619580 A	27-06-1996	EP 0799315 A	08-10-1997
WO 9513382 A	18-05-1995	US 5830644 A	03-11-1998
		AU 1178195 A	29-05-1995
		AU 682082 B	18-09-1997
		AU 1209095 A	29-05-1995
		AU 1330795 A	29-05-1995
		AU 6058298 A	04-06-1998
		CA 2173872 A	18-05-1995
		EP 0728207 A	28-08-1996
		JP 9502102 T	04-03-1997
		WO 9513381 A	18-05-1995
		US 5629154 A	13-05-1997
		US 5648215 A	15-07-1997
		US 5686306 A	11-11-1997
		US 5639613 A	17-06-1997
		US 5837453 A	17-11-1998
		US 5693474 A	02-12-1997
		US 5804380 A	08-09-1998
WO 9814593 A	09-04-1998	AU 4803697 A	24-04-1998
		AU 4807397 A	24-04-1998
		DE 19743497 A	20-08-1998
		DE 841396 T	24-09-1998
		EP 0841396 A	13-05-1998
		FR 2757177 A	19-06-1998
		GB 2317891 A, B	08-04-1998
		GB 2321642 A	05-08-1998
		JP 10234384 A	08-09-1998
		WO 9814592 A	09-04-1998
WO 9821343 A	22-05-1998	AU 5264498 A	03-06-1998
WO 9837181 A	27-08-1998	NONE	